

CITATION REPORT

List of articles citing

The positive and negative syndrome scale (PANSS) for schizo

DOI: 10.1093/schbul/13.2.261

Schizophrenia Bulletin, 1987, 13, 261-76.

Source: <https://exaly.com/paper-pdf/18847121/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2204	The role of the right hemisphere for language in schizophrenia. 147-156		8
2203	Testing multiple novel mechanisms for treating schizophrenia in a single trial. 115-120		2
2202	Neuromuscular transmission in neonatal mice injected with serum globulin of myasthenia gravis patients. 1982 , 32, 12-7		10
2201	A seventeenth-century case of jacksonian epilepsy. 1985 , 35, 30-30		1
2200	Hallucinations: Unintended or unexpected?. 1987 , 10, 532-533		47
2199	Are verbal hallucinations secondary to disordered thinking?. 1987 , 10, 534-534		1
2198	Cognitive models of verbal hallucinations in schizophrenia. 1987 , 10, 534-537		38
2197	Some information-processing models suggest possible connections between hallucinations and discourse failures. 1987 , 10, 532-532		40
2196	Negative Symptomatology and Schizophrenia: A Conceptual and Empirical Review. 1987 , 16, 3-45		53
2195	Temporal course of symptoms and social functioning in relapsing schizophrenics: a 6-year follow-up. 1988 , 29, 361-71		21
2194	Depressive symptoms in schizophrenia: comprehensive differential diagnosis. 1988 , 29, 467-83		93
2193	Reliability and validity of the positive and negative syndrome scale for schizophrenics. 1988 , 23, 99-110		741
2192	The positive/negative symptom distinction in schizophrenia. Validity and etiological relevance. 1988 , 1, 315-28		73
2191	The Positive and Negative Syndrome Scale (PANSS): Rationale and Standardisation. 1989 , 155, 59-65		706
2190	Depression, Affect and Negative Symptoms in Schizophrenia. 1989 , 155, 108-114		26
2189	The positive-negative distinction in drug-free schizophrenic patients. Stability, response to neuroleptics, and prognostic significance. 1989 , 46, 711-8		114
2188	Depression in schizophrenia: current guidelines to treatment. 1989 , 60, 337-57		8

2187	Is social skills performance a correlate of schizophrenia subtypes?. 1989 , 2, 301-9	16
2186	Rehabilitation research methods for schizophrenia. 1989 , 2, 425-37	4
2185	Correlations between the MMPI and the Brief Psychiatric Rating Scale in schizophrenic and schizoaffective patients. 1989 , 28, 135-43	7
2184	Distinction of schizoaffective from schizophrenic profile. Independent validation. 1989 , 2, 423-4	8
2183	Erratum. 1990 , 176, 879-879	
2182	Positive-negative symptom assessment in schizophrenia: psychometric issues and scale comparison. 1990 , 61, 163-78	95
2181	The Brief Psychiatric Rating Scale (BPRS) and the Nurses' Observation Scale for Inpatient Evaluation (NOSIE) in the evaluation of positive and negative symptoms. 1990 , 46, 168-74	17
2180	Blunted affect, blunted lives? negative symptoms, ADL functioning, and mental health among older adults. 1990 , 5, 233-238	9
2179	Significance of the positive-negative distinction in schizophrenia. <i>Schizophrenia Bulletin</i> , 1990 , 16, 635-52.3	53
2178	Is negative schizophrenia a variant of parkinsonism?. 1990 , 53, 235-40	4
2177	Pyramidal model of schizophrenia. <i>Schizophrenia Bulletin</i> , 1990 , 16, 537-45	1.3 361
2176	The relationship of negative schizophrenia to parkinsonism. 1990 , 55, 1-59	19
2175	Calcification of the choroid plexus as a marker of depression in schizophrenia. 1990 , 3, 361-3	5
2174	A depression rating scale for schizophrenics. 1990 , 3, 247-51	921
2173	Neurological signs and the positive-negative dimension in schizophrenia. 1990 , 28, 181-92	84
2172	Dilapidation in schizophrenia: relationship to negative syndrome and prefrontal impairment. 1990 , 34, 221-2	2
2171	Smooth pursuit eye tracking dysfunction and negative symptoms in schizophrenia. 1990 , 34, 89-97	19
2170	Negative schizophrenic symptoms are associated with backward masking vulnerability. 1990 , 3, 355-6	11

2169	Predicting outcome of schizophrenia: significance of symptom profiles and outcome dimensions. 1990 , 31, 91-102	33
2168	ROUNDS, a new time-sampling methodology for the quantitative behavioral assessment of schizophrenic withdrawal. Reliability and validity. 1991 , 5, 255-62	
2167	Measurement of therapeutic response in schizophrenia. A critical survey. 1991 , 5, 249-53	52
2166	The role of serotonin in schizophrenia. New findings. 1991 , 5, 181-2	11
2165	Schizophrenic patients with depression: psychopathological profiles and relationship with negative symptoms. 1991 , 32, 528-33	32
2164	Stability of psychopathology dimensions in chronic schizophrenia: response to clozapine treatment. 1991 , 32, 28-35	7
2163	SCID-PANSS: two-tier diagnostic system for psychotic disorders. 1991 , 32, 355-61	58
2162	Olfactory acuity in the positive and negative syndromes of schizophrenia. 1991 , 29, 774-8	37
2161	The MCPP challenge test in schizophrenia: hormonal and behavioral responses. 1991 , 30, 770-8	63
2160	A selective review of possible neurological etiologies of schizophrenia. 1991 , 11, 645-661	3
2159	Principal-component analysis of PANSS and SANS - SAPS global ratings in schizophrenic patients. 1991 , 6, 251-259	31
2158	Negative symptoms in chronic schizophrenia. Relationship to duration of illness. 1991 , 159, 495-9	16
2157	A case of drug-drug interaction involving clozapine. 1991 , 36, 234-5	2
2156	Changes in the positive and negative symptoms of schizophrenic in-patients in China. 1991 , 159, 226-31	15
2155	Atrophy of the cerebellar vermis: relevance to the symptoms of schizophrenia. 1991 , 57, 205-12	34
2154	Risk factors for neuroleptic-induced movement disorders. 1991 , 61, 149-88	13
2153	Neuroradiological facets of cognitive abnormality in schizophrenia. 1991 , 58, 83-93	5
2152	The neuropsychology of schizophrenia. 1991 , 14, 1-20	920

2151	A faulty negative feedback control underlies the schizophrenic syndrome?. 1991 , 14, 20-21	10
2150	Don't leave the psyche out of neuropsychology. 1991 , 14, 21-21	1
2149	The limbic-striatal interaction: A seesaw rather than a tandem. 1991 , 14, 22-22	1
2148	Motor disturbances in schizophrenia. 1991 , 14, 22-23	3
2147	The neuropsychology of schizophrenia: A perspective from neurobehavioral genetics. 1991 , 14, 23-24	5
2146	Heterogeneity, orienting and habituation in schizophrenia. 1991 , 14, 24-25	6
2145	How does the physiology change with symptom exacerbation and remission in schizophrenia?. 1991 , 14, 25-26	5
2144	Dopaminergic excess or dysregulation?. 1991 , 14, 26-26	
2143	A focalized deficit within an elegant system. 1991 , 14, 27-28	
2142	In what context is latent inhibition relevant to the symptoms of schizophrenia?. 1991 , 14, 28-29	11
2141	Novelty value in associative learning. 1991 , 14, 29-29	5
2140	Schizophrenia and stored memories: Left hemisphere dysfunction after all?. 1991 , 14, 30-30	
2139	The role of long-term memory (LTM) and monitoring in schizophrenia: Multiple functions. 1991 , 14, 30-31	4
2138	A cardinal principle for neuropsychology, with implications for schizophrenia and mania. 1991 , 14, 31-32	1
2137	The mechanism of positive symptoms in schizophrenia. 1991 , 14, 33-34	
2136	A neuropsychology of psychosis. 1991 , 14, 34-34	
2135	Excitatory amino acids, NMDA and sigma receptors: A role in schizophrenia?. 1991 , 14, 34-35	1
2134	Schizophrenia and attention: In and out of context. 1991 , 14, 35-36	5

2133	Approximations to a neuropsychological model of schizophrenia. 1991 , 14, 36-37	2
2132	Neuropsychological vulnerability or episode factors in schizophrenia?. 1991 , 14, 37-38	9
2131	Is another loop needed to explain schizophrenia?. 1991 , 14, 39-40	1
2130	Why don't preschizophrenic children have delusions and hallucinations?. 1991 , 14, 41-42	6
2129	A heuristically useful but empirically weak neuropsychological model of schizophrenia. 1991 , 14, 42-43	
2128	Neuro-developmental, brain imaging and psychophysiological perspectives on the neuropsychology of schizophrenia. 1991 , 14, 43-44	
2127	Dopamine-GABA-cholinergic interactions and negative schizophrenic symptomatology. 1991 , 14, 46-47	2
2126	A hippocampal theory of schizophrenia. 1991 , 14, 47-49	11
2125	A plausible theory marred by certain inconsistencies. 1991 , 14, 49-50	
2124	What is schizophrenia?. 1991 , 14, 50-51	37
2123	Neuropsychology of schizophrenia: The whole thing is wrong. 1991 , 14, 51-53	9
2122	Positive and negative symptoms, the hippocampus and P3. 1991 , 14, 53-54	1
2121	The accumbens-substantia nigra pathway, mismatch and amphetamine. 1991 , 14, 54-55	6
2120	The neuropsychology of schizophrenia: In step but not in time. 1991 , 14, 55-56	1
2119	Schiz bits: Misses, mysteries and hits. 1991 , 14, 56-84	63
2118	A realistic model will be much more complex and will consider longitudinal neuropsychodevelopment. 1991 , 14, 40-41	30
2117	What should a theory of schizophrenia be able to do?. 1991 , 14, 44-45	3
2116	The significance of the basal ganglia for schizophrenia. 1991 , 14, 45-46	

2115	Bases for irrelevant information processing in schizophrenia: Room for manoeuvre. 1991 , 14, 38-39	9
2114	Negative symptoms and reaction time in schizophrenia. 1991 , 25, 131-40	30
2113	Predicting schizophrenia outcome with self-report measures of family interaction. 1991 , 47, 33-41	9
2112	Effects of amperozide in schizophrenia. An open study of a potent 5-HT ₂ receptor antagonist. 1991 , 104, 287-92	52
2111	Schizophrenia: the characteristic symptoms. <i>Schizophrenia Bulletin</i> , 1991 , 17, 27-49	1.3 270
2110	Experimental models of schizophrenia. 1991 , 58, 69-82	15
2109	Neuroradiological covariates of drug-induced parkinsonism and tardive dyskinesia in schizophrenia. 1991 , 58, 7-53	6
2108	The positive-negative distinction in schizophrenia. Review of natural history validators. 1992 , 49, 63-72	198
2107	Affective deficits and social deficits in schizophrenia: what's what?. <i>Schizophrenia Bulletin</i> , 1992 , 18, 59-64	33
2106	Phenomenology and functioning in first-episode schizophrenia. <i>Schizophrenia Bulletin</i> , 1992 , 18, 449-62	1.3 86
2105	Attributions of symptomatology: an exploration of family factors associated with expressed emotion. 1992 , 26, 408-16	29
2104	Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. 1992 , 85, 295-305	256
2103	Tardive dyskinesia. Patients' lack of awareness of movement disorder. 1992 , 160, 110-2	21
2102	Study of chronic schizophrenics using ³¹ P magnetic resonance chemical shift imaging. 1992 , 86, 455-62	99
2101	Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients. 1992 , 85, 306-12	19
2100	The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability. 1992 , 86, 463-8	54
2099	The pineal gland and the mode of onset of schizophrenia. 1992 , 67, 9-17	17
2098	Validity of the negative/positive dichotomy for schizophrenic disorders under long-term conditions. 1992 , 7, 117-23	18

2097	Scanning eye movements in schizophrenic patients. Relationship to clinical symptoms and regional cerebral blood flow using 123I-IMP SPECT. 1992 , 7, 159-68	15
2096	Physical aspects of the EEG in schizophrenics. 1992 , 32, 595-606	92
2095	Relationship between symptoms rated with the Positive and Negative Syndrome Scale and brain measures in schizophrenia. 1992 , 44, 55-62	12
2094	Multivalent assessment of depression in schizophrenia. 1992 , 42, 199-207	12
2093	Efficacy of clozapine in treatment-resistant psychosis and neuroleptic sensitivity: results of the Dutch open multi-center project. 1992 , 7, 77-84	8
2092	Course of Illness and Predictors of Outcome in Chronic Schizophrenia: Implications for Pathophysiology. 1992 , 161, 38-43	21
2091	Regional cerebral blood flow in patients with schizophrenia. A preliminary report. 1992 , 241, 195-200	56
2090	Object relations deficits in subtypes of schizophrenia. 1992 , 48, 433-44	18
2089	Word associations and schizophrenic symptoms. 1993 , 27, 69-77	45
2088	Affective deficits and pain insensitivity in schizophrenia. 1993 , 17, 245-276	39
2087	Three syndrome concept of schizophrenia. A factor analytic study. 1993 , 10, 143-50	112
2086	Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential. 1993 , 46, 585-93	36
2085	Positive and negative symptoms in families with schizophrenia. 1993 , 11, 9-19	49
2084	Factor analysis of schizophrenic symptoms and comparison of different rating scales. 1993 , 10, 67-75	35
2083	Schizophrenia: impact of positive symptoms on gender social role. 1993 , 11, 41-5	19
2082	Disordered water homeostasis and cognitive impairment in schizophrenia. 1993 , 34, 630-3	13
2081	Principal component analysis of the Swedish version of the Positive and Negative Syndrome Scale for schizophrenia. 1993 , 47, 257-263	36
2080	Aggressive behavior in schizophrenia: relationship to age of onset and cortical atrophy. 1993 , 68, 1-10	5

2079	Choroid plexus calcification as a possible marker of hallucinations in schizophrenia. 1993 , 71, 87-92	17
2078	Lifetime DSM-III-R diagnostic outcomes in the offspring of schizophrenic mothers. Results from the Copenhagen High-Risk Study. 1993 , 50, 707-14	169
2077	Biological determinants and risk factors for tardive dyskinesia in schizophrenia. 1993 , 69, 35-51	4
2076	Third ventricular width and its relationship to mode of onset of schizophrenia. 1993 , 69, 119-24	1
2075	The composition of the negative syndrome of chronic schizophrenia. 1993 , 162, 744-50	83
2074	Negative symptom assessment of chronic schizophrenia patients. <i>Schizophrenia Bulletin</i> , 1993 , 19, 627-35.3	16
2073	A checklist for evaluating the usefulness of rating scales. 1993 , 38, 140-8	159
2072	Classification of the schizophrenias according to symptomatology: A two-factor model.. 1993 , 102, 259-270	29
2071	Patterns of mental health care in a seaside lodging house. 1993 , 17, 82-83	
2070	Assessing Depression in Schizophrenia: The Calgary Depression Scale. 1993 , 163, 39-44	669
2069	The Nithsdale Schizophrenia Surveys. XII. 'Neurodevelopmental' Schizophrenia: a search for clinical correlates and putative aetiological factors. 1994 , 165, 340-6	24
2068	The Nithsdale Schizophrenia Surveys. XIII. Parental rearing patterns, current symptomatology and relatives' expressed emotion. 1994 , 165, 347-52	21
2067	Differences in P3 amplitudes between schizophrenics and healthy controls vary between the different events presented in a guessing task. 1994 , 30, 114-23	3
2066	Swedish experiences with the structured clinical interview for the positive and negative syndrome scale for schizophrenia (SCI-PANSS). 1994 , 9, 145-147	2
2065	Smooth-pursuit eye movement dysfunction in schizophrenia: the role of attention and general psychomotor dysfunctions. 1994 , 244, 153-60	20
2064	Investigation of gestural and pantomime performance in chronic schizophrenic inpatients. 1994 , 244, 59-64	11
2063	Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. 1994 , 115, 221-8	63
2062	A new five factor model of schizophrenia. 1994 , 65, 299-322	184

2061	Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent. 1994 , 9, 303-305	13
2060	The clinical characteristics of schizophrenic patients consenting or not consenting to a placebo controlled trial of antipsychotic medication. 1994 , 9, 423-433	21
2059	The short-term course of familial and nonfamilial schizophrenic-spectrum disorder. 1994 , 28, 97-106	3
2058	An empirical analysis of latent structures underlying schizophrenic symptoms: a four-syndrome model. 1994 , 36, 726-36	98
2057	Temporal lobe abnormalities in multigenerational families with schizophrenia. 1994 , 36, 737-43	29
2056	A comparison of plasma homovanillic acid in the deficit and nondéficit subtypes of schizophrenia. 1994 , 36, 230-6	39
2055	Cerebral blood flow in schizophrenia: effects of memory processing on regional activation. 1994 , 35, 3-15	54
2054	Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients. 1994 , 36, 654-61	15
2053	Noradrenergic and dopaminergic interrelation in schizophrenia. 1994 , 53, 231-42	7
2052	Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessments. 1994 , 54, 51-8	122
2051	Persisting negative symptoms and information-processing deficits in schizophrenia: implications for subtyping. 1994 , 54, 59-69	9
2050	Five-component model of schizophrenia: assessing the factorial invariance of the positive and negative syndrome scale. 1994 , 52, 295-303	344
2049	Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. 1994 , 53, 31-40	373
2048	A latent structure analysis of the positive and negative symptoms in schizophrenia. 1994 , 35, 252-9	41
2047	Positive and negative symptoms in the psychoses: principal components analysis of items from the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms. 1994 , 35, 135-44	35
2046	Psychopharmacologic treatment of negative schizophrenic symptoms. 1994 , 35, 16-28	15
2045	An analysis of the subjective experience of schizophrenia. 1994 , 35, 430-6	18
2044	Risperidone. 1994 , 343, 457-60	78

2043	Possible noradrenergic dysfunction in schizophrenia. 1994 , 35, 529-43	17
2042	Seasonality of birth and ventricular enlargement in chronic schizophrenia. 1994 , 55, 65-73	17
2041	Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia. 1994 , 55, 111-8	7
2040	The side-effects of clozapine: a four year follow-up study. 1994 , 18, 537-44	59
2039	Testing Liddle's three-syndrome model in families with schizophrenia. 1994 , 12, 213-21	20
2038	Modern psychopharmacological treatment in schizophrenia from receptor proteins to antipsychotic effect. 1994 , 48, 35-40	
2037	Options for the Treatment of Negative Symptoms of Schizophrenia. 1994 , 1, 107-118	7
2036	Correlates of codisorders in homeless and never homeless indigent schizophrenic men. 1994 , 24, 681-8	43
2035	Evaluation and interpretation of symptom structures in patients with schizophrenia. 1994 , 89, 399-404	37
2034	Interrater reliability of the Structured Clinical Interview for the Positive and Negative Syndrome Scale for schizophrenia. 1994 , 89, 192-5	50
2033	Risk factors for homelessness among schizophrenic men: a case-control study. 1994 , 84, 265-70	111
2032	[Positive and negative symptoms in schizophrenia: a current overview]. 1994 , 39, 407-14	11
2031	Insight and psychosocial treatment compliance in schizophrenia. 1994 , 57, 307-15	93
2030	Symptoms in schizophrenic syndromes in relation to age, sex, duration of illness and number of previous hospitalizations. 1994 , 89, 274-8	29
2029	Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices. 1994 , 90, 354-7	29
2028	Elevated dopa decarboxylase activity in living brain of patients with psychosis. 1994 , 91, 11651-4	282
2027	Movement disorder in never and minimally treated Nigerian schizophrenic patients. 1994 , 164, 184-9	29
2026	New perspectives on the clinical neurobiology of treatment response in schizophrenia. 1994 , 39, 34-42	

2025	Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. A controlled retrospective study. 1994 , 90, 247-51	42
2024	Negative symptoms and vocational impairment in schizophrenia: repeated measurements of work performance over six months. 1995 , 91, 205-8	58
2023	Work and meaning: disturbance of volition and vocational dysfunction in schizophrenia. 1995 , 58, 392-400	24
2022	New Developments in Social Skills Training. 1995 , 12, 31-40	24
2021	Analysis of positive and negative symptoms in schizophrenia. A study from a population of long-term outpatients. 1995 , 92, 178-82	19
2020	Positive and negative symptoms/syndromes in schizophrenia: reliability and validity of different diagnostic systems. 1995 , 25, 43-50	47
2019	[Correlation between symptoms and social adjustment in patients suffering from schizophrenia or major affective disorder]. 1995 , 40, 27-34	12
2018	Correlations between the clinical picture and the intentionality in schizophrenic and schizoaffective patients. 1995 , 28, 168-72	0
2017	The use of placebos in clinical trials for acute schizophrenia. 1995 , 40, 171-6	18
2016	An Intervention for Substance Abuse in Schizophrenia. 1995 , 12, 20-30	25
2015	Psychopathology of Schizophrenia: initial validation of a 5-factor model. 1995 , 28, 22-31	126
2014	Linguistic reference performance in parents of schizophrenic patients. 1995 , 58, 20-7	26
2013	Towards an understanding of sensory soft signs of schizophrenia. 1995 , 28, 281-4	10
2012	Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. 1995 , 91, 271-7	89
2011	Risk factors for homelessness among women with schizophrenia. 1995 , 85, 1153-6	71
2010	Principal components and further possibilities with the PANSS. 1995 , 388, 5-10	39
2009	Clinical symptoms and regional cerebral blood flow in schizophrenia. 1995 , 246, 7-12	41
2008	Affective modulation of the startle reflex in schizophrenic patients. 1995 , 245, 309-18	49

2007	Asymmetry of the ventricle and age at the onset of schizophrenia. 1995 , 245, 142-4		17
2006	Electrodermal and vascular orienting response in schizophrenic patients: relationship to symptoms and medication. 1995 , 245, 152-8		6
2005	Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. 1995 , 121, 317-22		77
2004	Sexual victimization in women with schizophrenia and bipolar disorder. 1995 , 30, 78-84		105
2003	Treatment and diagnostic subtype in facial affect recognition in schizophrenia. 1995 , 29, 5-11		80
2002	The concordance between symptom information gathered from remitted schizophrenic patients and their relatives. 1995 , 29, 447-56		6
2001	MonthlyUpdateCentral & Peripheral Nervous Systems: Pharmacotherapeutic Potential for Compounds Acting at NMDA Receptors: Update 1995. 1995 , 4, 475-485		2
2000	Disordered water homeostasis in schizophrenia and cerebral ventricular size. 1995 , 166, 501-6		11
1999	Understanding Symptoms of Schizophrenia. 1995 , 40, 12-17		1
1998	Pharmacologic Treatment Of Delusions. 1995 , 18, 379-391		14
1997	Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. 1995 , 166, 712-26; discussion 727-33		485
1996	Psychopathological dimensions in schizophrenia. <i>Schizophrenia Bulletin</i> , 1995 , 21, 473-82	1.3	68
1995	Expressed emotion and language disturbances in parents of stable schizophrenia patients. <i>Schizophrenia Bulletin</i> , 1995 , 21, 411-8	1.3	7
1994	Information processing and social competence in chronic schizophrenia. <i>Schizophrenia Bulletin</i> , 1995 , 21, 269-81	1.3	116
1993	Risperidone: efficacy and safety. <i>Schizophrenia Bulletin</i> , 1995 , 21, 593-606	1.3	55
1992	Introduzione. 1995 , 4, 69-71		9
1991	Obstetric complications and severity of illness in schizophrenia. 1995 , 14, 113-20		11
1990	Schizophrenic symptoms and dietary intake of n-3 fatty acids. 1995 , 18, 85-6		62

1989	Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. 1995 , 17, 402-12	90
1988	Communication disturbances in schizophrenia: a two-process formulation. 1995 , 36, 182-6	8
1987	Olfactory identification ability in pre- and postmenopausal women with schizophrenia. 1995 , 38, 57-63	48
1986	Pharmacological augmentation of NMDA receptor function for treatment of schizophrenia. 1995 , 757, 487-91	13
1985	The gonadal axis in men with schizophrenia. 1995 , 57, 231-9	17
1984	Multiple-outcome criteria in schizophrenia: an overview of outcome with clozapine. 1995 , 10 Suppl 1, 19s-25s	16
1983	Principal-component analyses of PANSS and SANS-SAPS in schizophrenia: their stability in an acute phase. 1995 , 10, 97-106	41
1982	The role of serotonin in schizophrenia. 1995 , 5 Suppl, 11-23	46
1981	Insight in schizophrenia and its relationship to psychopathology. 1995 , 18, 21-8	103
1980	Neuropsychological and olfactory dysfunction in schizophrenia: relationship of frontal syndromes to syndromes of schizophrenia. 1995 , 17, 35-45	55
1979	A risk-benefit assessment of risperidone in schizophrenia. 1995 , 12, 139-45	19
1978	The Aims of Antipsychotic Medication. 1995 , 4, 8-16	19
1977	Routine assessment of patient progress: a multiformat, change-sensitive nurses' instrument for assessing psychotic inpatients. 1995 , 36, 289-95	9
1976	The frequency of associations between positive and negative symptoms and dysphoria in schizophrenia. 1995 , 36, 113-7	34
1975	Variability in BPRS definitions of positive and negative symptoms. 1995 , 17, 177-85	67
1974	Maintaining schizophrenic patients on benzodiazepines. 1995 , 17, 283-5	1
1973	Does affective blunting in schizophrenia reflect affective deficit or neuromotor dysfunction?. 1996 , 20, 301-6	32
1972	A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. 1996 , 19, 73-85	90

1971	The relationship of social cognition to ward behavior in chronic schizophrenia. 1996 , 20, 327-35	160
1970	Factor analysis of schizophrenic symptoms using the OPCRIT checklist. 1996 , 22, 233-9	61
1969	Do we need a European consensus on the use of antipsychotic medication?. 1996 , 11, 400-2	3
1968	Treatment-resistant schizophrenia: clinical experience with new antipsychotics. 1996 , 6 Suppl 2, S21-5	25
1967	Information processing, social skill, and gender in schizophrenia. 1996 , 59, 213-20	24
1966	Affective reactivity of cognitive functioning and family history in schizophrenia. 1996 , 39, 59-64	21
1965	Gating of auditory P50 in schizophrenics: unique effects of clozapine. 1996 , 40, 181-8	181
1964	Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. 1996 , 39, 296-8	50
1963	Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. 1996 , 39, 213-5	72
1962	Regional cerebral blood flow in patients with schizophrenia: relevance to symptom structures. 1996 , 67, 49-58	31
1961	Bilateral transfer deficit in schizophrenia: a trait marker. 1996 , 64, 115-20	9
1960	A comparison of instrument sensitivity to negative symptom change. 1996 , 63, 67-75	22
1959	Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment. 1996 , 37, 205-15	21
1958	Anhedonia and negative symptomatology in chronic schizophrenia. 1996 , 37, 5-11	27
1957	Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. 1996 , 40, 1298-300	101
1956	Phospholipases: in search of a genetic base of schizophrenia. 1996 , 55, 119-22	11
1955	Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. 1996 , 68, 23-30	16
1954	Validation of the Scale of Functioning in Older Outpatients With Schizophrenia. 1996 , 4, 218-228	24

1953	Risperidone in Elderly Schizophrenic Patients: An Open-Label Trial. 1996 , 4, 173-179	25
1952	A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. 1996 , 19, 205-12	170
1951	Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol. 1996 , 50, 357-63	5
1950	Adverse effects of antipsychotic agents. Do newer agents offer advantages?. 1996 , 51, 895-930	64
1949	Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures. 1996 , 168, 702-8	17
1948	Risperidone for Treatment-Resistant Schizophrenia: Initial Clinical Experience in a State Hospital. 1996 , 12, 271-275	6
1947	Performance on the Wisconsin Card Sorting Test as a predictor of rehospitalization in schizophrenia. 1996 , 184, 319-21	18
1946	Validation of three dimensions of schizophrenic symptoms in a large unselected sample of patients. 1996 , 26, 669-79	77
1945	A case study of temporal lobe development in familial schizophrenia. 1996 , 26, 191-5	17
1944	Prediction of positive placebo response among chronic schizophrenic outpatients. 1996 , 184, 109-13	12
1943	Relationship between insight, educational background and cognition in schizophrenia. 1996 , 168, 718-22	53
1942	Clozapine: current status and role in the pharmacotherapy of schizophrenia. 1996 , 41, 161-6	12
1941	Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. 1996 , 93, 9235-40	1057
1940	Emotional overinvolvement in parents of patients with schizophrenia or related psychosis: demographic and clinical predictors. 1996 , 169, 622-30	52
1939	Levels of expectation for work activity in schizophrenia: Clinical and rehabilitation outcomes.. 1996 , 19, 71-76	11
1938	Residential alternatives to hospitalization for patients with severe and persistent mental illness: should patients with comorbid substance abuse be excluded?. 1996 , 23, 348-55	5
1937	A subscale for negative symptoms from the Comprehensive Psychopathological Rating Scale (CPRS): a comparison with the Schedule for Assessment of Negative Symptoms (SANS). 1996 , 246, 219-23	7
1936	Neurological soft signs in schizophrenia: assessment and correlates. 1996 , 246, 240-8	79

1935	Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. 1996 , 246, 279-84		132
1934	Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. 1996 , 94, 175-80		75
1933	Dopamine DRD2/Cys311 is not associated with chronic schizophrenia. 1996 , 67, 483-4		19
1932	Omega-3 fatty acid supplementation in schizophrenic patients. 1996 , 11, 39-46		50
1931	First-episode schizophrenia: I. Early course parameters. <i>Schizophrenia Bulletin</i> , 1996 , 22, 241-56	1.3	268
1930	First-episode schizophrenia: II. Premorbid patterns by gender. <i>Schizophrenia Bulletin</i> , 1996 , 22, 257-69	1.3	108
1929	Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. 1996 , 6, 139-45		22
1928	Depression in schizophrenia: a descriptive study. 1996 , 30, 354-7		20
1927	Identifying subtypes of schizophrenia by cluster analyses. <i>Schizophrenia Bulletin</i> , 1996 , 22, 545-55	1.3	61
1926	Communication disturbances in schizophrenia and mania. 1996 , 53, 358-64		122
1925	Wisconsin Card Sorting Test dimensions in schizophrenia: factorial, predictive, and divergent validity. 1997 , 19, 933-41		28
1924	A study of enhanced management in patients with treatment-resistant schizophrenia. 1997 , 11, 349-56		5
1923	Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. 1997 , 6, 1729-41		18
1922	Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. 1997 , 154, 782-91		273
1921	Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia. 1997 , 27, 1303-10		64
1920	A neuropsychological study of prefrontal lobe function in the positive and negative subtypes of schizophrenia. 1997 , 158, 487-94		26
1919	The evaluation and treatment of first-episode psychosis. <i>Schizophrenia Bulletin</i> , 1997 , 23, 653-61	1.3	73
1918	Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. 1997 , 170, 422-5		95

1917	Attribution Therapy for Paranoid Delusions: A Case Study. 1997 , 25, 269-280		12
1916	Risperidone: how good is the evidence for efficacy?. <i>Schizophrenia Bulletin</i> , 1997 , 23, 155-61	1.3	21
1915	The long-term course of childhood-onset schizophrenia: a 42-year followup. <i>Schizophrenia Bulletin</i> , 1997 , 23, 105-17	1.3	114
1914	Aggressive behaviour in schizophrenia: the role of psychopathology. 1997 , 31, 62-7		34
1913	The deficit syndrome of schizophrenia: towards heterogeneity. 1997 , 30, 257-62		7
1912	Clinical correlates of memory in schizophrenia: differential links between depression, positive and negative symptoms, and two types of memory impairment. 1997 , 154, 1538-43		63
1911	The use of videotaped assessment in relation to a study of enhanced management in treatment-resistant schizophrenia. 1997 , 11, 357-60		3
1910	[Disturbances of body experience in schizophrenic patients]. 1997 , 65, 323-36		21
1909	Factor structure of the Brief Psychiatric Rating Scale in schizophrenia.. 1997 , 9, 196-204		113
1908	An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. 1997 , 170, 507-10		60
1907	Neurocognitive correlates of positive and negative syndromes in schizophrenia. 1997 , 42, 1066-71		70
1906	The Nithsdale Schizophrenia Surveys. 16. Breast-feeding and schizophrenia: preliminary results and hypotheses. 1997 , 170, 334-7		40
1905	Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. 1997 , 54, 1089-95		126
1904	Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic. 1997 , 1, 231-9		33
1903	Clozapine response in early treatment-resistant schizophrenia. 1997 , 1, 261-8		3
1902	Treatment-home care as a complement to hospital psychiatric care. 1997 , 51, 43-48		
1901	Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. 1997 , 11, 65-71		64
1900	Risperidone in adolescents with schizophrenia: an open pilot study. 1997 , 36, 694-700		132

1899	The Dose Reduction in Schizophrenia (DORIS) Study: a final report. 1997 , 23, 31-43	9
1898	Aggressive behaviour and platelet 3H-paroxetine binding in schizophrenia. 1997 , 23, 61-7	13
1897	Factor-derived subsyndromes of schizophrenia and familial morbid risks. 1997 , 23, 231-8	50
1896	Neurocognitive deficits and neurological signs in schizophrenia. 1997 , 23, 139-46	67
1895	Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. 1997 , 25, 1-10	170
1894	Presynaptic dopaminergic function in the striatum of schizophrenic patients. 1997 , 23, 167-74	144
1893	Attentional vulnerability indicators in schizophrenia and bipolar disorder. 1997 , 23, 197-204	93
1892	Attention deficits assessed by Continuous Performance Test and Span of Apprehension Test in Japanese schizophrenic patients. 1997 , 23, 205-11	26
1891	Association of DNA polymorphism in the first intron of the tyrosine hydroxylase gene with disturbances of the catecholaminergic system in schizophrenia. 1997 , 23, 259-64	42
1890	Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects. 1997 , 25, 71-8	14
1889	Depressive symptoms in acute schizophrenic inpatients. 1997 , 25, 131-9	30
1888	Clinical symptom dimensions and deficits on the Continuous Performance Test in schizophrenia. 1997 , 25, 211-9	51
1887	Violence in schizophrenia: role of hallucinations and delusions. 1997 , 26, 181-90	142
1886	Reduced auditory P300 amplitude, medial temporal volume reduction and psychopathology in schizophrenia. 1997 , 26, 107-15	52
1885	Effects of schizophrenia and aging on pupillographic measures of working memory. 1997 , 27, 119-28	19
1884	Insight, neurocognitive function and symptom clusters in chronic schizophrenia. 1997 , 27, 37-44	102
1883	Neuroleptic dose reduction in older psychotic patients. 1997 , 27, 241-8	18
1882	Rating scale for the assessment of communication disorders in schizophrenics. 1997 , 12, 352-61	17

1881	Correlations between standard auditory evoked potentials and symptomatology in a group of 50 schizophrenic patients. 1997 , 12, 387-94	
1880	Cerebral investigation of healthy siblings of schizophrenics. 1997 , 12, 273-8	2
1879	The Glutamate Hypothesis of Schizophrenia. 1997 , 7, 47-67	15
1878	A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. 1997 , 337, 809-15	432
1877	Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia. 1997 , 76, 113-22	25
1876	Subjective experience and related symptoms in schizophrenia. 1997 , 38, 49-55	14
1875	Does insight affect long-term inpatient treatment outcome in chronic schizophrenia?. 1997 , 38, 283-8	94
1874	Insight and clinical correlates in schizophrenia. 1997 , 38, 117-23	54
1873	Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. 1997 , 349, 1735-9	133
1872	Use of a quantitative trait to map a locus associated with severity of positive symptoms in familial schizophrenia to chromosome 6p. 1997 , 61, 1388-96	62
1871	The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?. 1997 , 41, 507-13	66
1870	Factor structure of symptoms in functional psychoses. 1997 , 42, 806-15	67
1869	Affect recognition in schizophrenia: a function of global impairment or a specific cognitive deficit. 1997 , 71, 105-13	219
1868	Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine. 1997 , 72, 161-6	87
1867	Aggressive behaviour in schizophrenia: role of state versus trait factors. 1997 , 72, 41-50	14
1866	Relationship between the five-factor model of personality and unipolar, bipolar and schizophrenic patients. 1997 , 70, 83-94	135
1865	Construct validity of negative symptoms: an empirical and conceptual review. 1997 , 17, 167-89	46
1864	Recent Advances in the Understanding of Negative Symptoms in Schizophrenia. 1997 , 3, 111-117	

1863	Executive (frontal) dysfunction and negative symptoms in schizophrenia: apparent gender differences in 'static' v. 'progressive' profiles. 1997 , 171, 154-8	18
1862	Rorschach Findings and Neuropsychological Comparison of First-Episode Psychotic Depression with First-Episode Nonpsychotic Depression and Schizophrenia: A Preliminary Report. 1997 , 22, 198-210	4
1861	Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. 1997 , 95, 40-3	99
1860	The Nithsdale Schizophrenia Surveys. XV. Social adjustment in schizophrenia: associations with gender, symptoms and childhood antecedents. 1997 , 95, 254-8	18
1859	A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. 1997 , 95, 343-50	17
1858	Psychopathological and SPECT findings in never-treated schizophrenia. 1997 , 96, 51-7	47
1857	A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. 1997 , 96, 265-73	202
1856	Neuropsychological deficits in probands from multiply-affected schizophrenic families. 1997 , 31, 497-508	7
1855	Psychological treatments for schizophrenia. 1997 , 2, 5-10	
1854	Attention and clinical symptoms in schizophrenia. 1997 , 68, 343-59	48
1853	A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. 1997 , 6, 21-6	127
1852	General life satisfaction and domain-specific quality of life in chronic schizophrenic patients. 1997 , 6, 265-73	37
1851	Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms. 1997 , 247, 1-5	10
1850	Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. 1997 , 247, 291-6	22
1849	In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole--a 123I IBZM single photon emission tomography (SPET) study. 1997 , 130, 152-8	29
1848	Schizophrenia: revisited. 1997 , 4, 275-85	3
1847	Violence in schizophrenia and the syndrome of disorganisation. 1997 , 7, 131-139	10
1846	The use of risperidone in severely demented patients with persistent vocalizations. 1997 , 12, 73-7	25

1845	The relationship between insight, illness and treatment outcome in schizophrenia. 1998 , 69, 1-22	52
1844	Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. 1998 , 1, 318-23	487
1843	Dopamine D3 receptor gene variants and substance abuse in schizophrenia. 1998 , 3, 337-41	70
1842	Conceptualization and measurement of insight. 1998 , 12, 32-40	14
1841	Predictive saccade behavior is enhanced in schizophrenia. 1998 , 68, B81-91	21
1840	Calgary Depression Scale for Schizophrenia: a study of the validity of a French-language version in a population of schizophrenic patients. 1998 , 97, 36-41	40
1839	Neurocognitive function and insight in schizophrenia: support for an association with impairments in executive function but not with impairments in global function. 1998 , 97, 297-301	96
1838	Sex difference in age at onset of schizophrenia: discrepant findings from India. 1998 , 97, 321-5	40
1837	Eye movements in patients with schizophrenia: visual stimuli, semantic content and psychiatric symptoms. 1998 , 97, 364-73	9
1836	Regional cerebral blood flow in first-episode schizophrenia patients before and after antipsychotic drug treatment. Scottish Schizophrenia Research Group. 1998 , 97, 440-9	22
1835	Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. 1998 , 98, 65-72	113
1834	Improvement of inter-rater reliability of PANSS items and subscales by a standardized rater training. 1998 , 98, 135-9	47
1833	Rehabilitation needs of institutionalized patients. 1998 , 98, 427-8	
1832	Is there an association between the effects of clozapine on the production of reactive oxygen metabolites by blood monocytes and clinical outcome in neuroleptic-resistant schizophrenia?. 1998 , 13, 231-237	2
1831	Neuropsychological impairment and psychopathology in first-episode schizophrenic patients related to the early course of illness. 1998 , 248, 70-7	30
1830	Dimensions of schizophrenic positive symptoms: an exploratory factor analysis investigation. 1998 , 248, 130-5	12
1829	Instruments for assessment of auditory hallucinations. 1998 , 12, 255-63	14
1828	Saccadic eye movements in schizophrenic patients. 1998 , 77, 9-19	85

1827	Affect recognition in deficit syndrome schizophrenia. 1998 , 77, 113-20	45
1826	Olfactory identification deficiency and WCST performance in men with schizophrenia. 1998 , 81, 251-7	29
1825	An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. 1998 , 81, 333-9	30
1824	Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. 1998 , 20, 58-71	47
1823	Abstraction is impaired at the perceptual level in schizophrenic patients. 1998 , 243, 93-6	8
1822	Smoking and cognitive deficits in schizophrenia: a pilot study. 1998 , 23, 263-6	50
1821	Insight and illness in chronic schizophrenia. 1998 , 39, 249-54	60
1820	Insight in paranoid schizophrenia—its relationship to psychopathology and premorbid adjustment. 1998 , 39, 255-60	55
1819	Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. 1998 , 43, 24-30	36
1818	Factor structure and clinical validity of competing models of positive symptoms in schizophrenia. 1998 , 44, 107-14	36
1817	P300 and the thought disorder factor extracted by factor-analytic procedures in schizophrenia. 1998 , 44, 115-20	59
1816	Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. 1998 , 44, 475-82	30
1815	High-density recording and topographic analysis of the auditory oddball event-related potential in patients with schizophrenia. 1998 , 44, 982-9	56
1814	D-serine added to antipsychotics for the treatment of schizophrenia. 1998 , 44, 1081-9	539
1813	Facial affect recognition and information processing in schizophrenia and bipolar disorder. 1998 , 32, 171-81	368
1812	Abnormal patterns of cerebral glucose metabolism in a pair of monozygotic twins with recent onset schizophrenia. 1998 , 2, 221-4	
1811	Resistance to Interference and Positive Symptomatology in Schizophrenia. 1998 , 3, 179-190	9
1810	Perceptual Organisation of Configural and Visual Patterns in Schizophrenia: Effects of Repeated Exposure. 1998 , 3, 209-223	80

1809	Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study. 1998 , 15, 29-35	13
1808	MRI correlates of treatment response in first episode psychosis. 1998 , 30, 81-90	32
1807	Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia. 1998 , 31, 185-96	47
1806	Training schizophrenic patients to manage their symptoms: predictors of treatment response to the German version of the Symptom Management Module. 1998 , 31, 121-30	15
1805	Validity study of the Brazilian version of the Calgary Depression Scale for Schizophrenia. 1998 , 32, 41-9	74
1804	Emotional response as a function of symptoms in schizophrenia. 1998 , 32, 31-9	64
1803	Left nostril olfactory identification impairment in a subgroup of male patients with schizophrenia. 1998 , 33, 35-43	32
1802	Evaluation of standardized rater training for the Positive and Negative Syndrome Scale (PANSS). 1998 , 32, 151-60	37
1801	Visual attention and symptoms in schizophrenia: a 1-year follow-up. 1998 , 34, 95-9	18
1800	Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics. 1998 , 13, 310-4	4
1799	Prediction of duration of psychosis before first admission. 1998 , 13, 346-52	61
1798	Treatment-refractory schizophrenia: Update on concepts and interventions. 1998 , 4, S18-S28	
1797	Comprehension of irony in Schizophrenia. 1998 , 3, 127-138	70
1796	Psychopathy: Theory, Research and Implications for Society. 1998 ,	40
1795	Acute and longer-term effects of risperidone in a case of first-episode catatonic schizophrenia. 1998 , 12, 314-7	22
1794	An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. 1998 , 31, 25-9	46
1793	Symptomatology and insight in schizophrenia. 1998 , 82, 227-33	22
1792	Psychopharmacological Treatment of Schizophrenia: What Social Workers Need to Know. 1998 , 8, 384-405	4

1791	Cerebral blood flow velocity in acute schizophrenic patients. A transcranial Doppler ultrasonography study. 1998 , 29, 1149-54		23
1790	Psychopathological dimensions and lack of insight in schizophrenia. 1998 , 83, 895-8		33
1789	D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. 1998 , 1, 95-101		19
1788	Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study. 1998 , 24, 343-60		35
1787	5-HT ₂ and D ₂ receptor occupancy of olanzapine in schizophrenia: a PET investigation. 1998 , 155, 921-8		308
1786	'Pfpopschizophrenie' revisited. Schizophrenia in people with mild learning disability. 1998 , 173, 145-53		112
1785	Relatives' participation in a clinical drug trial of schizophrenic outpatients improves their psychological well-being. 1998 , 52, 389-393		3
1784	Positive and negative syndromes, and Borna disease virus infection in schizophrenia. 1998 , 37, 59-64		16
1783	Disturbances of affective prosody in patients with schizophrenia; a cross sectional study. 1998 , 64, 375-8		37
1782	Postmortem studies in schizophrenia. <i>Schizophrenia Bulletin</i> , 1998 , 24, 325-41	1.3	185
1781	"Full recovery" from schizophrenia in the long term: a ten-year follow-up of eight former schizophrenic patients. 1998 , 61, 20-34		28
1780	A community-based clinic survey of antidepressant use in persons with schizophrenia. 1998 , 43, 513-6		6
1779	Low-dimensional chaos in bipolar disorder?. 1998 , 55, 275-6		10
1778	Family caregiving in schizophrenia: domains and distress. <i>Schizophrenia Bulletin</i> , 1998 , 24, 609-18	1.3	170
1777	Jet lag and relapse of schizoaffective psychosis despite maintenance clozapine treatment. 1998 , 173, 268		9
1776	Untreated psychosis and long-term outcome in schizophrenia. <i>Schizophrenia Bulletin</i> , 1998 , 24, 34-5	1.3	4
1775	Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. 1998 , 55, 618-25		50
1774	Treatment-refractory Schizophrenia: Update on Concepts and Interventions. 1998 , 4, S18-S28		1

1773	Impairment of semantic categorization processes among thought-disordered schizophrenic patients. 1998 , 43, 271-8	4
1772	Symptom structure in schizophrenia: two-, three- or four-factor models?. 1998 , 31, 120-30	41
1771	Auditory mismatch negativity in schizophrenia: topographic evaluation with a high-density recording montage. 1998 , 155, 1281-4	101
1770	Interrater reliability of the Japanese version of the Positive and Negative Syndrome Scale and the appraisal of its training effect. 1998 , 52, 467-70	48
1769	Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. 1998 , 43, 1018-25	43
1768	5-HT _{2A} receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT _{2A} ligand 123I-5-I-R-91150. 1998 , 173, 236-41	91
1767	[Subsyndromes in chronic schizophrenia. The heterogeneity of schizophrenic psychoses]. 1998 , 66, 15-31	3
1766	[German version of the Snaith-Hamilton-Pleasure Scale (SHAPS-D). Anhedonia in schizophrenic and depressive patients]. 1998 , 66, 407-13	50
1765	A comparative study of insight scales and their relationship to psychopathological and clinical variables. 1998 , 28, 437-46	197
1764	Theory of mind and psychoses. 1998 , 28, 397-405	187
1763	Aspects of dysphoria and symptoms of schizophrenia. 1998 , 28, 1433-41	44
1762	Electrodermal activity and obstetric complications in schizophrenia.. 1998 , 107, 228-237	7
1761	P50 suppression in recent-onset schizophrenia: Clinical correlates and risperidone effects.. 1998 , 107, 691-698	108
1760	Kognitiv funktion, negative symptomter, livskvalitet. 1998 , 51, 31-37	
1759	Behandlingsresistent skizofreni. 1998 , 51, 9-23	
1758	The Partial Responder to Antipsychotic Medications: Putting the Pieces together. 1998 , 4, S10-S17	
1757	Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy. 1998 , 55, 1003-16	39
1756	Letters to the Editor. 1998 , 43, 746-750	14

1755	Group treatment for substance abuse in schizophrenia. 1998 , 43, 843-5		16
1754	First-episode schizophrenia with long duration of untreated psychosis: Pathways to care. 1998 , 172, 45-52		157
1753	Effect of substance misuse in early psychosis. 1998 , 172, 134-136		95
1752	Pharmacotherapy of first-episode schizophrenia. 1998 , 172, 66-70		53
1751	Which atypical antipsychotic. 1998 , 172, 106-9		45
1750	Psychopharmacology of olanzapine: A review. 1999 , 174, 52-58		36
1749	Plasmapheresis in thyrotoxicosis. 1999 , 131, 71-2		13
1748	Nitric Oxide and Impaired Oxygenation before and after Liver Transplantation. 1999 , 131, 69		
1747	Psychotherapy for depression in diabetes. 1999 , 131, 70; author reply 70-1		
1746	Elevated international normalized ratio associated with trovafloxacin. 1999 , 131, 72		2
1745	Attributional style and depression in schizophrenia. 1999 , 44, 697-700		4
1744	Insight and major mental illness: an update for clinicians. 1999 , 5, 163-170		7
1743	Contemplating the white coat. 1999 , 131, 73; author reply 74		2
1742	Contemplating the white coat. 1999 , 131, 74		2
1741	Abnormal involuntary movements in people with schizophrenia in the community. 1999 , 171, 111-2		2
1740	Functional neuropsychophysiological asymmetry in schizophrenia: a review and reorientation. <i>Schizophrenia Bulletin</i> , 1999 , 25, 91-120	1.3	143
1739	Effects of risperidone on auditory event-related potentials in schizophrenia. 1999 , 2, 299-304		103
1738	Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. <i>Schizophrenia Bulletin</i> , 1999 , 25, 721-9	1.3	163

- 1737 Effects of cognitive treatment in psychiatric rehabilitation. *Schizophrenia Bulletin*, **1999**, 25, 657-76 1.3 202
- 1736 Structured Interview for Assessing Perceptual Anomalies (SIAPA). *Schizophrenia Bulletin*, **1999**, 25, 577-923 97
- 1735 Reliability and validity of the functional assessment rating scale. **1999**, 84, 389-91 17
- 1734 Functional imaging of memory retrieval in deficit vs nondéficit schizophrenia. **1999**, 56, 1117-23 148
- 1733 Quality of life and new antipsychotics in schizophrenia. Are patients better off?. **1999**, 45, 268-75 57
- 1732 Cognitive deficits and psychopathology in institutionalized versus community-dwelling elderly schizophrenia patients. **1999**, 12, 11-5 30
- 1731 Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. **1999**, 96, 13432-7 241
- 1730 The electrically elicited startle blink reflex in patients with schizophrenia: A threshold study of different reflex components. **1999**, 39, 76-80 8
- 1729 Impairments in judgment of chimeric faces by schizophrenic and affective patients. **1999**, 97, 185-209 17
- 1728 Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. **1999**, 156, 869-75 224
- 1727 Cognitive Measures: What Can They Tell Us About Social Competence?. **1999**, 3, 99-123 2
- 1726 Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. **1999**, 13, 358-71 402
- 1725 Care provision and community adjustment of rural consumers with serious mental illness. **1999**, 13, 19-29 1
- 1724 Folate levels in psychiatric outpatients. **1999**, 53, 531-3 27
- 1723 Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. **1999**, 24, 49-52 23
- 1722 Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. **1999**, 24, 369-74 48
- 1721 PTSD and comorbid psychotic disorder: comparison with veterans diagnosed with PTSD or psychotic disorder. **1999**, 12, 73-88 90
- 1720 "Ecstasy"-induced changes of cerebral glucose metabolism and their correlation to acute psychopathology. An 18-FDG PET study. **1999**, 26, 1572-9 16

1719	A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. 1999 , 99, 160-70	79
1718	Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [^{18F}]FDG. 1999 , 20, 565-81	116
1717	No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. 1999 , 20, 650-61	43
1716	D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. 1999 , 21, 203-10	63
1715	Reasons for non-prescription of clozapine in treatment-resistant schizophrenia. 1999 , 9, 207-214	10
1714	Are importance ratings useful in the assessment of subjective quality of life in schizophrenic patients?. 1999 , 8, 204-211	4
1713	Syndromes of schizophrenia and language dysfunction. 1999 , 55, 233-40	5
1712	Clozapine-induced decrease in the production of reactive oxygen metabolites by monocytes in vitro may predict clinical response to clozapine in treatment-resistant schizophrenia. 1999 , 14, 203-209	
1711	Using measures of readiness to change in individuals with schizophrenia. 1999 , 25, 151-61	15
1710	Active and remitted schizophrenia: psychopathological and regional cerebral blood flow findings. 1999 , 90, 17-30	23
1709	Positive and negative symptoms and regional cerebral perfusion in antipsychotic-naive schizophrenic patients: a high-resolution SPECT study. 1999 , 90, 159-68	29
1708	Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. 1999 , 92, 33-44	34
1707	Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. 1999 , 86, 113-29	85
1706	Generality and specificity of emotion-recognition deficit in schizophrenic patients with positive and negative symptoms. 1999 , 87, 39-46	65
1705	Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report. 1999 , 88, 119-30	153
1704	Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. 1999 , 88, 107-17	146
1703	Evaluation of depression in schizophrenia: psychometric properties of a French version of the Calgary Depression Scale. 1999 , 89, 123-32	25
1702	Executive functioning and verbal memory in young patients with unipolar depression and schizophrenia. 1999 , 89, 171-87	183

1701	P300 and disability of daily life in schizophrenia. 1999 , 23, 423-30	14
1700	The influence of psychotic states on the autonomic nervous system in schizophrenia. 1999 , 31, 147-54	102
1699	Learned control of slow potential interhemispheric asymmetry in schizophrenia. 1999 , 34, 341-8	60
1698	Clozapine treatment and post-traumatic psychotic disorders: A case report. 1999 , 9, 257-258	1
1697	Distress Scale for Adverse Symptoms: A new instrument for measuring the relationship between adverse drug symptoms and associated distress. 1999 , 9, 258	7
1696	Selective impairment of sensory-perceptual functions in unaffected relatives of schizophrenic patients. 1999 , 9, 258-259	
1695	Three dimensions of depression in patients with acute psychotic disorders: a replication study. 1999 , 40, 449-57	9
1694	Symptom correlates of global measures of severity in schizophrenia. 1999 , 40, 458-61	21
1693	P300 subcomponents reflect different aspects of psychopathology in schizophrenia. 1999 , 45, 116-26	55
1692	Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. 1999 , 45, 1653-6	25
1691	Genetic antecedents of dopamine dysfunction in schizophrenia. 1999 , 45, 1143-50	14
1690	Psychotic features and illness severity in combat veterans with chronic posttraumatic stress disorder. 1999 , 45, 846-52	147
1689	Elevation of CD5+ B lymphocytes in schizophrenia. 1999 , 46, 110-8	33
1688	Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. 1999 , 45, 1128-37	324
1687	Spatial working memory deficits and clinical symptoms in schizophrenia: a 4-month follow-up study. 1999 , 46, 392-400	131
1686	Eye movements reflect impaired face processing in patients with schizophrenia. 1999 , 46, 963-9	85
1685	Increased dopamine transmission in schizophrenia: relationship to illness phases. 1999 , 46, 56-72	595
1684	Deficit psychopathology and a paradigm shift in schizophrenia research. 1999 , 46, 352-60	53

1683	Risperidone in the Treatment of Elderly Patients With Psychotic Disorders. 1999 , 7, 132-138	38
1682	A Bioequivalence Study of Brand and Generic Clozapine in Patients with Schizophrenia. 1999 , 17, 51-58	6
1681	Slow EEG potentials (contingent negative variation and post-imperative negative variation) in schizophrenia: their association to the present state and to Parkinsonian medication effects. 1999 , 110, 1175-92	43
1680	Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. 1999 , 35, 51-68	696
1679	Event-related potentials in schizophrenic patients during a degraded stimulus version of the visual continuous performance task. 1999 , 35, 263-78	23
1678	Correlates of insight and insight change in schizophrenia. 1999 , 35, 247-53	108
1677	Impairment in visual-spatial function in catatonia: a neuropsychological investigation. 1999 , 37, 133-47	42
1676	Application of pharmacogenetics to psychotic disorders: the first consensus conference. The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies. 1999 , 37, 191-6	32
1675	Investigating theory of mind in schizophrenia: influence of verbalization in disorganized and non-disorganized patients. 1999 , 37, 183-90	147
1674	Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. 1999 , 35 Suppl, S23-33	43
1673	Internal consistency, temporal stability and neuropsychological correlates of three cognitive components of the Positive and Negative Syndrome Scale (PANSS). 1999 , 38, 27-35	48
1672	A rating scale for psychotic symptoms (RSPS) part I: theoretical principles and subscale 1: perception symptoms (illusions and hallucinations). 1999 , 38, 101-22	24
1671	Month of birth in deficit and non-deficit schizophrenic patients. 1999 , 14, 349-51	13
1670	Discriminant cognitive factors in responder and non-responder patients with schizophrenia. 1999 , 14, 442-50	14
1669	Psychometric qualities of the French version of the Heinrichs quality of life rating scale. 1999 , 14, 386-91	8
1668	Apolipoprotein E-varepsilon4 frequency in deficit schizophrenia. 1999 , 14, 148-51	8
1667	Fluency versus conscious recollection in category-production performance: the performance of schizophrenic patients. 1999 , 39, 100-15	10
1666	Optimal haloperidol dosage in first-episode psychosis. 1999 , 44, 164-7	31

1665	Anhedonia in the deficit syndrome of schizophrenia. 1999 , 32, 207-19			20
1664	Serum concentrations and clinical effects of risperidone in schizophrenic patients in Singapore preliminary report. 1999 , 47, 460-461			9
1663	Demographics, Prevalence, and Clinical Features of the Schizo-obsessive Subtype of Schizophrenia. 1999 , 4, 50-6			14
1662	An exploration of the psychometric properties of the French version of the Positive and Negative Syndrome Scale. 1999 , 44, 893-900			18
1661	Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia. 1999 , 44, 887-92			6
1660	Personality and psychopathology in schizophrenia: the association between personality traits and symptoms. 1999 , 62, 36-48			68
1659	Olanzapine versus haloperidol treatment in first-episode psychosis. 1999 , 156, 79-87			181
1658	Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia. 1999 , 174, 505-11			114
1657	How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. <i>Schizophrenia Bulletin</i> , 1999 , 25, 709-19	1.3		54
1656	Neurocognitive and social functioning in schizophrenia. <i>Schizophrenia Bulletin</i> , 1999 , 25, 173-82	1.3		241
1655	Altered parallel auditory processing in schizophrenia patients. <i>Schizophrenia Bulletin</i> , 1999 , 25, 601-7	1.3		13
1654	[Frequency of immunologic disorders in acute schizophrenia]. 1999 , 67, 218-24			
1653	[Aspects of cerebral connectivity in schizophrenia. A comparative CBF study on treated schizophrenics before and after medication]. 1999 , 67, 318-26			10
1652	How do people with schizophrenia explain the behaviour of others? A study of theory of mind and its relationship to thought and speech disorganization in schizophrenia. 1999 , 29, 613-20			200
1651	Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. 1999 , 156, 88-93			59
1650	Parenting and adjustment in schizophrenia. 1999 , 50, 239-43			18
1649	Real-World Pharmacotherapy with Novel Antipsychotics. 1999 , 5, 37-43			1
1648	A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. 1999 , 56, 21-7			349

1647	Transcallosal inhibition and motor conduction studies in patients with schizophrenia using transcranial magnetic stimulation. 1999 , 175, 375-9		65
1646	Training Individuals with Schizophrenia to Manage Their Illnesses: Experiences from Germany and Switzerland. 1999 , 3, 246-267		7
1645	Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia. 2000 , 176, 290-3		34
1644	Sertindole for schizophrenia. 2000 , CD001715		9
1643	Ziprasidone for schizophrenia and severe mental illness. 2000 , CD001945		11
1642	Chronic late-onset schizophrenia-like psychosis that remitted: revisiting Newton's psychosis?. 2000 , 157, 444-9		14
1641	Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. 2000 , 157, 287-9		59
1640	A program for relapse prevention in schizophrenia: a controlled study. 2000 , 57, 277-83		160
1639	Letters to the Editor. 2000 , 45, 196-202		0
1638	Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. 2000 , 157, 987-93		66
1637	Is anhedonia a specific dimension in chronic schizophrenia?. <i>Schizophrenia Bulletin</i> , 2000 , 26, 495-506	1.3	29
1636	Clozapine augmentation: safety and efficacy. <i>Schizophrenia Bulletin</i> , 2000 , 26, 421-40	1.3	55
1635	Risk factors for homelessness among indigent urban adults with no history of psychotic illness: a case-control study. 2000 , 90, 258-63		48
1634	Experience of caregiving: relatives of people experiencing a first episode of psychosis. 2000 , 177, 529-33		120
1633	Differences in health values among patients, family members, and providers for outcomes in schizophrenia. 2000 , 38, 1011-21		46
1632	Theta rhythm increases in left superior temporal cortex during auditory hallucinations in schizophrenia: a case report. 2000 , 11, 3283-7		87
1631	Risperidone in the treatment of patients with Alzheimer's disease with negative symptoms. 2000 , 12, 527-36		21
1630	Can verbalization remedy the theory of mind deficit in schizophrenia?. 2000 , 33, 246-51		51

1629	Course patterns of psychosocial functioning in schizophrenia patients attending a vocational rehabilitation program. <i>Schizophrenia Bulletin</i> , 2000 , 26, 681-98	1.3	31
1628	A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. 2000 , 30, 95-105		123
1627	The perception of self-produced sensory stimuli in patients with auditory hallucinations and passivity experiences: evidence for a breakdown in self-monitoring. 2000 , 30, 1131-9		350
1626	Continuous performance test differences among schizophrenic out-patients living in high and low expressed emotion environments. 2000 , 30, 1141-53		8
1625	Determinants of neurological dysfunction in first episode schizophrenia. 2000 , 30, 1433-41		95
1624	Object relations and reality testing in early- and late-onset schizophrenia. 2000 , 56, 505-17		7
1623	Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. 2000 , 15, 1230-7		75
1622	A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. 2000 , 15, 506-14		75
1621	Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. 2000 , 25, 131-7		80
1620	Use of quantitative rating scales to assess outcome in schizophrenia prevention studies. 2000 , 34, S150-S160		
1619	The classification of first episode schizophrenia: a cluster-analytical approach. 2000 , 102, 26-31		33
1618	Patient education in schizophrenia: a review. 2000 , 102, 98-106		52
1617	Measurement of violence during in-patient treatment and association with psychopathology. 2000 , 102, 107-12		67
1616	Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. 2000 , 102, 203-10		150
1615	Outcome of schizophrenia in a non-industrialized society: comparative study between Bali and Tokyo. 2000 , 101, 148-52		15
1614	Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. 2000 , 5, 150-8		109
1613	Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. 2000 , 5, 418-24		73
1612	Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. 2000 , 5, 558-62		156

1611	Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. 2000 , 22, 311-9	51
1610	Psychiatric rehabilitation of schizophrenia: Unresolved issues, current trends, and future directions. 2000 , 9, 227-247	28
1609	Comparison of preferences for health outcomes in schizophrenia among stakeholder groups. 2000 , 34, 201-10	34
1608	Neuromuscular and psychomotor abnormalities in patients with schizophrenia and their first-degree relatives. 2000 , 34, 355-64	11
1607	Health values of patients with bipolar disorder. 2000 , 9, 579-86	22
1606	Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. 2000 , 12, 11-8	11
1605	Employment outcomes in family-aided assertive community treatment. 2000 , 70, 203-14	86
1604	Stimulant psychosis: symptom profile and acute clinical course. 2000 , 9, 28-37	99
1603	Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. 2000 , 68, 242-4	244
1602	Selective impairments in the stress response in schizophrenic patients. 2000 , 149, 319-25	146
1601	Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. 2000 , 150, 132-40	62
1600	High 5HT2A receptor occupancy in M100907-treated schizophrenic patients. 2000 , 148, 400-3	51
1599	[Evaluation of standardized training for the "Positive and Negative Syndrome Scale" (PANSS)]. 2000 , 71, 195-204	13
1598	[The Eppendorf Schizophrenia Inventory (ESI). Development and evaluation of a questionnaire for assessment of characteristic self perception of cognitive dysfunctions by schizophrenic patients]. 2000 , 71, 885-92	17
1597	[Community psychiatric management of severely ill schizophrenic patients. An exemplary case study]. 2000 , 71, 915-8	2
1596	Differential sustained attention/vigilance changes over time in schizophrenics and controls during a degraded stimulus Continuous Performance Test. 2000 , 250, 24-30	32
1595	A study of visual and auditory verbal working memory in schizophrenic patients compared to healthy subjects. 2000 , 250, 79-85	23
1594	Relationships between subjective experiences of deficit and other psychopathological features in schizophrenia. 2000 , 33, 110-4	11

1593	Third ventricle enlargement and developmental delay in first-episode psychosis: preliminary findings. 2000 , 177, 354-9		33
1592	Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. 2000 , 157, 269-71		130
1591	IS TARGETING COGNITIVE THERAPY DURING RELAPSE IN PSYCHOSIS FEASIBLE?. 2000 , 28, 161-174		21
1590	Use of Quantitative Rating Scales to Assess Outcome in Schizophrenia Prevention Studies. 2000 , 34, A150-A160		2
1589	Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study. 2000 , 12, 91-4		106
1588	Sertindole improves both the positive and negative symptoms of schizophrenia: Results of a phase III trial. 2000 , 4, 55-62		31
1587	Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. 2000 , 157, 514-20		844
1586	Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. 2000 , 97, 8104-9		822
1585	Determinants of quality of life at first presentation with schizophrenia. 2000 , 176, 173-6		151
1584	Visual pointing and speed / accuracy trade-off in schizophrenia. 2000 , 5, 123-134		8
1583	Multiple imputation compared with some informative dropout procedures in the estimation and comparison of rates of change in longitudinal clinical trials with dropouts. 2000 , 10, 165-81		22
1582	Cognitive impairment and enduring negative symptoms: a comparative study of geriatric and nongeriatric schizophrenia patients. <i>Schizophrenia Bulletin</i> , 2000 , 26, 867-78	1.3	34
1581	Psychopathological syndromes of schizophrenia: evaluation of the dimensional structure of the positive and negative syndrome scale. <i>Schizophrenia Bulletin</i> , 2000 , 26, 167-77	1.3	110
1580	Neuropsychological deficit in siblings discordant for schizophrenia. <i>Schizophrenia Bulletin</i> , 2000 , 26, 893-902		106
1579	Characteristic subjective experiences of schizophrenia. <i>Schizophrenia Bulletin</i> , 2000 , 26, 921-31	1.3	35
1578	Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. <i>Schizophrenia Bulletin</i> , 2000 , 26, 659-66	1.3	85
1577	[Clinical characteristics of patients with tardive dyskinesias]. 2000 , 68, 321-31		7
1576	Random number generation deficit in schizophrenia characterized by oral vs written response modes. 2000 , 91, 1091-105		13

1575	Olanzapine: an atypical antipsychotic for schizophrenia. 2000 , 1, 305-23	13
1574	Efficacy and Tolerability of Olanzapine in Elderly Patients with Psychotic Disorders: A Prospective Study. 2000 , 12, 11-18	27
1573	Features of structural brain abnormality detected in first-episode psychosis. 2000 , 157, 1829-34	90
1572	Loss Of Trust: Correlates Of The Comorbidity Of Ptsd and Severe Mental Illness. 2000 , 5, 103-123	8
1571	Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. 2000 , 157, 1379-89	325
1570	In vivo investigation of white matter pathology in schizophrenia with magnetisation transfer imaging. 2000 , 68, 70-4	83
1569	Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. 2000 , 157, 1835-42	311
1568	Use of quantitative rating scales to assess outcome in schizophrenia prevention studies. 2000 , 34 Suppl, S150-60	1
1567	Neuropsychological and clinical correlates of antisaccade task performance in schizophrenia. 2000 , 54, 866-71	52
1566	Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. 2000 , 321, 1371-6	704
1565	Influence of stimulus control on the excitability of the electrically elicited blink reflex in patients with schizophrenia. 2000 , 47, 43-50	5
1564	Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients. 2000 , 47, 61-70	187
1563	Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. 2000 , 47, 371-9	129
1562	Muscle biopsy, macro EMG, and clinical characteristics in patients with schizophrenia. 2000 , 47, 991-9	22
1561	The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. 2000 , 31, 371-84	271
1560	Paroxetine binding in aggressive schizophrenic patients. 2000 , 94, 77-81	13
1559	Higher levels of serum copper in schizophrenic patients treated with depot neuroleptics. 2000 , 94, 51-8	26
1558	Estrogen affects cognition in women with psychosis. 2000 , 94, 201-9	20

1557	Semantic verbal fluency deficit as a familial trait marker in schizophrenia. 2000 , 95, 133-48	68
1556	Positive symptomatology and source-monitoring failure in schizophrenia--an analysis of symptom-specific effects. 2000 , 95, 119-31	159
1555	A prospective longitudinal 10-year study of schizophrenia's three major factors and depression. 2000 , 97, 61-77	64
1554	Emotional discomfort and impairments in verbal memory in schizophrenia. 2000 , 97, 51-9	20
1553	Fixation stability in schizophrenia, bipolar, and control subjects. 2000 , 97, 119-28	23
1552	The effect of clozapine on the speed and accuracy of information processing in schizophrenia. 2000 , 24, 1329-38	17
1551	Evolution of plasma homovanillic acid (HVA) levels during treatment in schizo-affective disorder. 2000 , 24, 1319-28	3
1550	Clozapine and negative symptoms. An open study. 2000 , 24, 373-84	7
1549	Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. 2000 , 98, 163-75	65
1548	Aspects cognitifs des hallucinations auditives chez les patients schizophrènes. 2000 , 65, 325-339	3
1547	Priapism associated with risperidone treatment. 2000 , 4, 237-9	8
1546	Pharmacoeconomics of Clozapine, Risperidone and Olanzapine. 2000 , 13, 47-76	9
1545	Schizophrenia in the Elderly. 2000 , 13, 103-115	13
1544	Rating Scales in Schizophrenia. 2000 , 14, 23-32	9
1543	Symptom dimensions, social network, and caregiver burden in chronic schizophrenia. 2000 , 54, 121-125	
1542	Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial. 2000 , 4, 47-54	12
1541	Prototypical profiles of the Brief Psychiatric Rating Scale. 2000 , 75, 373-86	12
1540	Causes and consequences of duration of untreated psychosis in schizophrenia. 2000 , 177, 511-5	265

1539	Event-related potentials in a working-memory task in schizophrenics and controls. 2000 , 46, 175-86	13
1538	Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS?. 2000 , 46, 81-9	32
1537	Alteration of event related potentials in siblings discordant for schizophrenia. 2000 , 41, 325-34	62
1536	Determinants of smoking behaviour in outpatients with schizophrenia. 2000 , 41, 373-81	76
1535	Regional cerebral blood flow in male schizophrenic patients performing an auditory discrimination task. 2000 , 42, 29-39	16
1534	Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). 2000 , 42, 231-9	145
1533	Event-related potentials and thought disorder in schizophrenia. 2000 , 42, 187-91	24
1532	Habituation of the blink reflex in first-episode schizophrenia, psychotic depression and non-psychotic depression. 2000 , 44, 69-79	37
1531	Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. 2000 , 43, 135-45	197
1530	Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. 2000 , 44, 47-56	206
1529	Context-dependent information processing in patients with schizophrenia. 2000 , 45, 93-101	63
1528	Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. 2000 , 45, 1-9	146
1527	Leukotomy revisited: late cognitive and behavioral effects in chronic institutionalized schizophrenics. 2000 , 43, 57-64	14
1526	Perceptual organization, the disorganization syndrome, and context processing in chronic schizophrenia. 2000 , 43, 11-20	203
1525	Visual search in schizophrenia: latent inhibition and novel pop-out effects. 2000 , 45, 145-56	104
1524	Self-Appraisal of Illness Questionnaire (SAIQ): relationship to researcher-rated insight and neuropsychological function in schizophrenia. 2000 , 45, 203-11	105
1523	Asymmetrical olfactory acuity and neuroleptic treatment in schizophrenia. 2000 , 44, 221-32	36
1522	Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). 2000 , 15, 321-9	78

1521	Social integration and the quality of life of schizophrenic patients in different types of complementary care. 2000 , 15, 450-60	22
1520	Actigraphic monitoring (actigraphy) of circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisia. 2000 , 10, 171-6	29
1519	MEG gamma band activity in schizophrenia patients and healthy subjects in a mental arithmetic task and at rest. 2000 , 111, 2079-87	135
1518	Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. 2000 , 48, 99-109	424
1517	Relationships between depression and psychotic symptoms of schizophrenia during an acute episode and stable period. 2001 , 47, 135-40	54
1516	Relationship of extrapyramidal symptoms to age at onset and drug treatment in middle-aged and elderly schizophrenic patients. 2001 , 47, 69-75	17
1515	Dopamine transporter density in young patients with schizophrenia assessed with [¹²³ I]FP-CIT SPECT. 2001 , 47, 59-67	70
1514	Relationship of the factor structure of psychopathology in schizophrenia to the timing of initial intervention with antipsychotics. 2001 , 50, 95-103	8
1513	Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients. 2001 , 49, 231-41	120
1512	Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. 2001 , 49, 243-51	259
1511	Estrogen - a potential treatment for schizophrenia. 2001 , 48, 137-44	211
1510	Psychomotor slowing and planning deficits in schizophrenia. 2001 , 48, 317-33	79
1509	Memory and attention deficits in drug naive patients with schizophrenia. 2001 , 48, 45-55	50
1508	Stroop interference and facilitation effects in first-episode schizophrenic patients. 2001 , 48, 29-44	34
1507	Auditory distraction and thought disorder in chronic schizophrenic inpatients. Evidence for separate contributions by incapacity and poor allocation and a subsyndrome related to the allocation deficit. 2001 , 51, 163-70	10
1506	Cerebral gray and white matter reductions and clinical correlates in patients with early onset schizophrenia. 2001 , 50, 19-26	155
1505	Duration of untreated psychosis predicts treatment outcome in an early psychosis program. 2001 , 47, 215-22	92
1504	A morphometric MRI study of the hippocampus in first-episode, neuroleptic-naïve schizophrenia. 2001 , 50, 3-7	37

1503	Clinical features of latent inhibition in schizophrenia. 2001 , 51, 149-61	120
1502	Language lateralization in schizophrenia, an fMRI study. 2001 , 52, 57-67	228
1501	Stability of exploratory eye movements as a marker of schizophrenia--a WHO multi-center study. World Health Organization. 2001 , 52, 203-13	74
1500	Phospholipid patterns of erythrocytes in schizophrenia: relationships to symptomatology. 2001 , 52, 121-6	26
1499	Early detection strategies for untreated first-episode psychosis. 2001 , 51, 39-46	178
1498	Saccadic and smooth-pursuit eye movements in deficit and non-deficit schizophrenia. 2001 , 48, 145-53	45
1497	Vulnerability to involuntary movements over a lifetime trajectory of schizophrenia approaches 100%, in association with executive (frontal) dysfunction. 2001 , 49, 79-87	22
1496	Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. 2001 , 16, 57-63	37
1495	Affective symptomatology in schizophrenia: a risk factor for tardive dyskinesia?. 2001 , 16, 71-4	6
1494	Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. 2001 , 16, 293-8	86
1493	Incidence of obsessive-compulsive phenomena in the course of acute schizophrenia and schizoaffective disorder. 2001 , 16, 336-41	44
1492	Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. 2001 , 11, 289-93	51
1491	Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. 2001 , 11, 295-9	20
1490	Olanzapine: an updated review of its use in the management of schizophrenia. 2001 , 61, 111-61	143
1489	Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. 2001 , 49, 510-22	147
1488	Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms?. 2001 , 49, 47-51	87
1487	Altered hemispheric asymmetry of auditory magnetic fields to tones and syllables in schizophrenia. 2001 , 49, 694-703	39
1486	Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. 2001 , 49, 52-63	156

1485	Source distribution of neuromagnetic slow waves and MEG-delta activity in schizophrenic patients. 2001 , 50, 108-16	72
1484	Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. 2001 , 50, 418-24	215
1483	Self, Solipsism, and Schizophrenic Delusions. 2001 , 8, 101-120	96
1482	Bimanual coordination in chronic schizophrenia. 2001 , 45, 325-41	12
1481	Deficit in schizophrenia: the relationship between negative symptoms and neurocognition. 2001 , 42, 64-9	29
1480	Improvement of patient attitude toward treatment among inpatients with schizophrenia and its related factors: controlled study of a psychological approach. 2001 , 42, 240-6	11
1479	Gender differences in a sample of schizophrenic outpatients. 2001 , 42, 301-5	50
1478	Factors affecting smoking in schizophrenia. 2001 , 42, 393-402	78
1477	A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. 2001 , 23, 1839-54	126
1476	Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach. 2001 , 23, 942-56	19
1475	The changes of biological markers and treatment efficacy in schizophrenia. 2001 , 25, 323-35	10
1474	Specific body image pathology in acute schizophrenia. 2001 , 101, 289-301	64
1473	Poor performance in smooth pursuit and antisaccadic eye-movement tasks in healthy siblings of patients with schizophrenia. 2001 , 101, 209-19	56
1472	Memory and executive function impairments in deficit syndrome schizophrenia. 2001 , 102, 29-37	86
1471	Concordance of deficit and non-deficit subtypes in siblings affected with schizophrenia. 2001 , 102, 59-64	7
1470	Assessment of reliability in the clinical evaluation of depressive symptoms among multiple investigators in a multicenter clinical trial. 2001 , 102, 163-73	21
1469	Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. 2001 , 102, 65-72	112
1468	Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients. 2001 , 103, 69-78	65

1467	No association between T102C polymorphism of serotonin-2A receptor gene and clinical phenotypes of Chinese schizophrenic patients. 2001 , 105, 175-85	52
1466	Semantic structure in schizophrenia as assessed by the category fluency test: effect of verbal intelligence and age of onset. 2001 , 105, 187-99	41
1465	Olanzapine treatment for patients with schizophrenia and substance abuse. 2001 , 21, 217-21	72
1464	Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. 2001 , 107, 87-97	20
1463	Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. 2001 , 107, 135-49	43
1462	Comparison of clinical and best-estimate research DSM-IV diagnoses in a Finnish sample of first-admission psychosis and severe affective disorder. 2001 , 55, 107-111	4
1461	Perospirone. 2001 , 15, 329-37; discussion 338	46
1460	The effect of treatment with risperidone, olanzapine or phenothiazines on cognitive functions in patients with schizophrenia. 2001 , 5, 249-56	7
1459	The clinical value of risperidone and olanzapine: A meta-analysis of efficacy and safety. 2001 , 5, 179-87	4
1458	Vocational rehabilitation for people with severe mental illness. 2001 , CD003080	108
1457	Determining the optimal dose of haloperidol in first-episode psychosis. 2001 , 15, 251-5	38
1456	Diagnosis of Schizophrenia: A Review. 2001 , 1-74	2
1455	Acute tryptophan depletion in schizophrenia. 2001 , 31, 75-84	34
1454	Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. 2001 , 16, 111-5	34
1453	A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. 2001 , 21, 389-97	184
1452	Subjective quality of life in schizophrenic outpatients in a Catalan urban site. 2001 , 189, 685-90	10
1451	Impact of clozapine prescription on inpatient resource utilization. 2001 , 189, 766-73	13
1450	A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. 2001 , 21, 360-8	27

1449	The relationship between insight and social skill in persons with severe mental illness. 2001 , 189, 822-9	51
1448	Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. 2001 , 16, 87-92	74
1447	Zotepine in the treatment of acute hospitalized schizophrenic episodes. 2001 , 16, 163-8	6
1446	Anhedonia in depression and schizophrenia: a reexamination. 2001 , 189, 735-40	26
1445	Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. 2001 , 24, 290-4	28
1444	The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia. 2001 , 21, 575-82	35
1443	Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. 2001 , 16, 265-74	16
1442	Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). 2001 , 55, 5-69	5
1441	Aberrant tyrosine transport across the cell membrane in patients with schizophrenia. 2001 , 58, 953-8	31
1440	Shortened duration of untreated first episode of psychosis: changes in patient characteristics at treatment. 2001 , 158, 1917-9	130
1439	Increased semantic and repetition priming in schizophrenic patients.. 2001 , 110, 67-75	40
1438	Measuring readiness-to-change substance misuse among psychiatric outpatients: I. Reliability and validity of self-report measures. 2001 , 62, 79-88	64
1437	Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response. 2001 , 46, 534-41	17
1436	Effects of long-term treatment with antipsychotics on serum leptin levels. 2001 , 179, 59-62	63
1435	Use of Olanzapine for Elderly Patients With Psychotic Disorders: A Review. 2001 , 13, 201-213	9
1434	Duration of untreated psychosis: are we ignoring the mode of initial development?. An extensive naturalistic case study of phenomenal continuity in first-episode schizophrenia. 2001 , 34, 8-14	25
1433	Basic symptoms and their contribution to the differential typology of acute schizophrenic and schizoaffective disorders. 2001 , 34, 15-22	6
1432	Medication treatments for schizophrenia: translating research findings into better outcomes. 2001 , 7, 260-5	1

1431	Drug development in psychiatry and genomics: from E. coli to man. 2001 , 7, 415-9	4
1430	Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. 2001 , 16, 325-30	36
1429	Impaired sensory processing as a basis for object-recognition deficits in schizophrenia. 2001 , 158, 1818-26	117
1428	Disturbed circadian rest-activity cycles in schizophrenia patients: an effect of drugs?. <i>Schizophrenia Bulletin</i> , 2001 , 27, 497-502	13 74
1427	A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. 2001 , 158, 1305-13	130
1426	Self-monitoring dysfunction and the positive symptoms of schizophrenia. 2001 , 34, 198-202	29
1425	Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. 2001 , 153, 238-43	101
1424	Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. 2001 , 155, 128-34	146
1423	Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A [123I]-IDEX SPECT study. 2001 , 156, 53-7	28
1422	P300 and symptom improvement in schizophrenia. 2001 , 158, 55-65	42
1421	Hypofrontality in neuroleptic-naive schizophrenic patients during the Wisconsin Card Sorting Test--a fMRI study. 2001 , 251, 66-71	66
1420	Sylvian fissure and medial temporal lobe structures in patients with schizophrenia: a magnetic resonance imaging study. 2001 , 55, 49-56	5
1419	Changes in auditory P300 with clinical remission in schizophrenia: effects of facial-affect stimuli. 2001 , 55, 347-52	12
1418	Criminality and aggression among psychotic in-patients: frequency and clinical correlates. 2001 , 103, 294-300	16
1417	Quality of life in treated and never-treated schizophrenic patients. 2001 , 103, 131-42	20
1416	A randomized, controlled trial of a brief interventional package for schizophrenic out-patients. 2001 , 103, 362-9	42
1415	Relatives' distress and patients' symptoms and behaviours: a prospective study of patients with schizophrenia and their relatives. 2001 , 104, 42-50	53
1414	Predictors and outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of first-admitted subjects. 2001 , 103, 347-54	81

1413	Cognitive behaviour therapy with coping training for persistent auditory hallucinations in schizophrenia: a naturalistic follow-up study of the durability of effects. 2001 , 103, 393-9	38
1412	Subject and observer-rated quality of life in schizophrenia. 2001 , 103, 387-92	130
1411	A comparison of community-dwelling older schizophrenia patients by residential status. 2001 , 103, 380-6	29
1410	The Florence Psychiatric Interview. 2001 , 10, 157-171	12
1409	Seeing the wood from the trees—a continuum model of psychopathology advocating cognitive behaviour therapy for schizophrenia. 2001 , 8, 149-175	14
1408	Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia. 2001 , 16, 321-326	104
1407	Plasma serotonin response to carbohydrate-rich food in chronic schizophrenic patients: clozapine versus classic antipsychotic agents. 2001 , 16, 403-407	2
1406	Differential efficacy of risperidone versus haloperidol in psychopathological subtypes of subchronic schizophrenia. 2001 , 16, 439-448	1
1405	Patterns of object relations and reality testing deficits in schizophrenia: clusters and their symptom and personality correlates. 2001 , 57, 1353-67	10
1404	Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. 2001 , 16, 1163-7	30
1403	Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. 2001 , 105, 749-52	87
1402	The effects of cognitive impairment and substance abuse on psychiatric hospitalizations. 2001 , 37, 303-12	18
1401	. 2001 , 22, 175-186	1
1400	Work interest as a predictor of competitive employment: policy implications for psychiatric rehabilitation. 2001 , 28, 279-97	51
1399	Reliability of instruments in a cooperative, multisite study: employment intervention demonstration program. 2001 , 3, 129-39	27
1398	Symptom severity and personal functioning among patients with schizophrenia discharged from long-term hospital care into the community. 2001 , 37, 145-55	12
1397	Cognitive components of self esteem for individuals with severe mental illness. 2001 , 71, 457-65	25
1396	Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizophrenic and residual subtypes of schizophrenia. 2001 , 6, 179-85	79

1395	Ser9Gly dopamine D3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients. 2001 , 6, 6-7		14
1394	Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. 2001 , 67, 133-40		22
1393	The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology. 2001 , 67, 33-44		137
1392	Increased serum S100B protein in schizophrenia: a study in medication-free patients. 2001 , 35, 11-4		120
1391	Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. Wisconsin Card Sorting Test. Continuous Performance Test. 2001 , 35, 119-25		239
1390	Obstetric complications and Apgar score in early-onset schizophrenic patients with prominent positive and prominent negative symptoms. 2001 , 35, 249-57		26
1389	The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. 2001 , 24, 47-54		90
1388	The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. 2001 , 25, 468-75		30
1387	A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. 2001 , 158, 2071-4		225
1386	Magnetic resonance imaging of the thalamus in first-episode psychosis. 2001 , 158, 116-8		74
1385	The NISAD Schizophrenia Research Register: why do we need a database of schizophrenia volunteers?. 2001 , 35, 660-7		24
1384	Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. 2001 , 158, 1706-13		392
1383	Depressive factors and their relationships with other symptom domains in schizophrenia, schizoaffective disorder, and psychotic depression. <i>Schizophrenia Bulletin</i> , 2001 , 27, 19-28	1.3	30
1382	Staff expressed emotion and causal attributions for client problems on a low security unit: an exploratory study. <i>Schizophrenia Bulletin</i> , 2001 , 27, 517-26	1.3	42
1381	Detecting improvement in quality of life and symptomatology in schizophrenia. <i>Schizophrenia Bulletin</i> , 2001 , 27, 227-34	1.3	48
1380	An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. 2001 , 158, 625-31		98
1379	Neuropathological abnormalities in schizophrenia: evidence from magnetization transfer imaging. 2001 , 124, 882-92		121
1378	Work rehabilitation in schizophrenia: does cognitive impairment limit improvement?. <i>Schizophrenia Bulletin</i> , 2001 , 27, 269-79	1.3	118

1377	Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophrenia. 2001 , 158, 644-6	58
1376	The Stanley Foundation Bipolar Network: 2. Preliminary summary of demographics, course of illness and response to novel treatments. 2001 , 178, s177-s183	31
1375	Update and recommendations for the use of antipsychotics in early-onset psychoses. 2001 , 11, 113-30	27
1374	Effects of Cigarette Smoking on Psychopathology Scores in Patients With Schizophrenia: An Experimental Study. 2001 , 22, 175-186	36
1373	The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. 2001 , 4, 239-50	36
1372	Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). 2001 , 55 Suppl 44, 5-69	30
1371	Comparison of clinical and best-estimate research DSM-IV diagnoses in a Finnish sample of first-admission psychosis and severe affective disorder. 2001 , 55, 107-11	25
1370	Assessing predictive factors for extended hospitalization at acute psychiatric admission. 2001 , 52, 1367-73	46
1369	Clinical advantages of amisulpride in the treatment of acute schizophrenia. 2001 , 29, 451-66	11
1368	Clinical and cognitive factors associated with verbal memory task performance in patients with schizophrenia. 2001 , 158, 758-64	43
1367	[Symptoms and social functioning features in chronic schizophrenia are aggregate in a tripartite structure]. 2001 , 10, 186-93	2
1366	Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. 2001 , 158, 1140-2	74
1365	Dysfunction of early-stage visual processing in schizophrenia. 2001 , 158, 1126-33	282
1364	Quality of life in schizophrenia: Impact of psychopathology, patients' gender and antipsychotic treatment. 2001 , 5, 19-26	7
1363	Late-onset schizophrenia with epileptiform discharge. 2001 , 5, 67-70	4
1362	A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. 2001 , 158, 765-74	298
1361	Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. 2001 , 158, 234-43	398
1360	Schwer chronisch kranke schizophrene Langzeitpatienten - Welche Merkmale beeinflussen den Prozess der Enthospitalisierung? Teil 4 der Hessischen Enthospitalisierungsstudie -. 2001 , 12, S95-S100	1

1359	[Deinstitutionalization, housing situation and subjective satisfaction of schizophrenic patients]. 2001 , 28, 10-7	4
1358	Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. 2001 , 158, 1105-13	509
1357	[Imperative auditory hallucinations in schizophrenia]. 2001 , 69, 203-10	2
1356	Emotional reactivity to daily life stress in psychosis. 2001 , 58, 1137-44	437
1355	Phenomenology of Self-Disturbances in Schizophrenia: Some Research Findings and Directions. 2001 , 8, 347-356	46
1354	A study of quetiapine: efficacy and tolerability in psychotic adolescents. 2001 , 11, 415-24	81
1353	Dementia as a complication of schizophrenia. 2001 , 70, 588-96	42
1352	The impact of coping on the relation between symptoms and quality of life in schizophrenia. 2001 , 64, 304-8	28
1351	Multiple dimensions of recovery in early psychosis. 2002 , 14, 273-283	64
1350	Brain morphology in antipsychotic-naïve schizophrenia: a study of multiple brain structures. 2002 , 43, s66-72	85
1349	Investigating the criterion validity of psychiatric symptom scales using surrogate marker validation methodology. 2002 , 12, 161-78	20
1348	Risperidone for the treatment of delusional disorder. 2002 , 6, 113-6	3
1347	Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests. 2002 , 46, 85-9	10
1346	Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. 2002 , 59, 347-54	232
1345	Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. 2002 , 59, 1002-10	327
1344	Short-term cognitive improvement in schizophrenics treated with typical and atypical neuroleptics. 2002 , 45, 74-80	22
1343	Executive function in patients with remitted bipolar disorder and schizophrenia and its relationship with functional outcome. 2002 , 71, 39-46	146
1342	The Stanley Foundation Bipolar Network: results of the naturalistic follow-up study after 2.5 years of follow-up in the German centres. 2002 , 46 Suppl 1, 2-9	42

1341	Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study. 2002 , 14, 454-60		16
1340	Clinical profile of an atypical antipsychotic: risperidone. <i>Schizophrenia Bulletin</i> , 2002 , 28, 43-61	1.3	44
1339	A comparison between schizophrenia patients and healthy controls on the expression of attentional blink in a rapid serial visual presentation (RSVP) paradigm. <i>Schizophrenia Bulletin</i> , 2002 , 28, 443-58	1.3	30
1338	The concept of hebephrenia over the course of time with particular reference to the Wernicke-Kleist-Leonhard School. 2002 , 3, 200-6		5
1337	Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. <i>Schizophrenia Bulletin</i> , 2002 , 28, 589-605	1.3	36
1336	Electrodermally nonresponsive schizophrenia patients make more errors in the Stroop Color Word Test, indicating selective attention deficit. <i>Schizophrenia Bulletin</i> , 2002 , 28, 459-66	1.3	11
1335	Clinical outcome of patients with schizophrenia without maintenance treatment in a nonindustrialized society. <i>Schizophrenia Bulletin</i> , 2002 , 28, 515-24	1.3	9
1334	Insight and personal narratives of illness in schizophrenia. 2002 , 65, 197-206		237
1333	Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. 2002 , 159, 255-62		335
1332	Disruption of neural systems of visual attention in schizophrenia. 2002 , 59, 418-24		40
1331	Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. 2002 , 159, 1029-34		304
1330	[The risk of rehospitalisation during therapy with atypical and typical neuroleptics--a contribution to differential indication]. 2002 , 29, 388-91		3
1329	The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. 2002 , 35, 50-6		59
1328	[Subgroups and Prognosis of "Difficult-to-Place" Schizophrenic Long-Stay Patients: Distinguishing "Hard Core" Patients]. 2002 , 29, 301-5		3
1327	Clozapine in patients with chronic schizophrenia: serum level, EEG and memory performance. 2002 , 35, 190-4		17
1326	[Reasons for Hospital Treatment of Psychiatric Patients before and after the Opening of a Satellite Ward]. 2002 , 70, 192-7		3
1325	Longitudinal Wisconsin card sorting performance in schizophrenia patients in rehabilitation. 2002 , 9, 203-9		6
1324	A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. 2002 , 159, 227-37		154

1323	[Pathways to psychiatric care and duration of untreated psychosis in first-episode psychosis patients]. 2002 , 70, 40-5	5
1322	[The vigilance paradigm in schizophrenia research - studies on the Continuous Performance Test (CPT)]. 2002 , 70, 34-9	7
1321	[Subjective quality of life in severely disabled long-stay schizophrenic patients]. 2002 , 29, 306-10	7
1320	[Schizophrenic patients, who still live in psychiatric hospitals despite decades of deinstitutionalization. Part 1 of the Hessian Deinstitutionalisation Study]. 2002 , 29, 245-50	1
1319	Neuronal substrate of the saccadic inhibition deficit in schizophrenia investigated with 3-dimensional event-related functional magnetic resonance imaging. 2002 , 59, 313-20	111
1318	Ratings of different olfactory judgements in schizophrenia. 2002 , 27, 407-16	48
1317	Habit and skill learning in schizophrenia: evidence of normal striatal processing with abnormal cortical input. 2002 , 9, 430-42	89
1316	Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. 2002 , 159, 1018-28	448
1315	The feasibility of enhancing psychiatric outpatients' readiness to change their substance use. 2002 , 53, 602-8	47
1314	Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. 2002 , 159, 480-2	151
1313	A magnetization transfer analysis of the thalamus in schizophrenia. 2002 , 14, 443-8	18
1312	Structural magnetic resonance imaging in patients with first-episode schizophrenia, psychotic and severe non-psychotic depression and healthy controls. Results of the schizophrenia and affective psychoses (SAP) project. 2002 , 43, s58-65	44
1311	Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. 2002 , 181, 422-7	64
1310	Proton magnetic resonance spectroscopy (1H MRS) in schizophrenia: investigation of the right and left hippocampus, thalamus, and prefrontal cortex. <i>Schizophrenia Bulletin</i> , 2002 , 28, 329-39	1.3 47
1309	Effects of interrater reliability of psychopathologic assessment on power and sample size calculations in clinical trials. 2002 , 22, 318-25	47
1308	Object relations deficits in schizophrenia: a cross-cultural comparison between Brazil and the United States. 2002 , 190, 73-9	10
1307	Are cognitive impairments associated with sensitivity to stress in schizophrenia? An experience sampling study. 2002 , 159, 443-9	82
1306	1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. 2002 , 13, 2133-7	60

1305	Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. 2002 , 22, 20-5	41
1304	Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics. 2002 , 22, 353-8	6
1303	Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. 2002 , 17, 1-8	35
1302	Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. 2002 , 22, 419-23	80
1301	Controlled trial of hydroxychloroquine in schizophrenia. 2002 , 22, 507-10	10
1300	Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. 2002 , 17, 59-64	23
1299	Factor structure of the Multnomah Community Ability Scale. 2002 , 190, 399-406	18
1298	Substance abuse among patients with schizophrenia. 2002 , 8, 70-80	13
1297	The PACE Clinic: identification and management of young people at "ultra" high risk of psychosis. 2002 , 8, 255-69	54
1296	Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. 2002 , 190, 604-10	82
1295	Caregiver burden in recent-onset schizophrenia and spectrum disorders: the influence of symptoms and personality traits. 2002 , 190, 241-7	54
1294	Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. 2002 , 8, 205-15	17
1293	Visuospatial memory and learning in first-episode schizophreniform psychosis and established schizophrenia: a functional correlate of hippocampal pathology?. 2002 , 32, 429-38	80
1292	A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. 2002 , 17, 207-15	137
1291	Subjective experiences of Japanese inpatients with chronic schizophrenia. 2002 , 190, 80-5	11
1290	Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia. 2002 , 22, 359-65	87
1289	Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study. 2002 , 22, 545-53	7
1288	Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. 2002 , 22, 554-60	24

1287	Double-blind antiglucocorticoid treatment in schizophrenia and schizoaffective disorder: a pilot study. 2002 , 3, 156-61	11
1286	Visual filtering and focusing among persons with schizophrenia, major depressive disorder, and no psychiatry history.. 2002 , 34, 239-249	2
1285	Motivational interviewing to improve insight and treatment adherence in schizophrenia. 2002 , 26, 23-32	85
1284	The search for dimensional structure differences between normality and abnormality: A statistical review of published data on personality and psychopathology.. 2002 , 83, 962-982	132
1283	Cognitive Therapy for Schizophrenia: From Conceptualization to Intervention. 2002 , 47, 41-50	47
1282	Amisulpride for schizophrenia. 2002 , CD001357	22
1281	Serotonin syndrome and atypical antipsychotics. 2002 , 159, 672-3	28
1280	High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia. 2002 , 159, 130-3	53
1279	Impaired cortical network for preattentive detection of change in speech sounds in schizophrenia: a high-resolution event-related potential study. 2002 , 159, 546-53	96
1278	Stress regulation and self-mutilation. 2002 , 159, 672	84
1277	Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. 2002 , 159, 1593-5	130
1276	Dr. Butler and Colleagues Reply. 2002 , 159, 678-a-679	3
1275	Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission. 2002 , 159, 1375-81	64
1274	Command hallucinations: who obeys and who resists when?. 2002 , 35, 272-9	15
1273	Kognitive Verhaltenstherapie bei einer schizophrenen Patientin mit persistierenden produktiven Symptomen. 2002 , 12, 54-62	2
1272	Essential fatty acids: theoretical aspects and treatment implications for schizophrenia and depression. 2002 , 8, 223-229	10
1271	Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. 2002 , 43, s78-84	81
1270	Review of antipsychotic medication administration: a proposal of intermittent dosing. <i>Schizophrenia Bulletin</i> , 2002 , 28, 203-22	1.3 16

1269	Quality of life benefits of paid work activity in schizophrenia. <i>Schizophrenia Bulletin</i> , 2002 , 28, 249-57	1.3	44
1268	Impaired temporal lobe processing of preattentive auditory discrimination in schizophrenia. <i>Schizophrenia Bulletin</i> , 2002 , 28, 467-74	1.3	47
1267	Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. 2002 , 22, 115-20		32
1266	The Lifetime Dimensions of Psychosis Scale (LDPS): description and interrater reliability. <i>Schizophrenia Bulletin</i> , 2002 , 28, 683-95	1.3	36
1265	Excessive recruitment of neural systems subserving logical reasoning in schizophrenia. 2002 , 125, 1793-807		62
1264	Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. 2002 , 41, 337-43		198
1263	Spatial selective attention and inhibition in schizophrenia patients during acute psychosis and at 4-month follow-up. 2002 , 51, 498-506		44
1262	An association of CAG repeats at the KCNN3 locus with symptom dimensions of schizophrenia. 2002 , 51, 788-94		30
1261	Schizophrenic subjects show deficient inhibition but intact task switching on saccadic tasks. 2002 , 51, 816-26		82
1260	Alterations in tonotopy and auditory cerebral asymmetry in schizophrenia. 2002 , 52, 32-9		38
1259	A volumetric MRI study of the entorhinal cortex in first episode neuroleptic-naïve schizophrenia. 2002 , 51, 1005-7		67
1258	Motor cortical excitability in schizophrenia. 2002 , 52, 24-31		70
1257	Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. 2002 , 52, 729-39		111
1256	Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients. 2002 , 52, 863-73		129
1255	Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. 2002 , 52, 701-7		286
1254	Do high or low doses of anxiolytics and hypnotics affect mismatch negativity in schizophrenic subjects? An EEG and MEG study. 2002 , 113, 141-50		62
1253	Reduced binocular depth inversion in schizophrenic patients. 2002 , 53, 101-8		112
1252	De-coupling of cognitive performance and cerebral functional response during working memory in schizophrenia. 2002 , 53, 45-56		98

1251	Personal evaluation of transitions in treatment (PETiT):a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. 2002 , 56, 37-46	80
1250	Effects of the 5HT antagonist cyproheptadine on neuropsychological function in chronic schizophrenia. 2002 , 53, 17-24	19
1249	Effects of risperidone on information processing and attention in first-episode schizophrenia. 2002 , 53, 7-16	27
1248	Color discrimination in schizophrenia. 2002 , 55, 197-204	34
1247	Clinical and neuropsychological correlates of the P300 in schizophrenia. 2002 , 55, 105-13	41
1246	Deficits in language-mediated mental operations in patients with schizophrenia. 2002 , 53, 171-9	26
1245	Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. 2002 , 55, 129-37	93
1244	Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia. 2002 , 56, 121-7	55
1243	Latent inhibition and schizophrenia: Pavlovian conditioning of autonomic responses. 2002 , 55, 147-58	71
1242	Symptom patterns and subgrouping of schizophrenic patients: significance of negative symptoms assessed on admission. 2002 , 56, 105-19	39
1241	The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms. 2002 , 56, 87-94	63
1240	Spatial working memory performance in patients with schizoaffective psychosis versus schizophrenia: a tale of two disorders?. 2002 , 53, 209-18	56
1239	Verbal and procedural memory in schizophrenia with milder symptoms: implications for psychosocial intervention. 2002 , 53, 263-5	5
1238	Procedural learning in schizophrenia: a functional magnetic resonance imaging investigation. 2002 , 57, 97-107	84
1237	Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. 2002 , 55, 139-46	87
1236	Cerebral signs of altered adaptability in females with acute psychosis. 2002 , 55, 291-301	3
1235	Overlap between emotional blunting, depression, and extrapyramidal symptoms in schizophrenia. 2002 , 57, 307	11
1234	Neural damage in the lenticular nucleus linked with tardive dyskinesia in schizophrenia: a preliminary study using proton magnetic resonance spectroscopy. 2002 , 57, 273-9	14

1233	Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources. 2002 , 57, 51-67	136
1232	Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. 2002 , 57, 221-6	53
1231	Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients. 2002 , 57, 311-3	77
1230	Neurological soft signs in schizophrenic patients and their nonpsychotic siblings. 2002 , 58, 241-6	59
1229	A Janusian perspective on the nature, development and structure of schizophrenia and schizotypy. 2002 , 54, 95-103	21
1228	An MRI study of temporal lobe abnormalities and negative symptoms in chronic schizophrenia. 2002 , 58, 123-34	90
1227	Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia. 2002 , 58, 247-52	35
1226	Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. 2002 , 58, 313-21	58
1225	5HTR2A gene polymorphism and personality traits in patients with major psychoses. 2002 , 17, 24-8	18
1224	Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. 2002 , 17, 148-54	77
1223	Cognitive patterns in subtypes of schizophrenia. 2002 , 17, 155-62	73
1222	Sinistrality in subtypes of schizophrenia. 2002 , 17, 272-7	16
1221	Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow-up of patients on depot medication. 2002 , 17, 459-65	10
1220	A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. 2002 , 346, 16-22	508
1219	Neural network identification of high-risk suicide patients. 2002 , 27, 39-47	9
1218	A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. 2002 , 18, 355-62	50
1217	Patients' subjective experiences of antipsychotics: clinical relevance. 2002 , 16, 457-71	53
1216	Symptom dimensions and their association with outcome and treatment setting in long-term schizophrenia. Results of the DSP project. 2002 , 56, 319-27	29

1215	Frontal and temporal dysfunction of auditory stimulus processing in schizophrenia. 2002 , 17, 110-27	114
1214	Multidimensional scaling of integrated neurocognitive function and schizophrenia as a disconnection disorder. 2002 , 17, 1227-39	27
1213	Assessing psychological distress in psychiatric patients: validation of the Talbieh Brief Distress Inventory. 2002 , 43, 229-34	45
1212	Neurocognitive and psychosocial correlates of hostility among persons in a post-acute phase of schizophrenia spectrum disorders. 2002 , 43, 319-24	17
1211	Symptom trajectories in psychotic episodes. 2002 , 43, 311-8	10
1210	Dual Diagnosis Motivational Interviewing: a modification of Motivational Interviewing for substance-abusing patients with psychotic disorders. 2002 , 23, 297-308	55
1209	Psychotic symptoms and violence toward others a literature review of some preliminary findings: Part 1. Delusions. 2002 , 7, 617-631	77
1208	Psychotic symptoms and violence toward others a literature review of some preliminary findings: Part 2. Hallucinations. 2002 , 7, 605-615	68
1207	Clinical and economic outcomes associated with olanzapine for the treatment of psychotic symptoms in a county mental health population. 2002 , 24, 803-17	5
1206	Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. 2002 , 109, 297-302	36
1205	Working memory correlates of three symptom clusters in schizophrenia. 2002 , 110, 49-61	63
1204	Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia. 2002 , 110, 9-17	40
1203	Spatial working memory span, delayed response and executive function in schizophrenia. 2002 , 110, 259-71	41
1202	Visual processing and neuropsychological function in schizophrenia and schizoaffective disorder. 2002 , 111, 125-36	33
1201	Clinical characteristics and risk factors for Kraepelinian subtype of schizophrenia: replication of previous findings and relation to summer birth. 2002 , 111, 147-54	15
1200	Perseveration in schizophrenia: failure to generate a plan and relationship with the psychomotor poverty subsyndrome. 2002 , 112, 13-26	20
1199	Source monitoring impairments in schizophrenia: characterisation and associations with positive and negative symptomatology. 2002 , 112, 27-39	105
1198	Correlation between clinical syndromes and neuropsychological tasks in unmedicated patients with recent onset schizophrenia. 2002 , 113, 83-92	36

1197	Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. 2002 , 26, 481-5	33
1196	Biological markers and possibilities for predicting therapeutic results in schizophrenia: a methodological contribution. 2002 , 26, 683-91	4
1195	Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. 2002 , 26, 1199-202	30
1194	REM sleep latency and wakefulness in the first sleep cycle as markers of major depression: a controlled study vs. schizophrenia and normal controls. 2002 , 26, 1211-5	25
1193	Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations. 2002 , 26, 975-88	11
1192	Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. 2002 , 26, 1055-62	10
1191	Theory of mind deficit in people with schizophrenia during remission. 2002 , 32, 1125-9	118
1190	The California Scale of Appreciation: A New Instrument to Measure the Appreciation Component of Capacity to Consent to Research. 2002 , 10, 166-174	23
1189	Treatment-Related Decision-Making Capacity in Middle-Aged and Older Patients With Psychosis: A Preliminary Study Using the MacCAT-T and HCAT. 2002 , 10, 207-211	22
1188	Improving Understanding of Research Consent in Middle-Aged and Elderly Patients With Psychotic Disorders. 2002 , 10, 142-150	62
1187	Social and clinical consequences of cognitive deficits in early psychosis: a two-year follow-up study of first-admitted patients. 2002 , 56, 149-59	61
1186	Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. 2002 , 47, 870-4	25
1185	Characterization of depressive syndrome in schizophrenic outpatients. 2002 , 24, 18-25	1
1184	Economic evaluations of olanzapine and risperidone. 2002 , 59, 1366-75	4
1183	Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. 2002 , 181, 135-137	24
1182	Prefrontal dopamine D1 receptors and working memory in schizophrenia. 2002 , 22, 3708-19	610
1181	Is there a gender difference in a factorial structure of the positive and negative syndrome scale? A test by structural equation modeling. 2002 , 35, 28-35	22
1180	Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. 2002 , 43, s45-9	43

1179	Topiramate antagonizes MK-801 in an animal model of schizophrenia. 2002 , 449, 121-5	37
1178	Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. 2002 , 72, 15-9	44
1177	A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. 2002 , 36, 7-18	243
1176	Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. 2002 , 36, 87-95	107
1175	Recognition memory for faces in schizophrenia patients and their first-degree relatives. 2002 , 40, 2314-24	38
1174	Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. 2002 , 27, 479-97	181
1173	Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. 2002 , 27, 1056-70	134
1172	Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. 2002 , 27, 1071-81	79
1171	A transcranial magnetic stimulation study of inhibitory deficits in the motor cortex in patients with schizophrenia. 2002 , 114, 11-22	86
1170	Cerebral correlates of selective attention in schizophrenic patients with formal thought disorder: a controlled H2 15O-PET study. 2002 , 115, 137-53	10
1169	Reversed hemispheric asymmetry during simple visual perception in schizophrenia. 2002 , 116, 25-32	20
1168	Itemized clinician ratings versus global ratings of symptom severity in patients with schizophrenia. 2002 , 11, 45-53	2
1167	Negative symptoms, depression and Alzheimer's disease. 2002 , 17, 383-7	14
1166	Functional neuroanatomy of sustained attention in schizophrenia: contribution of parietal cortices. 2002 , 17, 116-30	41
1165	Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. 2002 , 17, 95-8	9
1164	Olanzapine in the treatment of anorexia nervosa: an open label trial. 2002 , 32, 146-54	85
1163	Access to new medications to treat schizophrenia. 2002 , 29, 15-29	27
1162	[An acute psychiatric ward moves into the community. An empirical test of the satellite model]. 2002 , 73, 1088-93	6

1161	Subjective well-being and quality of life under atypical antipsychotic treatment. 2002 , 162, 3-10	109
1160	A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia. 2002 , 162, 74-81	51
1159	Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. 2002 , 162, 37-41	39
1158	Clinical applications of pharmacogenetics in psychiatry. 2002 , 162, 18-23	64
1157	Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. 2002 , 162, 396-405	158
1156	Recent advances in the genetics of schizophrenia. 2002 , 59, 331-48	33
1155	Depression, emotional blunting, and akinesia in schizophrenia. Overlap and differentiation. 2002 , 3 Suppl 2, S99-103	7
1154	[Not Available]. 2002 , 3 Suppl 2, S121-30	0
1153	[Not Available]. 2002 , 3 Suppl 2, S131-4	
1152	A clinical trial of adjunctive oestrogen treatment in women with schizophrenia. 2002 , 5, 99-104	42
1151	Antipsychotic drugs, menstrual regularity and osteoporosis risk. 2002 , 5, 93-8	22
1150	Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. 2002 , 252, 86-92	119
1149	No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. 2002 , 252, 232-4	30
1148	Influence of gender on social outcome in schizophrenia. 2002 , 106, 337-42	53
1147	Pathways to care: help seeking behaviour in first episode psychosis. 2002 , 106, 358-64	124
1146	One-year outcome in first episode psychosis patients in the Swedish Parachute project. 2002 , 106, 276-85	90
1145	Medication adherence of individuals with a first episode of psychosis. 2002 , 106, 286-90	295
1144	The influence of neurocognitive deficits and symptoms on disability in schizophrenia. 2002 , 105, 196-201	53

1143	Do cenesthesias and body image aberration characterize a subgroup in schizophrenia?. 2002 , 105, 276-82	26
1142	Could the hypofrontality pattern in schizophrenia be modified through neuropsychological rehabilitation?. 2002 , 105, 202-8	42
1141	Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia. 2002 , 27, 453-9	9
1140	Bizarre delusions and DSM-IV schizophrenia. 2002 , 56, 391-5	11
1139	Aktivität und Tag-Nachtrhythmus bei Patienten mit Depression und Schizophrenie: Eine Pilotstudie zur Anwendung der Aktimetrie bei psychiatrischen Patienten. 2002 , 6, 124-132	1
1138	Depressive, positive, negative and parkinsonian symptoms in schizophrenia. 2002 , 36, 340-6	26
1137	Antisaccades and task switching: studies of control processes in saccadic function in normal subjects and schizophrenic patients. 2002 , 956, 250-63	33
1136	Subjective quality of life in severely mentally ill patients: a comparison of two instruments. 2002 , 11, 553-61	58
1135	Psychometric validation of the State Scale of Dissociation (SSD). 2002 , 75, 33-51	31
1134	The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. 2002 , 72, 438-52	152
1133	Clinical comparability of schizophrenia patients at two public mental health systems. 2003 , 30, 231-45	
1132	Quality of life and coping with schizophrenia symptoms. 2003 , 12, 1-9	83
1131	Efficacy of second-generation antipsychotics in the treatment of schizophrenia. 2003 , 1, 7-14	
1130	Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia. 2003 , 115, 58-62	4
1129	[Individual needs and allocation of home-based community psychiatric services. Analysis of an example for ambulatory care living]. 2003 , 74, 755-61	9
1128	Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. 2003 , 166, 391-9	199
1127	Problem areas in the understanding of informed consent for research: study of middle-aged and older patients with psychotic disorders. 2003 , 171, 81-5	25
1126	Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. 2003 , 169, 398-403	51

1125	Can cognitive deficits explain differential sensitivity to life events in psychosis?. 2003 , 38, 262-8	12
1124	Influence of genetic loading, obstetric complications and premorbid adjustment on brain morphology in schizophrenia: a MRI study. 2003 , 253, 92-9	27
1123	Is executive function associated with symptom severity in schizophrenia?. 2003 , 253, 216-8	11
1122	Reexamination of the characteristics of the deficit schizophrenia patients. 2003 , 253, 221-7	32
1121	Determinants of subjective quality of life in post acute patients with schizophrenia. 2003 , 253, 228-35	80
1120	Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. 2003 , 122, 99-113	139
1119	Searching for a structural endophenotype in psychosis using computational morphometry. 2003 , 122, 153-67	57
1118	Impairment in basal limbic function in schizophrenia during affect recognition. 2003 , 122, 115-24	123
1117	Brain activation patterns during a selective attention test-a functional MRI study in healthy volunteers and patients with schizophrenia. 2003 , 123, 1-15	58
1116	Rightward cerebral asymmetry in subtypes of schizophrenia according to Leonhard's classification and to DSM-IV: a structural MRI study. 2003 , 123, 65-79	21
1115	Neuropsychological correlates of P300 abnormalities in patients with schizophrenia and obsessive-compulsive disorder. 2003 , 123, 109-23	57
1114	Altered auditory processing in acutely psychotic never-medicated first-episode patients. 2003 , 17, 747-58	55
1113	A critique of the Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities/Mental Retardation (DC-LD) chapter on non-affective psychotic disorders. 2003 , 47 Suppl 1, 16-25	13
1112	Efficacy of newer generation antipsychotics in the treatment of schizophrenia. 2003 , 28 Suppl 1, 9-26	130
1111	Potential use of the topical niacin skin test in early psychosis -- a combined approach using optical reflection spectroscopy and a descriptive rating scale. 2003 , 37, 237-47	44
1110	Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patients. 2003 , 37, 549-56	36
1109	Abnormalities of brain function during a nonverbal theory of mind task in schizophrenia. 2003 , 41, 1574-82	150
1108	Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. 2003 , 18, 820-9	60

1107	The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. 2003 , 18, 551-7	22
1106	Alterations of liver function test in patients treated with antipsychotics. 2003 , 17, 216-8	8
1105	Validation of the Routine Assessment of Patient Progress (RAPP) in patients with psychosis in South India. 2003 , 12, 157-64	2
1104	Reproducibility of 1H-MRS measurements in schizophrenic patients. 2003 , 50, 704-7	35
1103	Dopamine D2 receptor gene Ser311Cys variant and schizophrenia: association study and meta-analysis. 2003 , 119B, 28-34	50
1102	The antecedents of aggressive behavior among men with schizophrenia: a prospective investigation of patients in community treatment. 2003 , 21, 523-46	103
1101	Neurological soft signs in never-treated schizophrenia. 2003 , 108, 144-6	53
1100	Shared decision making in psychiatry. 2003 , 107, 403-9	190
1099	Depression and subjective quality of life in chronic phase schizophrenic patients. 2003 , 108, 297-303	87
1098	Attention profile in schizophrenia compared with depression: differential effects of processing speed, selective attention and vigilance. 2003 , 108, 276-84	98
1097	The first episode of psychosis: the experience of relatives. 2003 , 108, 285-9	147
1096	The Family Questionnaire (FQ): a scale for measuring symptom appraisal in relatives of schizophrenic patients. 2003 , 108, 290-6	29
1095	Cerebral tissue alterations and daily life stress experience in psychosis. 2003 , 107, 54-9	6
1094	The serotonin-2A receptor polymorphism and clinical symptoms in mood disorders, schizophrenia and alcohol dependence in Japan. 2003 , 15, 129-32	5
1093	Disturbed cognitive functioning and clinical symptoms: two independent problem areas in schizophrenia. 2003 , 15, 280-3	3
1092	Motherhood and schizophrenic illnesses: a review of the literature. 2003 , 37, 24-30	36
1091	Dysexecutive syndrome and social adjustment in schizophrenia. 2003 , 37, 340-6	20
1090	Characteristics of trees drawn by patients with paranoid schizophrenia. 2003 , 57, 347-51	8

1089	Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial. 2003 , 57, 478-84	15
1088	Heart rate variability in acute psychosis. 2003 , 40, 716-26	76
1087	Juego patológico: un trastorno emergente. 2003 , 5, 75-87	1
1086	Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. 2003 , 53, 56-64	185
1085	Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. 2003 , 53, 431-41	101
1084	Attentional and executive dysfunctions in schizophrenia and depression: evidence from dichotic listening performance. 2003 , 53, 609-16	83
1083	Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia. 2003 , 53, 25-38	234
1082	Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. 2003 , 54, 121-8	208
1081	Studies characterizing 60 kda autoantibodies in subjects with schizophrenia. 2003 , 53, 361-75	25
1080	Developmental abnormalities of the hippocampus in first-episode schizophrenia. 2003 , 53, 555-61	37
1079	Source distribution of neuromagnetic slow wave activity in schizophrenic and depressive patients. 2003 , 114, 2052-60	60
1078	Neuromagnetic correlates of impaired automatic categorical perception of speech sounds in schizophrenia. 2003 , 59, 159-72	51
1077	Longitudinal study of symptoms and cognitive function in chronic schizophrenia. 2003 , 59, 137-46	149
1076	Auditory P300 amplitude as a state marker for positive symptoms in schizophrenia: cross-sectional and retrospective longitudinal studies. 2003 , 59, 147-57	42
1075	Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide. 2003 , 59, 59-66	35
1074	Visual object working memory function and clinical symptoms in schizophrenia. 2003 , 59, 261-8	32
1073	Source distribution of neuromagnetic slow-wave activity in schizophrenic patients--effects of activation. 2003 , 63, 63-71	60
1072	A tri-ethnic examination of symptom expression on the positive and negative syndrome scale in schizophrenia spectrum disorders. 2003 , 60, 259-69	52

1071	Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. 2003 , 61, 303-14	67
1070	Midline brain anomalies in a young schizophrenic patient with 22q11 deletion syndrome. 2003 , 60, 323-5	2
1069	Increased phospholipase A2 activity in schizophrenia with absent response to niacin. 2003 , 61, 1-6	94
1068	Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. 2003 , 62, 195-204	196
1067	The Maudsley early onset schizophrenia study: cognitive function in adolescents with recent onset schizophrenia. 2003 , 61, 137-48	68
1066	A confirmatory factor analytic evaluation of the pentagonal PANSS model. 2003 , 61, 97-104	24
1065	Language lateralization in female patients with schizophrenia: an fMRI study. 2003 , 60, 183-90	94
1064	The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. 2003 , 61, 47-57	284
1063	Morphometric abnormality of the insula in schizophrenia: a comparison with obsessive-compulsive disorder and normal control using MRI. 2003 , 60, 191-8	49
1062	Cognitive therapy for schizophrenia: a preliminary randomized controlled trial. 2003 , 63, 1-11	99
1061	Insight in schizophrenia: a meta-analysis. 2003 , 61, 75-88	424
1060	Perseveration and over-switching in schizophrenia. 2003 , 61, 315-21	24
1059	Neurological soft-signs and minor physical anomalies in schizophrenia: differential transmission within families. 2003 , 63, 181-7	49
1058	The evolution of symptoms in the early course of non-affective psychosis. 2003 , 63, 171-9	40
1057	Cognitive functioning in first episode psychosis: initial presentation. 2003 , 62, 59-64	97
1056	Reduced P3 amplitudes by negative facial emotional photographs in schizophrenia. 2003 , 64, 125-35	41
1055	The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. 2003 , 62, 37-44	112
1054	Inhibition in schizophrenia: association with auditory hallucinations. 2003 , 62, 275-80	127

1053	Cognitive mechanisms, psychosocial functioning, and neurocognitive rehabilitation in schizophrenia. 2003 , 63, 219-27	49
1052	The effects of atypical antipsychotic medications on psychosocial outcomes. 2003 , 63, 97-101	39
1051	Insight and neurocognition in schizophrenia. 2003 , 62, 165-73	119
1050	Patterns of premorbid functioning in first-episode psychosis: initial presentation. 2003 , 62, 23-30	61
1049	Dimensions of working memory dysfunction in schizophrenia. 2003 , 62, 259-68	60
1048	Apathy in schizophrenia: clinical correlates and association with functional outcome. 2003 , 63, 79-88	91
1047	Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. 2003 , 60, 117-23	67
1046	The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. 2003 , 61, 7-18	150
1045	The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. 2003 , 61, 19-30	123
1044	Semantic and syntactic processes during sentence comprehension in patients with schizophrenia: evidence from event-related potentials. 2003 , 64, 147-56	38
1043	The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia. 2003 , 65, 15-8	85
1042	The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy. 2003 , 62, 1-12	19
1041	Caudate and putamen volumes in good and poor outcome patients with schizophrenia. 2003 , 64, 53-62	79
1040	Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. 2003 , 64, 63-71	62
1039	Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1. 2003 , 65, 39-46	64
1038	Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. 2003 , 64, 115-24	76
1037	Brain volumes as predictor of outcome in recent-onset schizophrenia: a multi-center MRI study. 2003 , 64, 41-52	76
1036	Basic neuropsychological dimensions in schizophrenia. 2003 , 65, 105-16	50

1035	Cognitive basis of hallucinations in schizophrenia: role of top-down information processing. 2003 , 64, 175-85	166
1034	The Maudsley Early-Onset Schizophrenia Study: cognitive function in adolescent-onset schizophrenia. 2003 , 65, 95-103	61
1033	A psychopathological study of a group of schizophrenic patients after attempting suicide. Are there two different clinical subtypes?. 2003 , 18, 190-2	11
1032	Manic symptoms associated with quetiapine treatment. 2003 , 13, 135-6	8
1031	A prospective, open-label trial of olanzapine in adolescents with schizophrenia. 2003 , 42, 170-5	52
1030	Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study. 2003 , 183, 534-539	315
1029	Aripiprazole: An Antipsychotic with a Novel Mechanism of Action. 2003 , 19, 365-372	
1028	Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. 2003 , 69, 393-9	128
1027	Somatosensory evoked potentials during a rubber-hand illusion in schizophrenia. 2003 , 64, 157-63	98
1026	Relation entre niveau de conscience de la maladie et qualité de vie subjective des patients schizophrènes. 2003 , 161, 660-665	1
1025	The cognitive-behavioural treatment of low self-esteem in psychotic patients: a pilot study. 2003 , 41, 317-32	138
1024	The effects of focus of attention on attributional bias in patients experiencing auditory hallucinations. 2003 , 41, 895-907	39
1023	Association study between interleukin-1beta gene (IL-1beta) and schizophrenia. 2003 , 72, 3017-21	15
1022	Exploring cognitive complaints in schizophrenia: the subjective scale to investigate cognition in schizophrenia. 2003 , 44, 331-40	128
1021	Life satisfaction and suicidal attempts among persons with schizophrenia. 2003 , 44, 442-7	50
1020	Nonreplication of the association between ab-ridge count and cerebral structural measures in schizophrenia. 2003 , 44, 459-61	4
1019	Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. 2003 , 54, 587-98	59
1018	Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. 2003 , 54, 453-64	161

1017	The amygdala and schizophrenia: a volumetric magnetic resonance imaging study in first-episode, neuroleptic-naive patients. 2003 , 54, 1302-4	68
1016	Distigmine bromide induced acute psychotic disorder in a patient with multiple sclerosis. 2003 , 18, 318-9	5
1015	Local-global processing in early-onset schizophrenia: evidence for an impairment in shifting the spatial scale of attention. 2003 , 51, 48-65	51
1014	Substrate kinetics of erythrocyte membrane Na,K-ATPase and lipid peroxides in schizophrenia. 2003 , 27, 431-40	19
1013	Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients. 2003 , 27, 767-70	10
1012	Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia. 2003 , 27, 795-9	12
1011	On the relationship between methylnicotinate-induced skin flush and fatty acids levels in acute psychosis. 2003 , 27, 927-33	26
1010	Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. 2003 , 27, 1007-12	108
1009	Depressive episodes in stable schizophrenia: critical evaluation of the DSM-IV and ICD-10 diagnostic criteria. 2003 , 117, 47-56	47
1008	Verbal learning and memory in schizophrenic and Parkinson's disease patients. 2003 , 117, 25-34	18
1007	Clinician ratings vs. global ratings of symptom severity: a comparison of symptom measures in the bipolar disorder module, phase II, Texas Medication Algorithm Project. 2003 , 117, 167-75	5
1006	Determinants of expressed emotion in mothers of schizophrenia patients. 2003 , 117, 211-22	31
1005	Normative needs for community-based psychiatric care of patients with schizophrenia in different residential settings. 2003 , 118, 223-33	15
1004	A transcranial magnetic stimulation study of abnormal cortical inhibition in schizophrenia. 2003 , 118, 197-207	38
1003	A longitudinal study of patient- and observer-rated quality of life in schizophrenia. 2003 , 119, 55-62	56
1002	Behavioural dysregulation of decision-making in deficit but not nondéficit schizophrenia patients. 2003 , 119, 293-306	22
1001	Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression. 2003 , 119, 63-79	78
1000	Neuroticism and visual memory impairments as predictors of the severity of delusions in schizophrenia. 2003 , 119, 287-92	24

999	Detection of anti-Borna Disease Virus (BDV) antibodies from patients with schizophrenia and mood disorders in Japan. 2003 , 120, 201-6	33
998	Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. 2003 , 121, 109-22	310
997	Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity. 2003 , 121, 123-32	43
996	Theory, methods and new directions in the psychophysiology of the schizophrenic process and schizotypy. 2003 , 48, 221-45	27
995	Phenomenology of anomalous self-experience in early schizophrenia. 2003 , 44, 121-34	304
994	Functional analysis of the deficit in semantic context processes in schizophrenic patients: an event-related potentials study. 2003 , 33, 11-22	24
993	Challenges in the Management of Psychotic Symptoms in Long-Term Care. 2003 , 4, H17-H20	
992	Can specific deficits in executive functioning explain the negative symptoms of schizophrenia? A review. 2003 , 9, 97-108	47
991	Management of the negative symptoms of schizophrenia: new treatment options. 2003 , 17, 793-823	95
990	Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics. 2003 , 29, 553-66	26
989	Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. 2003 , 160, 741-8	269
988	Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case-control study. 2003 , 182, 50-6	122
987	Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. 2003 , 160, 1125-32	407
986	Regionally localized thinning of the cerebral cortex in schizophrenia. 2003 , 60, 878-88	740
985	Can recovery-focused multimodal psychotherapy facilitate symptom and function improvement in people with treatment-resistant psychotic illness? A comparison study. 2003 , 37, 720-7	9
984	COGNITIVE THERAPY FOR PREVENTING TRANSITION TO PSYCHOSIS IN HIGH RISK INDIVIDUALS: A CASE SERIES. 2003 , 31, 53-67	12
983	Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia. 2003 , 26, 65-82; discussion 82-137	404
982	Interpersonal distance in schizophrenic patients: relationship to negative syndrome. 2003 , 49, 166-74	25

981	Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study. 2003 , 9, 65-72	26
980	VNTR polymorphism of tyrosine hydroxylase gene and schizophrenia in the Korean population. 2003 , 47, 131-6	5
979	Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. 2003 , 160, 1396-404	335
978	Branded versus generic clozapine for treatment of schizophrenia. 2003 , 37, 350-3	18
977	Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. 2003 , 54, 1129-35	187
976	Sensitivity and specificity of memory dysfunction in schizophrenia: a comparison with major depression. 2003 , 25, 79-93	81
975	Reasoning about physical causality and other's intentions in schizophrenia. 2003 , 8, 129-39	76
974	Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. 2003 , 13, 311-7	33
973	Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. 2003 , 183, 418-26	164
972	Methodological issues and controversies in clinical trials with child and adolescent patients with bipolar disorder: report of a consensus conference. 2003 , 13, 13-27	65
971	Semantic context-processing deficit in thought-disordered schizophrenic patients: evidence from new semantic priming paradigms. 2003 , 8, 173-89	20
970	Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. 2003 , 13, 319-27	40
969	Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. 2003 , 160, 1263-71	250
968	Predicting engagement with services for psychosis: insight, symptoms and recovery style. 2003 , 182, 123-8	146
967	Effects of acute procyclidine administration on prepulse inhibition of the startle response in schizophrenia: a double-blind, placebo-controlled study. 2003 , 17, 89-95	33
966	Compliance therapy: a randomised controlled trial in schizophrenia. 2003 , 327, 834	141
965	Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. 2003 , 28, 527-9	49
964	Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. 2003 , 28, 787-94	95

963	Effects of procyclidine on eye movements in schizophrenia. 2003 , 28, 2199-208		31
962	Dissociation between inattentiveness during mental status testing and social inattentiveness in the Scale for the Assessment of Negative Symptoms attention subscale. 2003 , 36, 263-8		5
961	Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. 2003 , 6, 97-102		48
960	Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [¹¹ C]FLB 457. 2003 , 6, 361-70		99
959	The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. <i>Schizophrenia Bulletin</i> , 2003 , 29, 15-31	1.3	462
958	The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. <i>Schizophrenia Bulletin</i> , 2003 , 29, 247-56	1.3	30
957	Evaluation of a community-based rehabilitation model for chronic schizophrenia in rural India. 2003 , 182, 57-62		148
956	Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. <i>Schizophrenia Bulletin</i> , 2003 , 29, 73-80	1.3	37
955	The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. <i>Schizophrenia Bulletin</i> , 2003 , 29, 771-90	1.3	212
954	Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. 2003 , 60, 133-41		174
953	A meta-analysis of the efficacy of second-generation antipsychotics. 2003 , 60, 553-64		764
952	Drug-induced parkinsonism in relation to choline-containing compounds measured by ¹ H-MR spectroscopy in putamen of chronically medicated patients with schizophrenia. 2003 , 6, 353-60		11
951	New generation antipsychotics for first episode schizophrenia. 2003 , CD004410		21
950	Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. <i>Schizophrenia Bulletin</i> , 2003 , 29, 81-93	1.3	16
949	Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. 2003 , 290, 2693-702		226
948	Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. 2003 , 60, 1228-35		337
947	Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. 2003 , 28, 182-92		197
946	Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. 2003 , 28, 1491-500		62

945	Thalamic acalculia. 2003 , 15, 115-6		7
944	Cognitive deficits and social functioning in schizophrenia: a clinical perspective. 2003 , 17, 507-14		7
943	Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. 2003 , 19, 298-305		16
942	Combination antipsychotic therapy in clinical practice. 2003 , 54, 55-9		146
941	Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia. 2003 , 160, 2234-6		47
940	Reduced cortical folding in schizophrenia: an MRI morphometric study. 2003 , 160, 1606-13		112
939	Influences of an anticholinergic antiparkinsonian drug, parkinsonism, and psychotic symptoms on cardiac autonomic function in schizophrenia. 2003 , 23, 441-7		26
938	Initial and final work performance in schizophrenia: cognitive and symptom predictors. 2003 , 191, 87-92		85
937	Risk adjustment in studies using administrative data. <i>Schizophrenia Bulletin</i> , 2003 , 29, 267-71	1.3	11
936	The cognitive basis of disorganization symptomatology in schizophrenia and its clinical correlates: toward a pathogenetic approach to disorganization. <i>Schizophrenia Bulletin</i> , 2003 , 29, 459-71	1.3	141
935	The multidimensional scale of independent functioning: a new instrument for measuring functional disability in psychiatric populations. <i>Schizophrenia Bulletin</i> , 2003 , 29, 153-68	1.3	115
934	Disease management in Latinos with schizophrenia: a family-assisted, skills training approach. <i>Schizophrenia Bulletin</i> , 2003 , 29, 211-27	1.3	90
933	Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. 2003 , 183, 161-6		60
932	What About the Kids? Raising Your Children Before, During, and After Divorce.. 2003 , 191, 415-416		
931	. 2003 , 191, 287-294		35
930	Association study of CAG repeats in the KCNN3 gene in Israeli patients with major psychosis. 2003 , 13, 143-50		5
929	Do life events have their effect on psychosis by influencing the emotional reactivity to daily life stress?. 2003 , 33, 327-33		76
928	Social outcome in early psychosis. 2003 , 33, 1119-24		77

927	The detection of intentional contingencies in simple animations in patients with delusions of persecution. 2003 , 33, 1433-41		71
926	The family and compliance in schizophrenia: the influence of clinical variables, relatives' knowledge and expressed emotion. 2003 , 33, 91-6		38
925	Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy. 2003 , 33, 419-31		184
924	Schizophrenia, consciousness, and the self. <i>Schizophrenia Bulletin</i> , 2003 , 29, 427-44	1.3	809
923	Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. <i>Schizophrenia Bulletin</i> , 2003 , 29, 33-43	1.3	91
922	Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. 2003 , 23, 5-14		55
921	Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. 2003 , 23, 15-20		93
920	Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. 2003 , 18, 341-6		22
919	Patterns of neurocognitive deficits and unawareness of illness in schizophrenia. 2003 , 191, 38-44		36
918	Treatment of Depression: Bridging the 21st Century.. 2003 , 191, 413-414		
917	Living Longer Depression Free. A Family Guide to Recognizing, Treating, and Preventing Depression in Later Life.. 2003 , 191, 414		
916	Treating Mental Illness and Behavior Disorders in Children and Adults with Mental Retardation.. 2003 , 191, 414-415		
915	Primary Care of the Older Adult. A Multidisciplinary Approach.. 2003 , 191, 413		
914	Sexual Orientation and Psychoanalysis. Sexual Science and Clinical Practice.. 2003 , 191, 412-413		
913	Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. 2003 , 26, 199-206		30
912	. 2003 , 191, 87-92		28
911	Reading Psychoanalysis. Freud, Rank, Ferenczi, Groddeck.. 2003 , 191, 415		
910	Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. 2003 , 26, 12-7		45

909	Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. 2003 , 18, 1-8	123
908	Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. 2003 , 18, 251-60	12
907	Lives in Context: The Art of Life History Research.. 2003 , 191, 414	
906	Theory and Practice of Psychiatry.. 2003 , 191, 415	
905	. 2003 , 191, 80-86	33
904	Treatment of neuroleptic-induced akathisia with the 5-HT _{2A} antagonist trazodone. 2003 , 26, 137-41	17
903	The effect of risperidone treatment on superoxide dismutase in schizophrenia. 2003 , 23, 128-31	41
902	Auditory Susceptibility in Hallucinating Schizophrenic Patients. 2003 , 191, 410-411	1
901	Handbook of Diagnostic and Structured Interviewing.. 2003 , 191, 414	
900	The controversy over "chemical restraint" in acute care psychiatry. 2003 , 9, 59-70	31
899	Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study. 2003 , 26, 193-5	19
898	Sleep and Daily Activity Preferences in Schizophrenia: Associations with Neurocognition and Symptoms. 2003 , 191, 408-410	10
897	Transference: Shibboleth or Albatross. 2003 , 191, 411-412	
896	Psychiatric Intensive Care.. 2003 , 191, 414	
895	Emergency Psychiatry.. 2003 , 191, 414	
894	Anxiety and its Disorders. The Nature and Treatment of Anxiety and Panic. Second Edition.. 2003 , 191, 415	
893	Handbook of Obesity Treatment.. 2003 , 191, 415	
892	. 2003 , 41, 208-217	7

891	Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [¹²³ I]epidepride SPET study of amisulpride-treated patients. 2003 , 160, 1413-20	98
890	Neural correlates of episodic encoding and recognition of words in unmedicated patients during an acute episode of schizophrenia: a functional MRI study. 2003 , 160, 1802-8	36
889	MRI assessment of gray and white matter distribution in Brodmann's areas of the cortex in patients with schizophrenia with good and poor outcomes. 2003 , 160, 2154-68	98
888	The schizophrenia phenotype in 22q11 deletion syndrome. 2003 , 160, 1580-6	250
887	Auditory susceptibility in hallucinating schizophrenic patients. 2003 , 191, 410-1	1
886	Satisfaction with quality of life varies with temperament types of patients with schizophrenia. 2003 , 191, 668-74	35
885	Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. 2003 , 41, 208-17	40
884	Cognitive functioning and employment in severe mental illness. 2003 , 191, 789-98	52
883	Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. 2003 , 23, 342-8	73
882	Sleep and daily activity preferences in schizophrenia: associations with neurocognition and symptoms. 2003 , 191, 408-10	34
881	Olanzapine versus placebo in acute mania: treatment responses in subgroups. 2003 , 23, 370-6	49
880	Mild procedural learning disturbances in neuroleptic-naive patients with schizophrenia. 2003 , 15, 58-63	25
879	Personality dimensions in schizophrenia: associations with symptoms and coping. 2003 , 191, 80-6	47
878	Olfaction and social drive in schizophrenia. 2003 , 60, 578-84	82
877	Predicting changes in domain-specific quality of life of schizophrenia patients. 2003 , 191, 287-94	60
876	Symptom outcome 1 year after admission to an early psychosis program. 2003 , 48, 204-7	69
875	International Multisite Double-Blind Trial of the Atypical Antipsychotics Risperidone and Olanzapine in 175 Elderly Patients With Chronic Schizophrenia. 2003 , 11, 638-647	65
874	A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. 2003 , 48, 187-94	17

873	Amiodarone-Induced Delirium. 2003 , 11, 696-697	9
872	A Case Report of Pancytopenia With Quetiapine Use. 2003 , 11, 694	8
871	Case Report. 2003 , 11, 697-698	
870	Valproate for schizophrenia. 2004 , CD004028	10
869	Spontaneous dyskinesia in first-degree relatives of chronically ill, never-treated people with schizophrenia. 2003 , 183, 45-9	26
868	Risperidone versus typical antipsychotic medication for schizophrenia. 2003 ,	38
867	Depot risperidone for schizophrenia. 2003 , CD004161	14
866	Self-esteem in schizophrenia: Relationships between self-evaluation, family attitudes, and symptomatology.. 2003 , 112, 92-99	197
865	Trauma and posttraumatic stress disorder in people with schizophrenia. 2003 , 112, 415-23	163
864	Long-term memory deficits in schizophrenia: primary or secondary dysfunction?. 2003 , 17, 539-47	56
863	Substance use and schizophrenia: effects on symptoms, social functioning and service use. 2003 , 182, 324-9	38
862	Social network correlates among people with psychiatric disabilities. 2003 , 26, 393-402	81
861	Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. 2003 , 160, 310-5	22
860	An FMRI study of episodic encoding and recognition of words in patients with schizophrenia in remission. 2003 , 160, 911-8	61
859	Functional disconnection between the prefrontal and parietal cortices during working memory processing in schizophrenia: a[15(O)]H2O PET study. 2003 , 160, 919-23	130
858	Reduced hippocampal activation during encoding and recognition of words in schizophrenia patients. 2003 , 160, 1305-12	90
857	Factor structure of paranoid schizophrenia: a prospective study. 2003 , 36, 132-41	4
856	Fusiform gyrus volume reduction and facial recognition in chronic schizophrenia. 2003 , 60, 349-55	108

855	Diagnosis of Schizophrenia: A Review. 2003 , 1-74	1
854	Neuropsychophysiologische Grundlagen psychiatrischer Erkrankungen. 2003 , 163-177	
853	Spatial integration in perception and cognition: An empirical approach to the pathophysiology of schizophrenia. 2003 , 26, 86-87	
852	Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. 2003 , 18, 1-8	27
851	A wide-spectrum coordination model of schizophrenia. 2003 , 26, 84-85	
850	NMDA synapses can bias competition between object representations and mediate attentional selection. 2003 , 26, 100-101	2
849	Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. 2003 , 18, 341-346	
848	No blind schizophrenics: Are NMDA-receptor dynamics involved?. 2003 , 26, 103-104	7
847	Disorders of self-monitoring and the symptoms of schizophrenia. 2003 , 407-424	6
846	Reconciling schizophrenic deficits in top-down and bottom-up processes: Not yet. 2003 , 26, 96-96	1
845	Cognitive coordination and its neurobiological bases: A new continent to explore. 2003 , 26, 110-137	5
844	Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. 2003 , 18, 251-260	2
843	Self and schizophrenia: a phenomenological perspective. 2003 , 217-241	49
842	An electrophysiologic study: can semantic context processes be mobilized in patients with thought-disordered schizophrenia?. 2003 , 48, 615-23	12
841	The ketamine model for schizophrenia. 2003 , 26, 82-83	76
840	Is sensory gating a form of cognitive coordination?. 2003 , 26, 94-95	
839	Tayside-Fife clinical trial of cognitive-behavioural therapy for medication-resistant psychotic symptoms. Results to 3-month follow-up. 2003 , 182, 303-11	118
838	Context, connection, and coordination: The need to switch. 2003 , 26, 97-97	

- 837 Inferring contextual field interactions from scalp EEG. **2003**, 26, 99-100
- 836 Mechanisms of disrupted language comprehension in schizophrenia. **2003**, 26, 87-88 4
- 835 Abnormal neural synchrony in schizophrenia. **2003**, 23, 7407-11 546
- 834 Linking brain to mind in normal behavior and schizophrenia. **2003**, 26, 90-90 1
- 833 Combating fuzziness with computational modeling. **2003**, 26, 107-108
- 832 Cortical connectivity in high-frequency beta-rhythm in schizophrenics with positive and negative symptoms. **2003**, 26, 105-106 1
- 831 High-frequency synchronisation in schizophrenia: Too much or too little?. **2003**, 26, 109-110 4
- 830 Theory of mind in schizophrenia: Damaged module or deficit in cognitive coordination?. **2003**, 26, 95-96 7
- 829 Context rules. **2003**, 26, 85-85 6
- 828 Setting domain boundaries for convergence of biological and psychological perspectives on cognitive coordination in schizophrenia. **2003**, 26, 88-89 4
- 827 Where the rubber meets the road: The importance of implementation. **2003**, 26, 83-84
- 826 Why do schizophrenic patients hallucinate?. **2003**, 26, 101-103
- 825 Synchronous dynamics for cognitive coordination: But how?. **2003**, 26, 106-107
- 824 Guarding against over-inclusive notions of "context" - Psycholinguistic and electrophysiological studies of specific context functions in schizophrenia. **2003**, 26, 108-109 3
- 823 Cognitive coordination deficits: A necessary but not sufficient factor in the development of schizophrenia. **2003**, 26, 89-90
- 822 Peeling the onion: NMDA dysfunction as a unifying model in schizophrenia. **2003**, 26, 93-94 10
- 821 Phenomenology, context, and self-experience in schizophrenia. **2003**, 26, 104-105 2
- 820 Schizophrenic cognition: Taken out of context?. **2003**, 26, 91-91 2

819	Decreased production of reactive oxygen species by blood monocytes caused by clozapine correlates with EEG slowing in schizophrenic patients. 2003 , 47, 73-7	9
818	Schizophrenia: Putting context in context. 2003 , 26, 98-99	14
817	Implementing quality management in psychiatry: from theory to practice--shifting focus from process to outcome. 2003 , 48, 467-74	14
816	NMDA-receptor hypofunction versus excessive synaptic elimination as models of schizophrenia. 2003 , 26, 92-92	
815	References. 2004 , 331-371	
814	Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. 2004 , 55, 1250-7	227
813	Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. 2004 , 29, 2108-14	378
812	Quality of life assessment in Turkish patients with schizophrenia and their relatives. 2004 , 95, 197-206	7
811	Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. 2004 , 37, 52-6	53
810	[Deinstitutionalization of long-stay psychiatric patients in upper Austria - living situation, social and clinical characteristics more than one year after discharge]. 2004 , 31, 192-7	3
809	Abnormalities of inhibitory neuronal mechanisms in the motor cortex of patients with schizophrenia. 2004 , 37, 74-80	29
808	Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. 2004 , 37, 270-8	31
807	[Duration of untreated psychosis (DUP): an useful predictor of outcome in schizophrenia?]. 2004 , 72, 79-87	6
806	Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. 2004 , 161, 1496-8	65
805	Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. 2004 , 161, 466-72	140
804	A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. 2004 , 7, 117-23	72
803	Attenuation of perceptual asymmetries in patients with early-onset schizophrenia: evidence in favour of reduced hemispheric differentiation in schizophrenia?. 2004 , 9, 79-91	10
802	Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study. 2004 , 37, 119-22	29

801	[Schizophrenia]. 2004 , 72, 164-74	0
800	[Ziprasidone-augmentation of clozapine]. 2004 , 31, 259-61	13
799	[Voluntariness and coercion in patients with schizophrenia]. 2004 , 31, 28-33	4
798	[Frequent use of psychiatric inpatient services analysed from three different perspectives]. 2004 , 31, 241-9	3
797	Group Cognitive-Behavioral Social Skills Training for Older Outpatients With Chronic Schizophrenia. 2004 , 18, 265-279	12
796	[Assessing deinstitutionalization of the nursing home area of a large state mental hospital from the point of view of patients and staff]. 2004 , 72, 446-59	1
795	Dysfunctional Attitudes and Symptom Expression in Schizophrenia: Differential Associations With Paranoid Delusions and Negative Symptoms. 2004 , 18, 163-173	45
794	The relationship of sex hormones and cortisol with cognitive functioning in Schizophrenia. 2004 , 18, 366-74	60
793	The Effect of Symptoms Coping Program in Reducing Psychotic Symptoms and Enhancing Functions in Chinese with Schizophrenia. 2004 , 7, 69-82	3
792	Characteristics of schizophrenic patients with a history of suicide attempt. 2004 , 8, 227-34	12
791	The evolution of insight, paranoia and depression during early schizophrenia. 2004 , 34, 285-92	164
790	Neural synchrony indexes disordered perception and cognition in schizophrenia. 2004 , 101, 17288-93	487
789	CBT FOR ADOLESCENTS WITH PSYCHOSIS: INVESTIGATING THE FEASIBILITY AND EFFECTIVENESS OF EARLY INTERVENTION USING A SINGLE CASE DESIGN. 2004 , 32, 313-329	7
788	Insight and hopelessness in forensic patients with schizophrenia. 2004 , 38, 169-73	35
787	Gender, Estrogen, and Schizophrenia. 2004 , 2, 138-145	5
786	Medication adherence among psychotic patients before admission to inpatient treatment. 2004 , 55, 174-9	78
785	Negative beliefs about self and illness: a comparison of individuals with psychosis with or without comorbid social anxiety disorder. 2004 , 38, 960-4	46
784	Premorbid adjustment in first-episode non-affective psychosis: distinct patterns of pre-onset course. 2004 , 185, 108-15	124

783	Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. 2004 , 161, 975-84		290
782	Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. 2004 , 161, 985-95		253
781	Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. 2004 , 161, 414-25		566
780	Intramuscular olanzapine in the management of acute agitation. 2004 , 38, 2128-35		18
779	Life Skills Training in Schizophrenia. 2004 , 67, 217-224		25
778	Subtle disruption of the middle cerebellar peduncles in patients with schizophrenia. 2004 , 50, 119-23		65
777	Cerebellar, prefrontal cortex, and thalamic volumes over two time points in adolescent-onset schizophrenia. 2004 , 161, 1023-9		86
776	Violence in male patients with schizophrenia: risk markers in a South African population. 2004 , 38, 254-9		29
775	Pathways that make voices: white matter changes in auditory hallucinations. 2004 , 61, 658-68		393
774	Differences in quality of life and course of illness between cycloid and schizophrenic psychoses - a comparative study. 2004 , 5, 136-42		10
773	Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. 2004 , 161, 1837-47		138
772	Deficit of executive functions in schizophrenia: relationship to neurological soft signs and psychopathology. 2004 , 37, 118-23		28
771	Latent inhibition and overswitching in schizophrenia. <i>Schizophrenia Bulletin</i> , 2004 , 30, 713-26	1.3	19
770	The correlates of comorbid antisocial personality disorder in schizophrenia. <i>Schizophrenia Bulletin</i> , 2004 , 30, 791-802	1.3	99
769	Leukocyte elastase and autoantibodies to nerve growth factor in the acute phase of schizophrenia and their relationship to symptomatology. 2004 , 5, 143-8		8
768	Applicability of interactive evolutionary computation to mental health measurement.		5
767	Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia. <i>Schizophrenia Bulletin</i> , 2004 , 30, 241-53	1.3	19
766	Cerebrovascular response to cognitive tasks in patients with schizophrenia measured by near-infrared spectroscopy. <i>Schizophrenia Bulletin</i> , 2004 , 30, 435-44	1.3	53

765	Validation of polypharmacy process measures in inpatient schizophrenia care. <i>Schizophrenia Bulletin</i> , 2004 , 30, 1023-33	1.3	45
764	Heightened interpersonal dependency in schizophrenia: associations with graver impairment in neurocognition but not with negative or positive symptoms. 2004 , 68, 164-73		4
763	Suicide and awareness of illness in schizophrenia: an overview. 2004 , 68, 297-318		42
762	Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. 2004 , 184, 58-62		168
761	Relapse in schizophrenia: costs, clinical outcomes and quality of life. 2004 , 184, 346-51		197
760	Response to vocational rehabilitation during treatment with first- or second-generation antipsychotics. 2004 , 55, 59-66		18
759	Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. 2004 , 161, 1057-65		194
758	Effects of neurocognitive enhancement therapy in schizophrenia: normalisation of memory performance. 2004 , 9, 199-211		18
757	Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. 2004 , 61, 143-50		325
756	Postpsychotic PTSD Reactions. 2004 , 3, 73-95		2
755	S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. 2004 , 29, 1004-11		90
754	Cognitive therapy for command hallucinations: randomised controlled trial. 2004 , 184, 312-20		211
753	Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder. 2004 , 2, 59-67		3
752	Insight and its relationship to violent behavior in patients with schizophrenia. 2004 , 161, 1712-4		97
751	Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. 2004 , 6, 213-23		201
750	The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype. 2004 , 6, 314-8		100
749	Recognition of facial expression and visual P300 in schizophrenic patients: differences between paranoid type patients and non-paranoid patients. 2004 , 58, 585-92		15
748	The psychological well-being and associated factors of caregivers of outpatients with schizophrenia in Taiwan. 2004 , 58, 600-5		13

747	Does nicotine affect D2 receptor upregulation? A case-control study. 2004 , 109, 313-7; discussion 317-8	11
746	Invited comment. 2004 , 109, 317-318	1
745	Neurological soft signs discriminating mood disorders from first episode schizophrenia. 2004 , 110, 29-35	71
744	A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia. 2004 , 110, 21-8	90
743	Insight into current symptoms of schizophrenia. Association with frontal cortical function and affect. 2004 , 110, 14-20	43
742	The dental health of people with schizophrenia. 2004 , 110, 306-10	94
741	Does duration of untreated psychosis bias study samples of first-episode psychosis?. 2004 , 110, 286-91	40
740	Psychiatric comorbidity in first episode psychosis: the Early Psychosis Intervention Program (EPIP) experience. 2004 , 109, 23-9	39
739	HERV-W-related RNA detected in plasma from individuals with recent-onset schizophrenia or schizoaffective disorder. 2004 , 9, 12-3	73
738	Lack of false recognition in schizophrenia: a consequence of poor memory?. 2004 , 42, 546-54	44
737	Secondary verbal memory: a potential endophenotype of schizophrenia. 2004 , 38, 601-12	27
736	Étude de la rémission dans la schizophrénie – Étude du test de Rorschach. 2004 , 10, 365-377	1
735	Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. 2004 , 130, 79-84	12
734	Abnormal brain response of chronic schizophrenia patients despite normal performance during a visual vigilance task. 2004 , 130, 245-57	35
733	Positive and negative symptom profile schizophrenia and abnormalities in the P300 component of the event-related potential: a longitudinal controlled study. 2004 , 132, 131-9	23
732	Shape changes in prefrontal, but not parieto-occipital regions: brains of schizophrenic patients come closer to a circle in coronal and sagittal view. 2004 , 132, 261-71	12
731	Gray matter abnormalities in paranoid schizophrenia and their clinical correlations. 2004 , 132, 251-60	96
730	Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study. 2004 , 131, 195-207	118

729	Superior temporal gyrus and P300 in schizophrenia: a combined ERP/structural magnetic resonance imaging investigation. 2004 , 38, 153-62	28
728	Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia. 2004 , 38, 177-84	88
727	Prepulse inhibition in patients with non-psychotic major depressive disorder. 2004 , 81, 179-84	39
726	Living in a group dwelling: how do residents spend their time in a psychiatric group dwelling?. 2004 , 41, 651-9	9
725	Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. 2004 , 83, 263-75	43
724	Applying linear mixed models to estimate reliability in clinical trial data with repeated measurements. 2004 , 25, 13-30	56
723	Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. 2004 , 13, 461-70	39
722	Vocational function among persons with schizophrenia with and without history of childhood sexual trauma. 2004 , 17, 435-8	48
721	Perceived quality of life in schizophrenia: relationships to sleep quality. 2004 , 13, 783-91	103
720	Affective and schizoaffective mixed states. 2004 , 254, 76-81	23
719	Problem-solving ability in chronic schizophrenia. A comparison study of patients with traumatic brain injury. 2004 , 254, 236-41	13
718	Executive dysfunctions in schizophrenia. Relationships to clinical manifestation. 2004 , 254, 256-62	55
717	Neurocognitive and psychopathological correlates of self-monitoring ability in schizophrenia. 2004 , 254, 312-7	12
716	Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia--an open label study. 2004 , 254, 372-9	79
715	NPACT: enhancing programs of assertive community treatment for the seriously mentally ill. 2004 , 40, 549-59	29
714	[The initial dysphoric reaction (IDR) to the first dose of neuroleptics]. 2004 , 75, 36-43	8
713	[Comparative study of life quality in patients with cycloid and schizophrenic psychoses]. 2004 , 75, 460-6	0
712	[Changes in brain structure caused by neuroleptic medication]. 2004 , 75, 1112-7	12

711	Perception of stigma among patients with schizophrenia. 2004 , 39, 73-7	78
710	Substance misuse at presentation to an early psychosis program. 2004 , 39, 69-72	129
709	An RCT of early intervention in psychosis: Croydon Outreach and Assertive Support Team (COAST). 2004 , 39, 358-63	78
708	Patients with a first episode of schizophrenia spectrum psychosis and their pathways to psychiatric hospital care in South Germany. 2004 , 39, 375-80	32
707	Violent victimization in schizophrenia. 2004 , 39, 606-12	50
706	Factors contributing to frequent use of psychiatric inpatient services by schizophrenia patients. 2004 , 39, 744-51	49
705	Striatal dopamine D2 receptor density in neuroleptic-naïve and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study. 2004 , 172, 165-9	7
704	Two subtypes of schizophrenia identified by an individual-level atypical pattern of tensor-based morphometric measurement.	
703	Reduced cortical cerebral blood flow in antipsychotic-free first-episode psychosis and relationship to treatment response. 1-11	0
702	Ferdinando Rossi Lecture: the Cerebellar Cognitive Affective Syndrome—Implications and Future Directions.	
701	Increased serum homocysteine in first episode and drug-naïve patients with schizophrenia: Sex differences and correlations with pathophysiology.	
700	Clinical and psychosocial outcomes of Black Americans in the Recovery After an Initial Schizophrenia Episode Early Treatment Program (RAISE-ETP) study.	
699	Optical coherence tomography reveals retinal thinning in schizophrenia spectrum disorders.	1
698	A Longitudinal Study of Semantic Networks in Schizophrenia and other Psychotic Disorders using the Word Association Task.	1
697	Subjective cognitive functioning, depressive symptoms, and objective cognitive functioning in people with treatment-resistant psychosis. 1-19	
696	The relationship between negative symptoms, social cognition, and social functioning in patients with first episode psychosis. 2022 ,	0
695	Basic learning functions among young adults coping with schizophrenia. 1-14	
694	The effect of antipsychotics on glutamate levels in the anterior cingulate cortex and clinical response: A 1H-MRS study in first-episode psychosis patients. 13,	

- 693 Language production impairments in patients with a first episode of psychosis. **2022**, 17, e0272873
- 692 The impact of visual dysfunctions in recent-onset psychosis and clinical high-risk state for psychosis.
- 691 Behavioral inhibition in neutral and emotional contexts in acutely violent patients with schizophrenia spectrum disorders. ○
- 690 Extrapyramidal symptoms predict cognitive performance after first-episode psychosis. **2022**, 8,
- 689 Associations between aerobic fitness, negative symptoms, cognitive deficits and brain structure in schizophrenia: a cross-sectional study. **2022**, 8,
- 688 Mindfulness, cognitive fusion, and self-compassion in patients with schizophrenia spectrum disorders: a cross-sectional study. 13, ○
- 687 Information-Theoretic Analysis of EEG Signals to Differentiate Schizophrenic Patients with Positive and Negative Symptoms and Control Group. **2022**, In Press,
- 686 Theory of mind in schizophrenia: a comparison of subgroups with low and high IQ. 1-7
- 685 DNA Methylation Profiles of the DRD2 and NR3C1 Genes in Patients with Recent-Onset Psychosis. **2022**, 2022, 1-13 ○
- 684 Evaluation of the relationship between death anxiety and clinical features of the disease and functionality in patients with schizophrenia. **2022**, 8, e09911 ○
- 683 Posture, gait and self-disorders: An empirical study in individuals with schizophrenia.
- 682 Gender-associated role in patients with schizophrenia. Is there a connection with the resistance?. 13, ○
- 681 Efficacy and auditory biomarker analysis of fronto-temporal transcranial direct current stimulation (tDCS) in targeting cognitive impairment associated with recent-onset schizophrenia: study protocol for a multicentric randomized double-blind sham-controlled trial.
- 680 A Randomized Controlled Trial of the Effects of Early Intervention Services On Insight in First Episode Psychosis.
- 679 Sex differences in prevalence and clinical correlates of insomnia in Chinese patients with chronic schizophrenia. ○
- 678 GABA Levels in the Midcingulate Cortex and Clozapine Response in Patients with Treatment-Resistant Schizophrenia: A 1 H-MRS Study. 2
- 677 Bridge centrality network structure of negative symptoms in people with schizophrenia. ○
- 676 A systematic review and narrative synthesis of indirect psychological intervention in acute mental health inpatient settings.

- 675 Metacognitive Reflection and Insight Therapy (MERIT) Delivered Virtually During the COVID-19 Pandemic: An Illustration of Two Cases.
- 674 Homoeopathic Add-On Treatment in Schizophrenia A Case Report.
- 673 Association between globus pallidus volume and positive symptoms in schizophrenia.
- 672 Serum hyperhomocysteine and cognitive impairment in first-episode patients with schizophrenia: Moderated by brain cortical thickness. **2022**, 788, 136826 ○
- 671 Gesture-speech synchrony in schizophrenia: A pilot study using a kinematic-acoustic analysis. **2022**, 174, 108347
- 670 The plasma level of complement component 4A decreases with aripiprazole treatment in patients with early psychosis. **2022**, 316, 114775 ○
- 669 Neuroanatomical subtypes of schizophrenia and relationship with illness duration and deficit status. **2022**, 248, 107-113 1
- 668 Symptom monitoring based on digital data collection during inpatient treatment of schizophrenia spectrum disorders A feasibility study. **2022**, 316, 114773 ○
- 667 Diminished treatment response in relapsed versus first-episode schizophrenia as revealed by a panel of blood-based biomarkers: A combined cross-sectional and longitudinal study. **2022**, 316, 114762 ○
- 666 Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. **2022**, 316, 114737 ○
- 665 The influence of modifiable cardiovascular risk factors on cognition, functioning, and inflammatory markers in first-episode psychosis: Results from a 2-year follow-up study. **2022**, 316, 114760
- 664 Reduced task-evoked pupillary response in preparation for an executive cognitive control response among individuals across the psychosis spectrum. **2022**, 248, 79-88
- 663 Differences of affective and non-affective psychoses in early intervention services from Latin America. **2022**, 316, 83-90 ○
- 662 Measuring the longitudinal course of voice hearing under psychological interventions: A systematic review. **2022**, 97, 102191
- 661 Mentalizing abilities mediate the impact of the basic social perception on negative symptoms in patients with schizophrenia. **2022**, 155, 85-89
- 660 Default mode network alterations underlie auditory verbal hallucinations in schizophrenia. **2022**, 155, 24-32
- 659 Prevalence and related factors of anxiety in first episode and drug naïve Chinese Han outpatients with psychotic major depression. **2022**, 316, 217-222 ○
- 658 Subjective cognitive complaints in first episode psychosis: A focused follow-up on sex effect and alcohol usage. **2022**, 30, 100267

- 657 Cognitive and perceptual impairments in schizophrenia extend to other psychotic disorders but not schizotypy. **2022**, 30, 100266
- 656 Functional neurodevelopment of working memory in early-onset schizophrenia: A longitudinal fMRI study. **2022**, 30, 100268
- 655 Association Between Adverse Childhood Experiences and a Combination of Psychosis and Violence Among Adults: A Systematic Review and Meta-Analysis. 152483802211228 ○
- 654 Negative symptoms correlate with altered brain structural asymmetry in amygdala and superior temporal region in schizophrenia patients. 13, ○
- 653 Neuropsychological profile of executive functions in autism spectrum disorder and schizophrenia spectrum disorders: a comparative group study in adults. ○
- 652 Attentional M100 gain modulation localizes to auditory sensory cortex and is deficient in first-episode psychosis. ○
- 651 Insight orientation scale: A promising tool for organizational outcomes—a psychometric analysis using item response theory. 13, ○
- 650 Immunoglobulins G of Patients with Schizophrenia Protects from Superoxide: Pilot Results. **2022**, 12, 1449 1
- 649 The decoupling of structural and functional connectivity of auditory networks in individuals at clinical high-risk for psychosis. 1-13 ○
- 648 Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension. **2022**, 248, 271-278 1
- 647 Increased connectivity of insula sub-regions correlates with emotional dysregulation in patients with first-episode schizophrenia. **2022**, 326, 111535 ○
- 646 Relapse of first-episode schizophrenia patients and neurocognitive impairment: The role of dopaminergic and anticholinergic burden. **2022**, 248, 331-340 ○
- 645 Evolution of antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia in the real-life: A 4-year follow-up naturalistic study. **2022**, 248, 279-286 ○
- 644 Mixed-effects models reveal prediction of long-term outcome by duration of untreated psychosis (DUP) and illness (DUI) varies with quantile gradation but is invariant with time across 7 years in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS). **2022**, 248, 124-130 ○
- 643 Clinical insight in first-episode psychosis: Clinical, neurocognitive and metacognitive predictors. **2022**, 248, 158-167 ○
- 642 How voices change the brain. Two fMRI follow-up case reports. **2022**, 248, 329-330 ○
- 641 Association of serum lipid levels with psychotic symptoms in young, first-episode and drug naïve outpatients with major depressive disorder: A large-scale cross-sectional study. **2022**, 317, 114864 ○
- 640 Theory of Mind and social functioning among neuropsychiatric disorders: A transdiagnostic study. **2022**, 64, 19-29 ○

- 639 Psychedelics and schizophrenia: Distinct alterations to Bayesian inference. **2022**, 263, 119624 ○
- 638 Surface-based brain morphometry in schizophrenia vs. cannabis-induced psychosis: A controlled comparison. **2022**, 155, 286-294 ○
- 637 Evaluating how treatment adherence influences cognitive remediation outcomes. **2022**, 158, 104186 ○
- 636 Executive function in methamphetamine users with and without psychosis. **2022**, 317, 114820 ○
- 635 Sex-specific associations between metabolic hormones, severe mental disorders and antipsychotic treatment. **2022**, 146, 105927 ○
- 634 Irony comprehension in schizophrenia: Development, content validity and Known-Groups Validity of an Indian, comic-based, computerized task. **2022**, 6, 164 ○
- 633 Long-acting paliperidone in Ekbom's syndrome in Lewy body dementia: A case report. **2022**, 13, 201-210 ○
- 632 The age of violence: Mapping brain age in psychosis and psychopathy. **2022**, 36, 103181 ○
- 631 Abnormal patterns of regional homogeneity and functional connectivity across the adolescent first-episode, adult first-episode and adult chronic schizophrenia. **2022**, 36, 103198 ○
- 630 Delusion of pregnancy: Conception in brain. **2022**, 31, 341 ○
- 629 Involvement of cerebellar and subcortical connector hubs in schizophrenia. **2022**, 35, 103140 ○
- 628 Measuring Psychotropic Drug Effects and Side Effects. **2022**, 505-533 ○
- 627 Who is prescribed valproate and how carefully is this treatment reviewed in UK mental health services? Data from a clinical audit. **2022**, 12, 204512532211100 ○
- 626 The association of serum folate levels with schizophrenia symptoms. **2022**, 122, 128 ○
- 625 Individual Biological Interventions for Violence and Aggression. II. Other Biological Treatments. **2022**, 291-307 ○
- 624 Comparison of cognition and alexithymia in patients of schizophrenia with and without comorbid alcohol use: A cross-sectional exploratory study. **2022**, 31, 267 ○
- 623 SELF-DESTRUCTIVE BEHAVIOR IN PATIENTS WITH SCHIZOPHRENIA SPECTRUM DISORDERS. FEATURES OF PATHOGENESIS AND PATHODYNAMICS. **2022**, 75, 1832-1838 ○
- 622 Structural covariance predictors of clinical improvement at 2-year follow-up in first-episode psychosis. **2023**, 120, 110645 ○

- 621 Inflammation and cognition in severe mental illness: Patterns of covariation and subgroups. 0
- 620 Undiagnosed Psychotic Disorder in Autistic Individuals with Intellectual Disabilities and Suspected Obsessive-Compulsive Disorder: An Explorative, Clinical Study. 1-27 1
- 619 A randomized controlled trial of Goal Management Training for executive functioning in schizophrenia spectrum disorders or psychosis risk syndromes. **2022**, 22, 0
- 618 The Influence of Trial-By-Trial Feedback on Trust in Health, First-Episode and Chronic Psychosis. **2022**, 13, 59 1
- 617 Assessment and correlates of autistic symptoms in Schizophrenia Spectrum Disorders measured with the PANSS Autism Severity Score: A systematic review. 13, 0
- 616 Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial. **2022**, 22, 0
- 615 Personalized approach to early diagnosis of acute schizophrenia: an observational comparative study. **2022**, 28, 181-192 0
- 614 Structural and functional retinal alterations in patients with paranoid schizophrenia. **2022**, 12, 1
- 613 Transcranial direct current stimulation of the occipital lobes with adjunct lithium attenuates the progression of cognitive impairment in patients with first episode schizophrenia. 13, 0
- 612 Cognitive dysfunction and cortical structural abnormalities in first-episode drug-naïve schizophrenia patients with auditory verbal hallucination. 13, 0
- 611 Decreased BOLD signals elicited by 40-Hz auditory stimulation of the right primary auditory cortex in bipolar disorder: An fMRI study. 13, 0
- 610 The association between N-methyl-d-aspartate receptor availability and glutamate levels: A multi-modal PET-MR brain imaging study in first-episode psychosis and healthy controls. **2022**, 36, 1051-1060 0
- 609 Medication adherence and cognitive performance in schizophrenia-spectrum and bipolar disorder: results from the PsyCourse Study. 0
- 608 The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia. **2022**, 36, 1061-1069 0
- 607 Abnormal Information Flow in Schizophrenia Is Linked to Psychosis. 0
- 606 Corpus Callosum Microstructural Tract Integrity Relates to Longer Emotion Recognition Reaction Time in People with Schizophrenia. **2022**, 12, 1208 0
- 605 Referential communication in people with recent-onset schizophrenia-spectrum disorders. 13, 0
- 604 Feasibility and efficacy of an acceptance and mindfulness-based group intervention for young people with early psychosis (Feel-Good group). 13, 0

603	The topology, stability, and instability of learning-induced brain network repertoires in schizophrenia. 1-56	o
602	Construction of Deep Learning Model using RESNET 50 for Schizophrenia Prediction from rsfMRI Images.	o
601	Plasma metabolomics of schizophrenia with cognitive impairment: A pilot study. 13,	o
600	Audiovisual temporal processing in adult patients with first-episode schizophrenia and high-functioning autism. 2022 , 8,	o
599	A Network Approach to Trauma, Dissociative Symptoms, and Psychosis Symptoms in Schizophrenia Spectrum Disorders.	o
598	Relationship of Neuropeptide S (NPS) with Neurocognitive, Clinical, and Electrophysiological Parameters of Patients during Structured Rehabilitation Therapy for Schizophrenia. 2022 , 11, 5266	1
597	Evaluating the Acceptance of Cinematic Virtual Reality-Based Applications for Rehabilitative Interventions in Schizophrenia.	1
596	Sex differences and symptom based gray and white matter densities in schizophrenia. 2022 , 1, 493-530	o
595	Motion energy analysis during speech tasks in medication-naïve individuals with at-risk mental states for psychosis. 2022 , 8,	o
594	Effects of Fish-Oil Consumption on Psychological Function Outcomes in Psychosis: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.	o
593	The effects of AUT00206, a novel Kv3.1/3.2 potassium channel modulator, on task-based reward system activation: a test of mechanism in schizophrenia. 2022 , 239, 3313-3323	o
592	Pragmatic deficits in patients with schizophrenia and right hemisphere damage: A pilot study.	o
591	Associations of conservatism/jumping to conclusions biases with aberrant salience and default mode network.	o
590	The alternations of nucleus accumbent in schizophrenia patients with auditory verbal hallucinations during low-frequency rTMS treatment. 13,	o
589	Multimodal Magnetic Resonance Imaging Depicts Widespread and Subregion Specific Anomalies in the Thalamus of Early-Psychosis and Chronic Schizophrenia Patients.	o
588	The mirror mechanism in schizophrenia: A systematic review and qualitative meta-analysis. 13,	o
587	İzofreni hastalarında TSH, FT3 ve FT4 düzeylerinin nörobilişel belirtiler üzerine etkisi. 2022 , 47, 1263-1272	o
586	Assessment of compliance and relapse in patients with schizophrenia before and after the onset of COVID-19 pandemic. 1-7	o

- 585 Alterations of cerebellar white matter integrity and associations with cognitive impairments in schizophrenia. 13, 0
- 584 Association between cognition and color discrimination among Lebanese patients with schizophrenia. **2022**, 22, 0
- 583 Facial affect recognition in first-episode psychosis is impaired but not associated with psychotic symptoms. **2022**, 8, e10424 0
- 582 Meta-analysis of structural and functional brain abnormalities in schizophrenia with persistent negative symptoms using activation likelihood estimation. 13, 1
- 581 Association between formal thought disorder and cannabis use: a systematic review and meta-analysis. **2022**, 8, 0
- 580 Smartphone-based Ecological Momentary Intervention for secondary prevention of suicidal thoughts and behaviour: protocol for the SmartCrisis V.2.0 randomised clinical trial. **2022**, 12, e051807 0
- 579 Crisis-focused Cognitive Behavioural Therapy for psychosis (CBTp) in acute mental health inpatient settings (the CRISIS study): protocol for a pilot randomised controlled trial. **2022**, 8, 0
- 578 Positive and negative syndrome scale in forensic patients with schizophrenia spectrum disorders: a systematic review and meta-analysis. **2022**, 21, 1
- 577 Current (but not ex) cigarette smoking is associated with worse cognitive performances in schizophrenia: results from the FACE-SZ cohort. 1-12 0
- 576 Time of exposure to social defeat stress during childhood and adolescence and redox dysregulation on long-lasting behavioral changes, a translational study. **2022**, 12, 0
- 575 Depressed Mood in First Episode Schizophrenia: Findings From a 1-Year Follow-Up in an Italian Real-World Care Setting. 1-3 0
- 574 Schizophrenia, Bipolar and Major Depressive Disorders: Overview of Clinical Features, Neurotransmitter Alterations, Pharmacological Interventions, and Impact of Oxidative Stress in the Disease Process. **2022**, 13, 2784-2802 1
- 573 The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis. 0
- 572 Longitudinal Network Analysis Reveals Interactive Change of Schizophrenia Symptoms During Acute Antipsychotic Treatment. 0
- 571 Re-owning Motherhood in Metacognitive Reflection and Insight Therapy (MERIT) with A Woman Diagnosed with Schizophrenia: Lessons from A Case Study. 0
- 570 Cerebellar Functional Dysconnectivity in Drug-Naïve Patients With First-Episode Schizophrenia. 0
- 569 Brain activity changes with emotional words in different stages of psychosis. 1-27 0
- 568 Emergence of Language Related to Self-experience and Agency in Autobiographical Narratives of Individuals With Schizophrenia. 0

567	Autoimmune antibodies in first-episode psychosis with red flags: A hospital-based case-control study protocol. 13,	0
566	Method for persistent topological features extraction of schizophrenia patients' electroencephalography signal based on persistent homology. 16,	0
565	Anxious-depressive symptoms after a first episode of schizophrenia: response to treatment and psychopathological considerations from the 2-year Parma Early Psychosis Program.. 2022, 114887	0
564	Test-retest reliability of the Childhood Trauma Questionnaire in psychotic disorders. 2022,	0
563	Evidence that a working memory cognitive phenotype within schizophrenia has a unique underlying biology.. 2022, 114873	0
562	Abnormalities in visual cognition and associated impaired interactions between visual and attentional networks in schizophrenia and brief psychotic disorder. 2022, 111545	0
561	Smoke, GPx activity and symptoms improvement in patients with drug-naive first-episode schizophrenia: A large-scale 12-week follow-up study. 2022, 77, 103267	0
560	Effects of bilateral, bipolar-nonbalanced, frontal transcranial Direct Current Stimulation (tDCS) on negative symptoms and neurocognition in a sample of patients living with schizophrenia: Results of a randomized double-blind sham-controlled trial. 2022, 155, 430-442	0
559	Relationship between the domains of theory of mind, social dysfunction, and oxytocin in schizophrenia. 2022, 155, 420-429	1
558	Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach. 2022, 155, 572-578	2
557	Altered functional connectivity in psychotic disorder not otherwise specified. 2022, 317, 114871	1
556	Self-reported cognitive biases in psychosis: Validation of the Davos Assessment of Cognitive Biases Scale (DACOBS) in a Spanish sample of psychotic patients and healthy controls. 2022, 155, 526-533	0
555	DNA Methylation Pattern of Gene Promoters of MB-COMT, DRD2, and NR3C1 in Turkish Patients Diagnosed with Schizophrenia. 2022, 20, 685-693	1
554	Hearing voices in the head: Two meta-analyses on structural correlates of auditory hallucinations in schizophrenia. 2022, 36, 103241	0
553	Semantic and Acoustic Markers in Schizophrenia-Spectrum Disorders; a Combinatory Machine Learning Approach.	0
552	Psychosis and psychedelics: Historical entanglements and contemporary contrasts. 136346152211291	1
551	Unrecognized schizophrenia spectrum and other mental disorders in youth disconnected from education and work-life. 13,	0
550	Effectiveness of Acceptance and Commitment Therapy on the Positive and Negative Symptoms and Emotion Regulation of Patients with Schizophrenia Spectrum Disorders: A Single-case Clinical Trial Study. 2022, 16,	0

- 549 The animated assessment of theory of mind for people with schizophrenia (AToMS): development and psychometric evaluation. ○
- 548 Psychopathy subdomains in violent offenders with and without a psychotic disorder. 1-10 ○
- 547 A Role of DNA Methylation within the CYP17A1 Gene in the Association of Genetic and Environmental Risk Factors with Stress-Related Manifestations of Schizophrenia. **2022**, 23, 12629 ○
- 546 Heterogeneity in Response to MCT and Psychoeducation: A Feasibility Study Using Latent Class Mixed Models in First-Episode Psychosis. **2022**, 10, 2155 ○
- 545 Structural alterations of the motor cortex and higher order cortical areas suggest early neurodevelopmental origin of catatonia in schizophrenia. **2022**, ○
- 544 The Efficacy and Tolerability of Electroconvulsive Therapy in Psychiatric Patients with Arachnoid Cysts: A Retrospective Chart Study. **2022**, 12, 1393 ○
- 543 Model Building in Forensic Psychiatry: A Machine Learning Approach to Screening Offender Patients with SSD. **2022**, 12, 2509 ○
- 542 Altered Patterns of Brain Glucose Metabolism Involve More Extensive and Discrete Cortical Areas in Treatment-resistant Schizophrenia Patients Compared to Responder Patients and Controls: Results From a Head-to-Head 2-[18F]-FDG-PET Study. 3
- 541 Depression Mediates the Relationships between Hallucinations, Delusions, and Social Isolation in First-Episode Psychosis. ○
- 540 Talk-based approaches to support people who are distressed by their experience of hearing voices: A scoping review. 13, ○
- 539 Pilot-RCT Finds No Evidence for Modulation of Neuronal Networks of Auditory Hallucinations by Transcranial Direct Current Stimulation. **2022**, 12, 1382 ○
- 538 Psychotic Symptom, Mood, and Cognition-associated Multimodal MRI Reveal Shared Links to the Salience Network Within the Psychosis Spectrum Disorders. ○
- 537 Hippocampal network dysfunction in early psychosis: a 2-year longitudinal study. **2022**, ○
- 536 Learning from Label Relationships in Human Affect. **2022**, ○
- 535 E-Prevention: Advanced Support System for Monitoring and Relapse Prevention in Patients with Psychotic Disorders Analyzing Long-Term Multimodal Data from Wearables and Video Captures. **2022**, 22, 7544 ○
- 534 Genetic Analysis of Clozapine Metabolism in a Patient With Subtherapeutic Clozapine Plasma Concentrations—The Importance of CYP3A5. Publish Ahead of Print, ○
- 533 Association between MnSOD Activity and Cognitive Impairment in Unmedicated First-Episode Schizophrenia: Regulated by MnSOD Ala-9Val Gene Polymorphism. **2022**, 11, 1981 ○
- 532 Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome. **2022**, 12, 1655 1

- 531 Medial Prefrontal Cortex Dysfunction Mediates Working Memory Deficits in Patients with Schizophrenia. **2022,** ○
- 530 Exploring the association between brain-derived neurotrophic factor (BDNF) levels and longitudinal psychopathological and cognitive changes in Sardinian psychotic patients. 1-19 ○
- 529 Validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview among outpatients with schizophrenia. 026988112211319 ○
- 528 Associations of the serum kynurenine pathway metabolites with P50 auditory gating in non-smoking patients with first-episode schizophrenia. 13, ○
- 527 Art therapy as an adjuvant treatment for schizophrenia: A protocol for an updated systematic review and subgroup meta-analysis of randomized clinical trials following the PRISMA guidelines. **2022,** 101, e30935 ○
- 526 Switching Antipsychotic Medications in People with Schizophrenia: A 4-Year Naturalistic Study. **2022,** 11, 5965 ○
- 525 Three-year outcomes and predictors for full recovery in patients with early-stage psychosis. **2022,** 8, 1
- 524 STUDY OF LIFE EVENTS AND PREMORBID FUNCTION IN RECENT ONSET SCHIZOPHRENIA. 63-66 ○
- 523 Assessment of Cardiometabolic Risk Reveals Elevated C-Reactive Protein Levels in Patients with Deficit Schizophrenia after Adjustment for Lifestyle Characteristics. **2022,** 12, 10915 ○
- 522 Effectiveness of a community-based peer support service among persons suffering severe mental illness in China. 10, e14091 ○
- 521 The percentage and clinical correlates of alexithymia in stable patients with schizophrenia. ○
- 520 Influence of Maternal and Paternal History of Mental Health in Clinical, Social Cognition and Metacognitive Variables in People with First-Episode Psychosis. **2022,** 12, 1732 ○
- 519 Clinical profile of schizophrenia comorbid with obsessive-compulsive symptoms: A comparative study. **2022,** ○
- 518 Influence of clinical and neurocognitive factors in psychosocial functioning after a first episode non-affective psychosis: Differences between males and females. 13, ○
- 517 Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia. **2022,** 32, 434-443 ○
- 516 Cognitive and clinical characteristics of offenders and non-offenders diagnosed with schizophrenia spectrum disorders: results of the Recoviwel observational study. ○
- 515 The effects of a computerized clinical decision aid on clinical decision-making in psychosis care. **2022,** 1
- 514 Increased lipid peroxidation and lowered antioxidant defenses predict methamphetamine induced psychosis. ○

- 513 Aggression in Women with Schizophrenia Is Associated with Lower HDL Cholesterol Levels. **2022**, 23, 11858 ○
- 512 DNA methylation levels of RELN promoter region in ultra-high risk, first episode and chronic schizophrenia cohorts of schizophrenia. **2022**, 8, ○
- 511 Does short-term antipsychotic discontinuation worsen symptoms in acute schizophrenia? A pooled analysis of placebo washout data. ○
- 510 Ketamine induces multiple individually distinct whole-brain functional connectivity signatures. ○
- 509 Reduced magnetic mismatch negativity: a shared deficit in psychosis and related risk. 1-9 ○
- 508 Bayesian reasoning with emotional material in patients with schizophrenia. 13, ○
- 507 Effect of individualized occupational therapy on social functioning in patients with schizophrenia: A five-year follow-up of a randomized controlled trial. **2022**, ○
- 506 Understanding the relationship between apathy, cognition and functional outcome in schizophrenia: The significance of an ecological assessment. **2022**, 17, e0277047 ○
- 505 Abnormal cortisol profile during psychosocial stress among patients with schizophrenia in a Chinese population. **2022**, 12, ○
- 504 VStore: Feasibility and acceptability of a novel virtual reality functional cognition task. 3, ○
- 503 Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study. Volume 18, 2519-2527 ○
- 502 Stimulating learning: A functional MRI and behavioral investigation of the effects of transcranial direct current stimulation on stochastic learning in schizophrenia. **2022**, 317, 114908 ○
- 501 Primary and secondary negative symptoms severity and the use of psychiatric care resources in schizophrenia spectrum disorders: A 3-year follow-up longitudinal retrospective study. **2022**, 250, 31-38 2
- 500 A randomized controlled trial of a peer-facilitated self-management program for people with recent-onset psychosis. **2022**, 250, 22-30 ○
- 499 Sexual dysfunction in first-episode schizophrenia spectrum disorders. **2022**, 2, 100080 ○
- 498 Vergence eye movements impairments in schizophrenia and bipolar disorder. **2022**, 156, 379-389 ○
- 497 DNA methylation and copy number variation of the complement C4A gene in schizophrenia. **2022**, 29, 101702 ○
- 496 Duration of Illness, Regional Brain Morphology and Neurocognitive Correlates in Schizophrenia. **2009**, 38, 388-395 1

- 495 Common gray matter loss in the frontal cortex in patients with methamphetamine-associated psychosis and schizophrenia. **2022**, 36, 103259 ○
- 494 Smartphone digital phenotyping, surveys, and cognitive assessments for global mental health: Initial data and clinical correlations from an international first episode psychosis study. **2022**, 8, 205520762211337 ○
- 493 Mood Stabilizers: Risperidone for Treating Bipolar Disorders in Adults. **2022**, 1607-1638 ○
- 492 Randomized Controlled Trials and the Efficacy of Psychotropic Medications. **2022**, 305-359 ○
- 491 Psychopathology: Rating Scales for the Assessment of Mental Status. **2022**, 245-267 ○
- 490 Evidence-Based Treatment with Antipsychotics in Schizophrenia: S3-Guideline and Current References. **2022**, 2023-2034 ○
- 489 Adverse Drug Reactions, Intoxications and Interactions of Neuropsychotropic Medications. **2022**, 361-414 ○
- 488 Tactile, Olfactory, and Gustatory Hallucinations in Psychotic Disorders: A Descriptive Study. **2009**, 38, 383-387 10
- 487 Cerebello-Basal Ganglia Functional Network Integration in Psychosis. ○
- 486 Langzeittherapie der Schizophrenie. **2022**, 16, 493-511 ○
- 485 Do symptoms moderate the association between participation and executive function outcomes among people with schizophrenia?. ○
- 484 The Impact of Antipsychotic Treatment on Neurological Soft Signs in Patients with Predominantly Negative Symptoms of Schizophrenia. **2022**, 10, 2939 ○
- 483 Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation. ○
- 482 Clinical and cortical similarities identified between bipolar disorder I and schizophrenia: A multivariate approach. 16, ○
- 481 Altered functional connectivity of cerebellar networks in first-episode schizophrenia. 16, ○
- 480 Social affective forecasting and social anhedonia in schizophrenia-spectrum disorders: a daily diary study. **2022**, 8, ○
- 479 Identifying psychiatric manifestations in schizophrenia and depression from audio-visual behavioural indicators through a machine-learning approach. **2022**, 8, ○
- 478 Alteration of a brain network with stable and strong functional connections in subjects with schizophrenia. **2022**, 8, ○

477	Deficit Symptomatology of Schizophrenia Is Associated with Attenuated Taste Identification: Findings from a Cross-Sectional Study. 2022 , 12, 1520	0
476	Pharmacological interventions for people with borderline personality disorder. 2022 , 2022,	1
475	Violence in relation to cognitive deficits and symptom severity in a sample of Egyptian patients with schizophrenia. 002076402211327	0
474	Homocysteine Levels and Clinical Outcomes in Schizophrenia: A Pilot Randomized Controlled Trial. 0976500X2201286	0
473	Predictors of Internalized Stigma in Patients with Schizophrenia in Northern Chile: A Longitudinal Study. 2022 , 10, 2269	0
472	Mild vs. moderate: How behavioral speech measures predict metacognitive capacity across different levels of formal thought disorder. 2022 ,	0
471	The Prevalence of Self-Injurious Behavior in Patients with Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.	1
470	Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study. Volume 18, 2627-2637	0
469	Reduced grid-like theta modulation in schizophrenia.	0
468	Major neurocognitive psychosis: a novel schizophrenia endophenotype class that is based on machine learning and resembles Kraepelin's and Bleuler's conceptions. 1-47	0
467	Longitudinal alterations of modular functional-metabolic coupling in first-episode schizophrenia. 2022 ,	0
466	Association between fractional amplitude of low-frequency fluctuation (fALFF) and facial emotion recognition ability in first-episode schizophrenia patients: a fMRI study. 2022 , 12,	0
465	Facial and upper-limb movement abnormalities in individuals with psychotic-like experiences: a motion analysis study.	0
464	Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.	2
463	Language abnormalities in schizophrenia: binding core symptoms through contemporary empirical evidence. 2022 , 8,	0
462	Multi-model order spatially constrained ICA reveals highly replicable group differences and consistent predictive results from fMRI data.	0
461	Ecological Momentary Assessment of Social Approach and Avoidance Motivations in Serious Mental Illness: Connections to Suicidal Ideation and Symptoms. 1-18	0
460	Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial.	0

- 459 Analysis of CACNA1C and KCNH2 Risk Variants on Cardiac Autonomic Function in Patients with Schizophrenia. **2022**, 13, 2132 ○
- 458 A diffusion tensor imaging study in schizophrenia patients with clozapine induced obsessive compulsive symptoms. ○
- 457 Local alterations of left arcuate fasciculus and transcallosal white matter microstructure in schizophrenia patients with medication-resistant auditory verbal hallucinations: A pilot study. **2022**, ○
- 456 N -acetylcysteine for schizophrenia: A systematic review and meta-analysis. ○
- 455 Accuracy of immediate self-assessment of neurocognitive test performance: Associations with psychiatric diagnosis and longitudinal psychotic symptoms. **2022**, 156, 594-601 ○
- 454 Inflammatory monocyte gene signature predicts beneficial within group effect of simvastatin in patients with schizophrenia spectrum disorders in a secondary analysis of a randomized controlled trial. **2022**, 26, 100551 ○
- 453 Virtual-reality-based social cognition and interaction training for patients with schizophrenia: A preliminary efficacy study. 13, ○
- 452 ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile. **2022**, 8, ○
- 451 Childhood adversity, symptoms, and cortisol in first episode psychosis: a cross-sectional, secondary, observational analysis of a subsample of FEP patients. 1-8 ○
- 450 Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice. **2022**, 23, 1801-1818 ○
- 449 Treatment of schizophrenia with catatonic symptoms: A narrative review. **2022**, ○
- 448 Subtyping chronic catatonia: Clinical and neuropsychological characteristics of progressive periodic catatonia and chronic system catatonias vs. non-catatonic schizophrenia. **2022**, ○
- 447 Case report: Recovery of hallucinations and cognitive impairment after administration of donepezil in a patient with schizophrenia and carbon monoxide poisoning. 13, ○
- 446 Personality traits and coping strategies in recent-onset psychosis: Associations with symptom severity and psychosocial functioning. **2022**, 250, 143-151 ○
- 445 Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trial. ○
- 444 The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies. **2022**, 250, 152-163 ○
- 443 Thirty years of research on negative symptoms of schizophrenia: A scientometric analysis of hotspots, bursts, and research trends. **2023**, 144, 104979 ○
- 442 The use of integrated behavioural z-scoring in behavioural neuroscience [A perspective article. **2023**, 384, 109751 ○

- 441 Dysconnectivity between the anterior insula and the dorsal anterior cingulate cortex during an emotion go/nogo paradigm is associated with aggressive behaviors in male schizophrenia patients. **2023**, 328, 111579 ○
- 440 Association between motivation and engagement with changes in cognition and symptoms after digital cognitive training in schizophrenia. **2023**, 251, 1-9 ○
- 439 The effect of low-frequency rTMS on auditory hallucinations, EEG source localization and functional connectivity in schizophrenia. **2023**, 794, 136977 ○
- 438 Differential diagnosis of delusional symptoms in schizophrenia: Brain tractography data. **2023**, 77, 217-225 ○
- 437 Role of cyclin-dependent kinase 5 in psychosis and the modulatory effects of cannabinoids. **2023**, 176, 105942 ○
- 436 Working memory deterioration as an early warning sign for relapse in remitted psychosis: A one-year naturalistic follow-up study. **2023**, 319, 114976 ○
- 435 Smoking affects the association between cognitive impairment and P50 inhibition defects in patients with chronic schizophrenia: A case-control study. **2023**, 79, 103391 ○
- 434 Evaluating the mechanisms of social cognition intervention in schizophrenia: A proof-of-concept trial. **2023**, 319, 114963 ○
- 433 P50 inhibition defects, psychopathology and gray matter volume in patients with first-episode drug-naïve schizophrenia. **2023**, 80, 103421 ○
- 432 Clinical correlates of autoimmune thyroiditis and non-autoimmune hypothyroidism in treatment-naïve patients with major depressive disorders. **2023**, 323, 755-761 ○
- 431 Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial. **2023**, 21, 424-436 ○
- 430 Aberrant memory and delusional ideation: A pernicious partnership?. **2023**, 99, 102231 ○
- 429 Relapse, cognitive reserve, and their relationship with cognition in first episode schizophrenia: a 3-year follow-up study. **2023**, 67, 53-65 ○
- 428 Comparable repetition blindness effect in patients with schizophrenia. **2023**, 78, 101796 ○
- 427 The effect of cognitive behavioral therapy for insomnia on neuropsychological performance in schizophrenia patients with insomnia: A randomized controlled trial. **2022**, 0 ○
- 426 Different measures for auditory hallucinations in populations with psychosis. The Validation of the Spanish versions of the Auditory Vocal Hallucination Rating Scale (AVHRS) and the Positive and Useful Voices Inquiry (PUVI). **2022**, 15, 259-271 ○
- 425 Risk factors of deficit and non-deficit schizophrenia: Results from a cross-sectional study. **2022**, 15, 223-229 ○
- 424 Clinical symptoms and social functioning in schizophrenia. **2022**, 15, 251-258 ○

- 423 In Schizophrenia, the Effects of the IL-6/IL-23/Th17 Axis on Health-Related Quality of Life and Disabilities Are Partly Mediated by Generalized Cognitive Decline and the Symptomatology. **2022**, 19, 15281 0
- 422 The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders. **2022**, 0
- 421 Clinical and Psychopathological Phenomenology of Mild Acute Drug-Induced Akathisia. 0
- 420 Computerized cognitive and social cognition training in schizophrenia for impulsive aggression. **2022**, 0
- 419 Plasma neuropeptide levels in patients with schizophrenia, bipolar disorder, or major depressive disorder and healthy controls: A multiplex immunoassay study. 1
- 418 Discourse Diversity Database (3D) for Clinical Linguistics Research: Design, Development, and Analysis. 0
- 417 Deconstructing heterogeneity in schizophrenia through language: a semi-automated linguistic analysis and data-driven clustering approach. **2022**, 8, 1
- 416 A Mixed-Methods Outcomes Evaluation Protocol for a Co-Produced Psychoeducation Workshop Series on Recovery from Psychosis. **2022**, 19, 15464 0
- 415 Music as a Psychosocial Intervention with People Suffering from Schizophrenia: Challenges in Practice and Research. 0
- 414 Aberrant visual salience in participants with schizophrenia during free-viewing of natural images. 0
- 413 Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia. **2022**, 12, 1972 2
- 412 Dynamic Interactive Social Cognition Training in Virtual Reality (DiSCoVR) versus Virtual Reality Relaxation (VRRelax) for People With a Psychotic Disorder: A Single-Blind Multicenter Randomized Controlled Trial. 1
- 411 Toplum Ruh Sağlığı Merkezinde Takipli İyofreni Hastaların Fiziksel Etkinlik Deylerinin Değerlendirilmesi. 0
- 410 Evaluation of Electroconvulsive Therapy in Adolescents With Major Depressive and Bipolar Disorders. Publish Ahead of Print, 0
- 409 The Behavioral Mapping of Psychomotor Slowing in Psychosis Demonstrates Heterogeneity Among Patients Suggesting Distinct Pathobiology. 0
- 408 Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. **2022**, 12, 1
- 407 Increased Lipid Peroxidation and Lowered Antioxidant Defenses Predict Methamphetamine Induced Psychosis. **2022**, 11, 3694 0
- 406 Discourse Diversity Database (3D) para pesquisa em linguística clínica: projeto, construção e análise. 0

- 405 Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study. **2022**, 12, e062570 ○
- 404 Belief updating in subclinical and clinical delusions. ○
- 403 The Interplay Between Addictive Behaviour and Psychopathology and Personality in Substance Use Disorder: a Network Analysis in Treatment-Seeking Patients with Alcohol and Drug Use. ○
- 402 Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration. 1
- 401 Dysconnectivity in Schizophrenia Revisited: Abnormal Temporal Organization of Dynamic Functional Connectivity in Patients With a First Episode of Psychosis. ○
- 400 Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia. **2022**, 15, ○
- 399 MEJORA CLÍNICA Y FUNCIONAL EN LOS HOSPITALES DE DÍA DURANTE EL COVID-19. **2022**, ○
- 398 Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis. **2022**, 12, ○
- 397 A multiple baseline trial of adapted prolonged exposure psychotherapy for individuals with early phase psychosis, comorbid substance misuse, and a history of adversity: A study protocol. 13, ○
- 396 In vivo white matter microstructure in adolescents with early-onset psychosis: a multi-site mega-analysis. 1
- 395 Disrupted subcortical functional connectome gradient in drug-naïve first-episode schizophrenia and the normalization effects after antipsychotic treatment. ○
- 394 Safety and tolerability of KarXT (xanomeline/bospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. **2022**, 8, ○
- 393 Increased Prevalence of Rare Copy Number Variants in Treatment-Resistant Psychosis. ○
- 392 The relationship between psychopathology, occupational balance, and quality of life among people with schizophrenia. 1
- 391 Understanding Digital Mental Health Interventions: A Causal Analysis of Social Networking Functionality and Therapy Content (Preprint). ○
- 390 A comparative study of retinal layer changes among patients with schizophrenia and healthy controls. 1-34 1
- 389 Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. **2022**, 400, 2210-2220 ○
- 388 Advanced brain age correlates with greater rumination and less mindfulness in schizophrenia. **2022**, 103301 ○

- 387 Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: Two open-label pilot studies on treatment-resistant patients. **2022**, 1
- 386 IL-17 and TNF- α Predictive biomarkers for transition to psychosis in ultra-high risk individuals. 13, 0
- 385 Virtual histology of morphometric similarity network after risperidone monotherapy and imaging-epigenetic biomarkers for treatment response in first-episode schizophrenia. **2022**, 103406 0
- 384 Dorsal attention network activity during perceptual organization is distinct in schizophrenia and predictive of cognitive disorganization. 0
- 383 Brain correlates of speech perception in schizophrenia patients with and without auditory hallucinations. **2022**, 17, e0276975 0
- 382 Vascular age, cardiovascular disease risk factors, and hematological parameters in patients with Schizophrenia: An exploratory study. 1-5 0
- 381 Linguistic and non-linguistic markers of disorganization in psychotic illness. **2022**, 0
- 380 Insomnia in Chinese patients with chronic schizophrenia: prevalence, clinical correlates and relationship with cognitive impairment. 0
- 379 Effectiveness and safety of Baduanjin for schizophrenia: A protocol for systematic review and meta-analysis. **2022**, 101, e32007 0
- 378 Cerebellar stimulation in schizophrenia: A systematic review of the evidence and an overview of the methods. 13, 0
- 377 Multi-dimensional recording of long-term treatment of patients with schizophrenic disorders compared to patients with major depression measured with the ASSESS battery. **2022**, 8, e11924 0
- 376 Reinforcement learning profiles and negative symptoms across chronic and clinical high-risk phases of psychotic illness. 0
- 375 Elevated Systemic Levels of Markers Reflecting Intestinal Barrier Dysfunction and Inflammasome Activation Are Correlated in Severe Mental Illness. 0
- 374 Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia. 0
- 373 Prevalence of loneliness and its correlates among patients with schizophrenia. 002076402211416 1
- 372 Differences in white matter microstructure in first-episode schizophrenia spectrum disorders vs healthy volunteers and their association with cognition. **2022**, 250, 196-202 0
- 371 Cross-sectional associations between adaptive functioning and social cognitive and neurocognitive functions in adolescents with first-episode, early-onset schizophrenia spectrum disorders. 1-11 0
- 370 Aberrant hierarchical prediction errors are associated with transition to psychosis: A computational single-trial analysis of the mismatch negativity. 0

- 369 Lower fractional anisotropy without evidence for neuro-inflammation in patients with early-phase schizophrenia spectrum disorders. **2022**, ○
- 368 A psychological intervention for engaging dialogically with auditory hallucinations (Talking With Voices): A single-site, randomised controlled feasibility trial. **2022**, 250, 172-179 ○
- 367 Serum s100b protein levels as a neuroinflammatory biomarker of acutely relapsed paranoid schizophrenia patients. 1-27 ○
- 366 Increased serum homocysteine in first episode and drug-naïve individuals with schizophrenia: sex differences and correlations with clinical symptoms. **2022**, 22, ○
- 365 Improving autobiographical memory in schizophrenia using wearable cameras: A single-case experimental study. 1-30 ○
- 364 Restless arms syndrome with oral olanzapine: case based review. **2022**, e12258 ○
- 363 Psychometric and Clinical Evaluation of Schizophrenia Remission Criteria in Swedish Outpatients with Psychotic Disorders. ○
- 362 Circulating endothelial progenitor cell dysfunction in patients with bipolar disorder. ○
- 361 Digitally Assisted Standard Diagnostics in Insurance Medicine (DASDIM): psychometric data in psychiatric work disability evaluations. 1-14 ○
- 360 Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies. **2022**, 114997 ○
- 359 Specific facial emotion recognition deficits across the course of psychosis: A comparison of individuals with low-risk, high-risk, first-episode psychosis and multi-episode schizophrenia-spectrum disorders.. **2022**, 115029 ○
- 358 Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders. 1-6 ○
- 357 Carob Seed Peels Effect on Cognitive Impairment and Oxidative Stress Status in Methionine-Induced Mice Models of Schizophrenia. **2022**, 12, 1660 ○
- 356 Inpatient forensic psychiatry in the time of COVID-19: a survey study of perceived mental health implications on people with schizophrenia spectrum disorder. 1-17 ○
- 355 Low oxytocin levels in schizophrenia patients involved in crime and the relationship of these levels to aggression, empathy and forgiveness. 1-19 ○
- 354 Gut microbiota alterations in stable outpatients with schizophrenia: Findings from a case-control study. 1-23 ○
- 353 Gender Difference in Cognitive Function Among Stable Schizophrenia: A Network Perspective. Volume 18, 2991-3000 ○
- 352 Postpartum Psychosis: The Role of Women's Health Care Providers and the Health Care System. **2022**, 77, 763-777 ○

- 351 An Optimized Version of the Positive and Negative Symptoms Scale (PANSS) for Pediatric Trials. **2022**, 0
- 350 YouXin: A digital system to facilitate self-management in people with psychosis in China: protocol for a non-randomised validity and feasibility study with a mixed-methods design (Preprint). 0
- 349 Alpha transcranial alternating current stimulation reduces depressive symptoms in people with schizophrenia and auditory hallucinations: a double-blind, randomized pilot clinical trial. **2022**, 8, 0
- 348 Effectiveness of accelerated intermittent theta burst stimulation for social cognition and negative symptoms among individuals with schizophrenia: A randomized controlled trial. **2022**, 115033 0
- 347 Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders. **2022**, 12, 1666 1
- 346 Serum Inflammatory Markers and Integrity of the Superior Longitudinal Fasciculus and the Inferior Longitudinal Fasciculus in Schizophrenia, from Prodromal Stages to Chronic Psychosis: A Cross-Sectional Study. **2023**, 12, 683 0
- 345 Study protocol of the Berlin Research Initiative for Diagnostics, Genetics and Environmental Factors in Schizophrenia (BRIDGE-S). **2023**, 23, 1
- 344 Eye movement abnormalities can distinguish first-episode schizophrenia, chronic schizophrenia, and prodromal patients from healthy controls. 0
- 343 Gender differences in outcomes of early intervention services for first episode psychosis. 0
- 342 How Functional Connectivity Measures Affect the Outcomes of Global Neuronal Network Characteristics in Patients with Schizophrenia Compared to Healthy Controls. **2023**, 13, 138 1
- 341 Gamma Oscillations and Potassium Channel Modulation in Schizophrenia: Targeting GABAergic Dysfunction. 155005942211486 0
- 340 Evidence of Increased Oxidative Stress in the Placental Tissue of Women Who Suffered an Episode of Psychosis during Pregnancy. **2023**, 12, 179 0
- 339 Emotion-behaviour decoupling and experiential pleasure deficits predict negative symptoms and functional outcome in first-episode schizophrenia patients. **2023**, 103467 0
- 338 Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis. 026988112211486 0
- 337 Short-term Medication Effects on Brain Functional Activity and Network Architecture in First-Episode psychosis: a longitudinal fMRI study. 0
- 336 Divergent epigenetic responses to birth asphyxia in severe mental disorders. 0
- 335 Editorial: Can Less Be More When Measuring Psychotic Symptoms in Youth?. **2023**, 0
- 334 The Association of the Oral Microbiota with the Effects of Acid Stress Induced by an Increase of Brain Lactate in Schizophrenia Patients. **2023**, 11, 240 0

- 333 Validation of Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS) in Tamil and its Relationship with Objective Cognition and Psychopathology. ○
- 332 Automated detection of schizophrenia using deep learning: a review for the last decade. ○
- 331 Neurological soft signs and structural network changes: a longitudinal analysis in first-episode schizophrenia. **2023**, 23, ○
- 330 Detection of Cognitive Subtypes of Schizophrenia (with Assessment of Perceptual Disorders). A Pilot Study. **2023**, 20, 74-83 ○
- 329 The Placentas of Women Who Suffer an Episode of Psychosis during Pregnancy Have Increased Lipid Peroxidation with Evidence of Ferroptosis. **2023**, 13, 120 1
- 328 Frailty among inpatients with Schizophrenia: Status, influencing factors, and their correlation with quality of life. 13, ○
- 327 The Use of Machine Learning Techniques to Solve Problems in Forensic Psychiatry. **2023**, 223-235 ○
- 326 Alpha Event-related Desynchronization During Reward Processing in Schizophrenia. **2023**, ○
- 325 Improved estimation of the risk of manic relapse by combining clinical and brain scan data. **2023**, ○
- 324 Short-term Clinical Outcome of Previously Untreated and Treated Schizophrenia and Impact of Duration of Untreated Psychosis. 025371762211416 ○
- 323 Duration of untreated illness and clinical correlates in first-episode and drug-naïve patients with major depressive disorder. **2023**, 115056 ○
- 322 Longitudinal Changes in Cortical Surface Area Associated With Transition to Psychosis in Adolescents at Clinical High-Risk for the Disease. **2023**, ○
- 321 Self-esteem in stabilized individuals with chronic schizophrenia: association with residual symptoms and cognitive functioning. ○
- 320 Seventy Years of Antipsychotic Development: A Critical Review. **2023**, 11, 130 1
- 319 Cognitive reserve in patients with mood disorders: Validation study of the Chinese version of the cognitive reserve assessment scale in health. **2023**, ○
- 318 Do symptoms moderate the association between participation and executive functions outcomes among people with schizophrenia?. **2023**, 23, ○
- 317 Does social cognition change? Evidence after 4 years from the Italian Network of Research for Psychoses. 1-24 ○
- 316 Resting-State Brain Activity Dysfunctions in Schizophrenia and Their Associations with Negative Symptom Domains: An fMRI Study. **2023**, 13, 83 ○

- 315 Suicidal Offenders and Non-Offenders with Schizophrenia Spectrum Disorders: A Retrospective Evaluation of Distinguishing Factors Using Machine Learning. **2023**, 13, 97 ○
- 314 Longitudinal changes of cognitive function and its relationship with subdomains of negative symptoms in patients with adult-onset first-episode schizophrenia: A 4-year follow up study. **2023**, 252, 181-188 ○
- 313 Motor function in early onset schizophrenia: A 2-year follow-up study. ○
- 312 Genetic contributions to transdiagnostic symptom dimensions in patients with major depressive disorder, bipolar disorder, and schizophrenia spectrum disorders. **2023**, 252, 161-171 ○
- 311 Correlation between abnormal N-acetyl-aspartate levels in posterior cingulate cortex and persistent auditory verbal hallucinations in Chinese patients with chronic schizophrenia. **2023**, 80, 103416 ○
- 310 Automated measures of speech content and speech organization in schizophrenia: Test-retest reliability and generalizability across demographic variables. **2023**, 320, 115048 ○
- 309 Decrease in gamma-band auditory steady-state response in patients with treatment-resistant schizophrenia. **2023**, 252, 129-137 ○
- 308 Negative mood states as a correlate of cognitive performance and self-assessment of cognitive performance in bipolar disorder versus schizophrenia. **2023**, 252, 1-9 ○
- 307 Retrospectively assessed childhood trauma experiences are associated with illness severity in mental disorders adjusted for symptom state. **2023**, 320, 115045 ○
- 306 Relationships between neuropsychological performance, insight, medication adherence, and social metacognition in schizophrenia. **2023**, 252, 48-55 ○
- 305 Music rhythm perception and production relate to treatment response in schizophrenia. **2023**, 252, 69-76 ○
- 304 Predictors of full recovery in patients with early stage schizophrenia spectrum disorders. **2023**, 320, 115035 ○
- 303 Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder. **2023**, 27, 100584 ○
- 302 Depression trajectories and cytokines in schizophrenia spectrum disorders - A longitudinal observational study. **2023**, 252, 77-87 ○
- 301 Maladaptive personality traits in patients with recent-onset psychosis: A case-control study using the Personality Inventory for the DSM-5 (PID-5). **2023**, 252, 216-224 ○
- 300 Relationship between cognition and suicidal behavior in recent-onset psychosis. **2023**, 252, 172-180 ○
- 299 Prevalence and risk factors of psychotic symptoms in middle-aged patients with first-episode drug-naïve major depressive disorder: A large-scale cross-sectional study. **2023**, 325, 102-109 ○
- 298 Negative symptoms in drug-naïve patients with a first-episode psychosis (FEP). **2023**, 81, 103448 ○

- 297 P50 sensory gating, cognitive deficits and depressive symptoms in first-episode antipsychotics-naïve schizophrenia. **2023**, 324, 153-161 ○
- 296 Metabolic characteristics, prevalence of anxiety and its influencing factors in first-episode and drug-naïve major depressive disorder patients with impaired fasting glucose. **2023**, 324, 341-348 ○
- 295 The prevalence and clinical correlates of anxiety in Chinese patients with first-episode and drug-naïve major depressive disorder at different ages of onset. **2023**, 325, 306-312 ○
- 294 Sleep disturbance in a medium-secure forensic psychiatric unit: A pilot study. **2012**, 1, 32-38 ○
- 293 Remaining connected in the age of social distancing: Online strategies for relapse prevention in psychosis. **2022**, 1, 42-49 ○
- 292 Clinical Psychiatry in the Nursing Home. **2022**, ○
- 291 Electroconvulsive therapy or clozapine for adolescents with treatment-resistant schizophrenia: an explorative analysis on symptom dimensions. 1-7 ○
- 290 İzofreni hastalarında CYB mtDNA mutasyonları ve PI3K/AKT/mTOR sinyal yollarındaki genlerin ekspresyon durumu. **2022**, 47, 1695-1708 ○
- 289 History of learning disorders is associated with worse cognitive and functional outcomes in schizophrenia: results from the multicentric FACE-SZ cross-sectional dataset. ○
- 288 Inflammation and cognition in severe mental illness: patterns of covariation and subgroups. ○
- 287 Psychomotor slowing alters gait velocity, cadence, and stride length and indicates negative symptom severity in psychosis. **2022**, 8, ○
- 286 Genetic testing is superior over endogenous pharmacometabolomic markers to predict safety of haloperidol in patients with alcohol-induced psychotic disorder. **2022**, 24, ○
- 285 Onset of Action of Selected Second-Generation Antipsychotics (Pines) A Systematic Review and Meta-Analyses. **2023**, 11, 82 ○
- 284 Application of machine learning methods in predicting schizophrenia and bipolar disorders: A systematic review. **2023**, 6, ○
- 283 Response of Polish Psychiatric Patients to the Russian Invasion of Ukraine in February 2022 Predictive Role of Risk Perception and Temperamental Traits. **2023**, 20, 325 ○
- 282 Estradiol and raloxifene as adjunctive treatment for women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. ○
- 281 Weight Gain, Mental Symptoms and Self-Esteem in Patients with Schizophrenia. **2022**, 14, 100-109 ○
- 280 CRP and its relation to cognitive performance in schizophrenia patients: a cross-sectional study. **2022**, 43, 87 ○

- 279 Comparison of cognitive functions and other clinical correlates in patients with schizophrenia with and without comorbid obsessive-compulsive disorder. **2022**, 43, 169 ○
- 278 Cognitive versus emotional modulation within a Stroop paradigm in patients with schizophrenia. **2023**, 9, ○
- 277 Frequency-domain analysis of transient visual evoked potentials in schizophrenia. ○
- 276 Impact of Childhood Trauma and Adult Separation Anxiety Disorder on Quality of Life in Individuals with Schizophrenia. Volume 19, 181-196 ○
- 275 Comparing the Validity of the Rorschach Performance Assessment System and Exner's Comprehensive System to Differentiate Patients and Nonpatients. 107319112211465 1
- 274 Relapse prediction in schizophrenia with smartphone digital phenotyping during COVID-19: a prospective, three-site, two-country, longitudinal study. **2023**, 9, ○
- 273 Altered sex differences in hippocampal subfield volumes in schizophrenia. ○
- 272 Opposite Modulation of the NMDA Receptor by Glycine and S-Ketamine and the Effects on Resting State EEG Gamma Activity: New Insights into the Glutamate Hypothesis of Schizophrenia. **2023**, 24, 1913 ○
- 271 Differentiating people with schizophrenia from healthy controls in a developing Country: An evaluation of portable functional near infrared spectroscopy (fNIRS) as an adjunct diagnostic tool. 14, ○
- 270 The Static and dynamic functional connectivity characteristics of the left temporoparietal junction region in schizophrenia patients with auditory verbal hallucinations during low-frequency rTMS treatment. 14, ○
- 269 A pilot 1-year follow-up randomised controlled trial comparing metacognitive training to psychoeducation in schizophrenia: effects on insight. **2023**, 9, ○
- 268 Violence, neurocognitive function and clinical correlates in patients with schizophrenia. 13, ○
- 267 Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia. **2023**, 23, ○
- 266 Efficacy of Cognitive Training Program Given to Patients with Schizophrenia Using Computer Tablets: a Preliminary Study. ○
- 265 Considering dynamic nature of the brain: the clinical importance of connectivity variability in machine learning classification and prediction. ○
- 264 Does short-term antipsychotic discontinuation of up to 3 weeks worsen symptoms in acute schizophrenia? A pooled analysis of placebo washout data. ○
- 263 Impact of Cognitive Impairments on Health-Related Quality of Life in Schizophrenia. **2023**, 13, 215 1
- 262 Attenuated niacin response is associated with a subtype of first-episode drug-naïve psychosis characterized as serious negative symptoms. 1

261	Application of Machine Learning to Diagnostics of Schizophrenia Patients Based on Event-Related Potentials. 2023 , 13, 509	0
260	Fear of psychotic relapse: exploring dynamic relationships with common early warning signs of relapse using electronic once-a-day self-reports. 1-15	0
259	Preliminary evidence that fatigue contributes to anhedonia in stable individuals diagnosed with schizophrenia. 14,	1
258	Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM. Volume 19, 219-232	0
257	Closing the Gap: From Research to Practice in Mental Health Interventions. 2023 , 20, 2141	0
256	Outcome Prediction for Patients with Bipolar Disorder Using Prodromal and Onset Data. 2023 , 13, 1552	0
255	Negative symptoms and cognitive impairment are associated with distinct motivational deficits in treatment resistant schizophrenia.	0
254	Autistic features and executive functions in first episode psychosis: Associations with functionality and quality of life.	0
253	Gender differences in empathy and clinical symptoms in chronic schizophrenia patients: a large sample study based on a Chinese Han population. 1-8	1
252	Characteristic association of symbol coding test score with occupational function in Japanese patients with schizophrenia.	0
251	Beyond antipsychotics: the role of medication and nonmedication factors in female sexual dysfunctions in schizophrenia. Publish Ahead of Print,	0
250	Disease progression patterns of brain morphology in schizophrenia: More progressed stages in treatment-resistance.	0
249	The contribution of the cingulate cortex: treating depressive symptoms in first-episode drug naïve schizophrenia. 2023 , 23, 100372	0
248	Association of early life stress and cognitive performance in patients with schizophrenia and healthy controls. 2023 , 32, 100280	0
247	Reducing Polypharmacy Through the Introduction of a Treatment Algorithm: Use of a Treatment Algorithm on the Impact on Polypharmacy. 2006 , 35, 457-460	2
246	Understanding Digital Mental Health Interventions: A Secondary Causal Analysis of Social Networking Functionality and Therapy Content (Preprint).	0
245	Aripiprazole Used to Treat Capgras Syndrome in an Adolescent Diagnosed With Autism. 2023 , 46, 85-86	0
244	Long-term Outcomes of People With DSM Psychotic Disorder NOS. 2023 , 4,	0

- 243 Early identification of treatment non-response in first-episode psychosis. **2023**, 66, ○
- 242 Obsessive-compulsive symptoms in patient with schizophrenia: The influence of disorganized symptoms, duration of schizophrenia, and drug resistance. 14, ○
- 241 Neural substrates of verbal memory impairment in schizophrenia: A multimodal connectomics study. **2023**, 44, 2829-2840 ○
- 240 Assessment of electroencephalography modification by antipsychotic drugs in patients with schizophrenia spectrum disorders using frontier orbital theory: A preliminary study. ○
- 239 Treatment with Soteria-elements in acute psychiatry Effectiveness for acutely ill and voluntarily treated patients. 11, ○
- 238 What Drives Animal Fluency Performance in Cantonese-Speaking Chinese Patients with Adult-Onset Psychosis?. **2023**, 13, 372 ○
- 237 Spatiotemporal Alterations in Working Memory-Related Beta Band Neuromagnetic Activity of Patients With Schizophrenia On and Off Antipsychotic Medication: Investigation With MEG. ○
- 236 Executive Functions and Psychopathology Dimensions in Deficit and Non-Deficit Schizophrenia. **2023**, 12, 1998 ○
- 235 Cognitive Dysfunctions Measured with the MCCB in Deficit and Non-Deficit Schizophrenia. **2023**, 12, 2257 ○
- 234 Validity and reliability of a Chinese version of the self-evaluation of negative symptoms. **2023**, 13, ○
- 233 Confidence in visual detection, familiarity and recollection judgements is preserved in schizophrenia spectrum disorder. ○
- 232 Resting-state functional MRI in treatment-resistant schizophrenia. 2, ○
- 231 Serum Growth Factors in Schizophrenia Patients. **2023**, 45, 3291-3301 ○
- 230 Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia. **2023**, 11, 1072 ○
- 229 In the eyes of the beholders: Subjective experiences of positive symptoms among patients with symptoms of psychosis seeking psychotherapy. **2023**, 254, 14-21 ○
- 228 Polygenetic risk scores and phenotypic constellations of obsessive-compulsive disorder in clozapine-treated schizophrenia. ○
- 227 Impaired emotion perception in schizophrenia shows sex differences with channel- and category-specific effects: A pilot study. **2023**, 161, 150-157 ○
- 226 Association of circulatory Klotho levels and its expression with miRNA- 339 in patients with schizophrenia. **2023**, 445, 114359 ○

- 225 The RECAPACITA project: Description of the clinical, neuropsychological and functional profile of a sample of people with severe mental disorder and legal capacity modification in Spain. **2023**, 88, 101874 ○
- 224 Victimization in schizophrenia and its relation to violence. **2023**, 255, 52-58 ○
- 223 Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study. **2023**, 255, 173-181 ○
- 222 Contrasting Metacognitive, Emotion Recognition and Alexithymia Profiles in Bulimia, Anorexia, and Schizophrenia. **2023**, 211, 348-354 ○
- 221 Obsessive-compulsive symptoms in first episode psychosis and risk states: Systematic review with meta-analysis. **2023**, 255, 41-51 ○
- 220 Selective processing in attention and memory in schizophrenia: A meta-analysis of the negative priming effect. **2023**, 161, 112-122 ○
- 219 Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial. **2023**, 255, 148-154 ○
- 218 Differential effects of parental socioeconomic status on cortical thickness in patients with schizophrenia spectrum disorders and healthy controls. **2023**, 804, 137239 ○
- 217 Association between childhood trauma and white matter deficits in first-episode schizophrenia. **2023**, 323, 115111 ○
- 216 Impact of early negative symptom patterns on the long-term outcomes of patients with first-episode schizophrenia-spectrum disorders: A 12-year follow up study. **2023**, 323, 115180 ○
- 215 Rich-club connectivity and structural connectome organization in youth at clinical high-risk for psychosis and individuals with early illness schizophrenia. **2023**, 255, 110-121 ○
- 214 Comparisons of facial emotion recognition in different social contexts among patients with schizophrenia, major depressive disorder and bipolar disorder. **2023**, 83, 103566 ○
- 213 Verbal and visual learning ability in patients with treatment-resistant schizophrenia: A 1-year follow-up study. **2023**, 33, 100283 ○
- 212 Neurocognitive function and mortality in patients with schizophrenia spectrum disorders. **2023**, 33, 100284 ○
- 211 Effects of exercise intervention on psychotic symptoms: A meta-analysis and hypothetical model of neurobiological mechanisms. **2023**, 110771 ○
- 210 Social network characteristics of Black African and Caribbean people with psychosis in the UK. **2023**, 161, 62-70 ○
- 209 Increased parietal and occipital lobe gyrification predicts conversion to syndromal psychosis in a clinical high-risk cohort. **2023**, 255, 246-255 ○
- 208 Prevalence and risk factors of thyroid dysfunction in outpatients with overweight or obese first-episode and drug-naïve major depressive disorder. **2023**, 328, 135-140 ○

- 207 Inflammatory disequilibrium and lateral ventricular enlargement in treatment-resistant schizophrenia. **2023**, 72, 18-29 ○
- 206 Prolyl oligopeptidase activity (POP) in early stage and medicated schizophrenia and in an animal model for schizophrenia study: In vivo effects of psychopharmacological substances on enzyme activity. **2023**, 10, 100075 ○
- 205 Sex difference in association between tardive dyskinesia and cognitive deficits in patients with chronic schizophrenia. **2023**, 255, 140-147 ○
- 204 The deficit subtype of schizophrenia is associated with a pro-inflammatory phenotype but not with altered levels of zonulin: Findings from a case-control study. **2023**, 153, 106109 ○
- 203 First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation. **2023**, 320, 115053 ○
- 202 Comparative effects of clozapine and risperidone monotherapy on levels of immunoglobulins in patients with schizophrenia A 12 weeks' longitudinal study. **2022**, 27, 119 ○
- 201 Assessing emotional characteristics in Asian autistic adults without intellectual disability. **2023**, 82, 103472 ○
- 200 MiRNA Differences Related to Treatment-Resistant Schizophrenia. **2023**, 24, 1891 ○
- 199 Childhood trauma and real-world social experiences in psychosis. **2023**, 252, 279-286 ○
- 198 Visual processing of complex social scenes in 22q11.2 deletion syndrome: Relevance for negative symptoms. **2023**, 321, 115074 ○
- 197 Correlation of Health-Related Quality of Life with Negative Symptoms Assessed with the Self-Evaluation of Negative Symptoms Scale (SNS) and Cognitive Deficits in Schizophrenia: A Cross-Sectional Study in Routine Psychiatric Care. **2023**, 12, 901 ○
- 196 The complexity of theory of mind deficit in schizophrenia: A cross-sectional analysis of baseline data from a longitudinal schizophrenia study. **2023**, 233, 103842 ○
- 195 A Critical Review of the Psychomotor Agitation Treatment in Youth. **2023**, 13, 293 ○
- 194 Lipid Alteration Signature in the Blood Plasma of Individuals With Schizophrenia, Depression, and Bipolar Disorder. **2023**, 80, 250 ○
- 193 Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia. **2023**, 21, 57-67 ○
- 192 Evaluation Expression of the Caspase-3 and Caspase-9 Apoptotic Genes in Schizophrenia Patients. **2023**, 21, 171-178 1
- 191 The trajectory of two negative symptom dimensions in first-episode psychosis and the role of cannabis use: A 10-year follow-up study. **2023**, 252, 317-325 ○
- 190 Serum free thiols in recently diagnosed patients with schizophrenia spectrum disorder: A potentially useful biomarker of oxidative stress. **2023**, 321, 115075 ○

- 189 Relation of ATPase6 Mutations and Telomere Length in Schizophrenia Patients. **2023**, 21, 162-170 ○
- 188 Depressive symptoms are specifically related to speech pauses in schizophrenia spectrum disorders. **2023**, 321, 115079 ○
- 187 Sociodemographic and substance characteristics among adolescents with psychotic disorders. **2022**, 43, 34 ○
- 186 Prevalence and correlates of dyslipidemia in first-episode and drug-naïve major depressive disorder patients with comorbid abnormal glucose metabolism: Sex differences. 14, ○
- 185 COMT but Not 5HTTLPR Gene Is Associated with Depression in First-Episode Psychosis: The Role of Stressful Life Events. **2023**, 14, 350 ○
- 184 Five-year illness trajectories across racial groups in the UK following a first episode psychosis. **2023**, 58, 569-579 ○
- 183 Relationship between Neurocognition, Social Cognition, and Metacognition and Suicidal Behavior in Recent-Onset Psychosis. ○
- 182 Association of serum homocysteine levels with intestinal flora and cognitive function in schizophrenia. **2023**, 159, 258-265 ○
- 181 Visual processing deficits in patients with schizophrenia spectrum and bipolar disorders and associations with psychotic symptoms, and intellectual abilities. **2023**, 9, e13354 ○
- 180 Clustering of antipsychotic-naïve patients with schizophrenia based on functional connectivity from resting-state electroencephalography. ○
- 179 Higher stress response and altered quality of life in schizophrenia patients with low membrane levels of docosahexaenoic acid. 14, ○
- 178 Nicotine use and non-pathological alcohol use and their relationship to affective symptoms and sleep disturbances in bipolar disorder. **2023**, 327, 236-243 ○
- 177 The Associations of NeutrophilLymphocyte, PlateletLymphocyte, MonocyteLymphocyte Ratios and Immune-Inflammation Index with Negative Symptoms in Patients with Schizophrenia. **2023**, 13, 297 ○
- 176 Remember the attack? A pilot study investigating flashbulb memory in individuals with schizophrenia. ○
- 175 Dual orexin/hypocretin receptor antagonism attenuates attentional impairments in an NMDA receptor hypofunction model of schizophrenia. ○
- 174 Aberrant perception of environmental volatility during social learning in emerging psychosis. ○
- 173 A preliminary choroid plexus volumetric study in individuals with psychosis. **2023**, 44, 2465-2478 ○
- 172 Mechanisms of action and processes of yoga-based group intervention for inpatients with schizophrenia spectrum disorders: A longitudinal qualitative study. 14, ○

171	The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.	1
170	The relevance of processing speed in the functioning of people with first-episode psychosis. 2023 , 160, 171-176	0
169	Cerebral blood flow in striatum is increased by partial dopamine agonism in initially antipsychotic-naïve patients with psychosis. 1-11	0
168	Associations between theory of mind and clinical symptoms in recent onset schizophrenia spectrum disorders. 14,	0
167	Systematic review of probiotics as an adjuvant treatment for psychiatric disorders. 17,	1
166	Alteration of the Functional Connectivity of the Cortical Areas Characterized by the Presence of Von Economo Neurons in Schizophrenia, a Pilot Study. 2023 , 12, 1377	0
165	Cytokine alterations in CSF and serum samples of patients with a first episode of schizophrenia: results and methodological considerations.	0
164	Associations between N-Acetylaspartate and white matter integrity in individuals with schizophrenia and unaffected relatives. 2023 , 330, 111612	0
163	Shared and distinct structural brain alterations and cognitive features in drug-naïve schizophrenia and bipolar disorder. 2023 , 82, 103513	0
162	Functional connectivity and gray matter deficits within the auditory attention circuit in first-episode psychosis. 14,	0
161	An examination of plasma autoantibodies against voltage gated calcium channels in schizophrenia. 2023 , 28, 100603	0
160	Joint crisis plans and crisis cards in inpatient psychiatric treatment.	0
159	Quality of life and psychiatric distress in people with serious mental illness, the role of personal recovery.	0
158	Channel- and category-specific emotion recognition deficits and their associations with symptomatology and cognition in individuals with schizophrenia. 2023 , 254, 37-39	0
157	Association of thyroid function with abnormal lipid metabolism in young patients with first-episode and drug naïve major depressive disorder. 14,	0
156	Shared decision making with schizophrenic patients: a randomized controlled clinical trial with booster sessions (DECIDE Study). 2023 , 110, 107656	0
155	Abnormal resting-state functional connectivity underlies cognitive and clinical symptoms in patients with schizophrenia. 17,	0
154	Explainable Fuzzy Clustering Framework Reveals Divergent Default Mode Network Connectivity Dynamics in Schizophrenia.	0

- 153 Interactions between mood and paranoid symptoms affect suicidality in first-episode affective psychoses. **2023**, 254, 62-67 ○
- 152 Abnormal brain network community structure related to psychological stress in schizophrenia. **2023**, 254, 42-53 ○
- 151 A Potential Biomarker for Predicting Schizophrenia: Metallothionein-1. **2023**, 11, 590 ○
- 150 Eye-movement analysis on facial expression for identifying children and adults with neurodevelopmental disorders. 5, ○
- 149 Correlation between duration of untreated psychosis and long-term prognosis in chronic schizophrenia. 14, ○
- 148 Ensemble of machine learning based prediction methods for diagnosis of schizophrenia using peripheral blood gene expression profile. ○
- 147 Development of the Implementing Technologies to Enhance Coordinated Specialty Care (ITECSC) Framework: Protocol for a Hybrid Effectiveness and Implementation Study of Technologically Supported Treatment in Coordinated Specialty Care. (Preprint). ○
- 146 Similarities and differences between multivariate patterns of cognitive and socio-cognitive deficits in schizophrenia, bipolar disorder and related risk. **2023**, 9, ○
- 145 History of suicide attempt associated with amygdala and hippocampus changes among individuals with schizophrenia. ○
- 144 The phenomenology of auditory verbal hallucinations in schizophrenia assessed with the MiniVoiceQuestionnaire (MVQ). ○
- 143 Neurocognitive Functions Related to Parietal Lobe in Patients with Schizophrenia and Methamphetamine Induced Psychotic Disorder and Healthy Individuals: A Comparative Study. **2022**, 14, 244-249 ○
- 142 Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. **2023**, 254, 92-98 ○
- 141 Neuronal dysfunction in individuals at early stage of schizophrenia, A resting-state fMRI study. **2023**, 322, 115123 ○
- 140 Review of Male and Female Care Needs in Schizophrenia: A New Specialized Clinical Unit for Women. **2023**, 3, 107-120 1
- 139 Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. **2023**, 13, e064504 ○
- 138 Childhood trauma is associated with altered white matter microstructural organization in schizophrenia. **2023**, 330, 111616 ○
- 137 Ketamine Effects on Energy Metabolism, Functional Connectivity and Working Memory in Healthy Humans. ○
- 136 Investigating the Use of Pharmacogenetic and Pharmacometabolomic Markers to Predict Haloperidol Efficacy and Safety Rates. 001857872311558 ○

- 135 Internet Gaming Disorders and Early Onset Psychosis in Young People: A Case Study and Clinical Observations. **2023**, 20, 3920 ○
- 134 Preserved electrophysiological markers of confidence in schizophrenia spectrum disorder. **2023**, 9, ○
- 133 Efficacy and auditory biomarker analysis of fronto-temporal transcranial direct current stimulation (tDCS) in targeting cognitive impairment associated with recent-onset schizophrenia: study protocol for a multicenter randomized double-blind sham-controlled trial. **2023**, 24, ○
- 132 Clinical symptoms, thyroid dysfunction, and metabolic disturbances in first-episode drug-naïve major depressive disorder patients with suicide attempts: A network perspective. 14, ○
- 131 Lurasidone Augmentation of Clozapine in Refractory Schizophrenia. **2023**, 43, 157-160 ○
- 130 Levels of Matrix Metalloproteinase 9 Are Elevated in Persons With Schizophrenia or Bipolar Disorder: The Role of Modifiable Factors. **2023**, ○
- 129 Effects of Adjunctive Betahistine Therapy on Lipid Metabolism in Patients with Chronic Schizophrenia: A Randomized Double-Blind Placebo-Controlled Study. Volume 19, 453-460 ○
- 128 Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis. **2023**, 10, 260-271 ○
- 127 The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia. **2023**, 14, 575 ○
- 126 A seven-year longitudinal study of the association between neurocognitive function and basic self-disorders in schizophrenia. 14, ○
- 125 Digital phenotyping for mental disorders monitoring: a systematic review (Preprint). ○
- 124 Clinical and Social Correlates of Duration of Untreated Psychosis in First-episode Psychosis Patients. **2006**, 35, 24-26 ○
- 123 Correlates of Social Isolation in Forensic Psychiatric Patients with Schizophrenia Spectrum Disorders: An Explorative Analysis Using Machine Learning. **2023**, 20, 4392 ○
- 122 Evaluating STC-1 and STC-2 mRNA expressions in Schizophrenia patients with increased oxidative stress. **2023**, ○
- 121 Paranoia. **2022**, ○
- 120 Asenapine add-on treatment for schizophrenia adults who received antipsychotics: A 52-week, open-label study. ○
- 119 Religious hallucinations in Lebanese patients with schizophrenia and their association with religious coping. **2023**, 16, ○
- 118 Longitudinal multi-omics alterations response to 8-week risperidone monotherapy: Evidence linking cortical thickness, transcriptomics and epigenetics. 14, ○

- 117 Altered functional dynamics gradient in schizophrenia with cigarette smoking. ○
- 116 Longitudinal changes in neural gain and its relationship to cognitive control trajectory in young adults with early psychosis. **2023**, 13, ○
- 115 Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome. **2023**, 13, 376 ○
- 114 Introduction to psychotic disorders in adolescence. **2023**, 1-29 ○
- 113 Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. **2023**, 23, ○
- 112 Pairing Explainable Deep Learning Classification with Clustering to Uncover Effects of Schizophrenia Upon Whole Brain Functional Network Connectivity Dynamics. ○
- 111 Exploring engagement with the CBT-informed Actissist smartphone application for early psychosis. 1-12 ○
- 110 The Predictive Value of Monocyte/High-Density Lipoprotein Ratio (MHR) and Positive Symptom Scores for Aggression in Patients with Schizophrenia. **2023**, 59, 503 ○
- 109 Neutrophil gelatinase-associated lipocalin (NGAL) and tumor necrosis factor- α (TNF- α) levels in patients with schizophrenia. **2023**, 240, 1091-1101 ○
- 108 Identification of shared and distinct patterns of brain network abnormality across mental disorders through individualized structural covariance network analysis. 1-12 ○
- 107 A randomized controlled trial of social cognition and interaction training for persons with first episode psychosis in Hong Kong. 14, ○
- 106 Quirky conversations: how people with a diagnosis of schizophrenia do dialogue differently. **2023**, 378, 1
- 105 Examination of the Relationship between Peripheral Inflammation Markers and Impulsivity and Aggression in Schizophrenia Patients Involved and Not Involved in Crime. **2023**, 13, 475 ○
- 104 Symptoms and functioning: a content analysis of the PANSS under the ICF framework. 1-8 ○
- 103 Effect of Family Psychological Education Program on Positive and Negative Symptoms of Schizophrenic Patients: A Randomized Controlled Trial. **2023**, 12, ○
- 102 Practitioner Review: Psychosis in children and adolescents. ○
- 101 A Systematic Review of Intermittent Theta Burst Stimulation for Neurocognitive Dysfunction in Older Adults with Schizophrenia. **2023**, 13, 485 ○
- 100 Atypical frontotemporal cortical activity in first-episode adolescent-onset schizophrenia during verbal fluency task: A functional near-infrared spectroscopy study. 14, ○

- 99 Self-stigma in schizophrenia: a systematic review and meta-analysis of 37 studies from 25 high- and low-to-middle income countries. ○
- 98 A cognitive-behavioral suicide prevention treatment for adults with schizophrenia spectrum disorders in community mental health: preliminary findings of an open pilot study. 1-23 ○
- 97 Prevalence, risk factors and clinical correlates of glucose disturbances in a large sample of Han Chinese patients with first-episode drug-naïve major depressive disorder. ○
- 96 Case report: Successful administration of cariprazine in a young, severely ill patient with recurrent relapses of schizophrenia and persistent negative symptoms. 14, ○
- 95 Psychometric properties of the mini international neuropsychiatric interview (MINI) psychosis module: a Sub-Saharan Africa cross country comparison. 1-11 ○
- 94 A systematic review of the effectiveness and implementation readiness of psychosocial interventions for psychosis in South Asia. ○
- 93 Distinctive alterations in the mesocorticolimbic circuits in various psychiatric disorders. ○
- 92 Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers. **2023**, 254, 178-189 ○
- 91 Smartwatch digital phenotypes predict positive and negative symptom variation in a longitudinal monitoring study of patients with psychotic disorders. 14, ○
- 90 Social Stigma Towards Mental Health Problems in Spain: A Systematic Review. **2023**, 34, 23-34 ○
- 89 Striatum-related spontaneous coactivation patterns predict treatment response on positive symptoms of drug-naïve first-episode schizophrenia with risperidone monotherapy. 14, ○
- 88 Mismatch Negativity and Theta Oscillations Evoked by Auditory Deviance in Early Schizophrenia. **2023**, ○
- 87 The safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study. **2023**, 23, ○
- 86 Comprehensive Geriatric Assessment for younger outpatients with severe mental illness: protocol for a feasibility study. **2023**, 13, e069518 ○
- 85 Aberrant Large-Scale Network Interactions Across Psychiatric Disorders Revealed by Large-Sample Multi-Site Resting-State Functional Magnetic Resonance Imaging Datasets. ○
- 84 Oxidative Stress Biomarkers among Schizophrenia Inpatients. **2023**, 13, 490 ○
- 83 An α 7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine. **2023**, 37, 381-395 ○
- 82 Retinal layers and symptoms and inflammation in schizophrenia. ○

- 81 Successful ingredients of effective Collaborative Care programs in low- and middle-income countries: A rapid review. **2023**, 10, ○
- 80 Opposite effects of positive and negative symptoms on resting-state brain networks in schizophrenia. **2023**, 6, ○
- 79 Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review. **2023**, 11, 921 ○
- 78 Altered Functional Connectivity Strength in Distinct Brain Networks of Children With Early-Onset Schizophrenia. ○
- 77 Identification of Homogeneous Subgroups from Resting-State fMRI Data. **2023**, 23, 3264 ○
- 76 The change in disease severity and medication adherence of patients registered in community mental health center in the Covid-19 pandemic. **2023**, 13, 251-257 ○
- 75 Investigation of the Relationship Between Cognitive Functions and Retinal Findings From Spectral Optical Coherence Tomography in Patients With Schizophrenia and Their Healthy Siblings. **2023**, 20, 236-244 ○
- 74 Immunological routine laboratory parameters at admission influence the improvement of positive symptoms in schizophrenia patients after pharmacological treatment. 14, ○
- 73 Differences in olfactory dysfunction and its relationship with cognitive function in schizophrenia patients with and without auditory verbal hallucinations. ○
- 72 Aberrant intra- and internetwork functional connectivity patterns of the anterior and posterior hippocampal networks in schizophrenia. ○
- 71 Obesity, antioxidants and negative symptom improvement in first-episode schizophrenia patients treated with risperidone. **2023**, 9, ○
- 70 Analyzing structural and functional brain changes related to an integrative cognitive remediation program for schizophrenia: A randomized controlled trial. **2023**, 255, 82-92 ○
- 69 A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. ○
- 68 Medication adherence and cognitive performance in schizophrenia-spectrum and bipolar disorder: results from the PsyCourse Study. **2023**, 13, ○
- 67 Cognitive function in recovered COVID-19 Lebanese patients with schizophrenia. **2023**, 22, ○
- 66 Mediating roles of positive reappraisal and stigma resistance in the relationship between mindfulness and quality of life among stable schizophrenia patients. ○
- 65 The Relationship between Motor Symptoms, Signs, and Parkinsonism with Facial Emotion Recognition Deficits in Individuals with 22q11.2 Deletion Syndrome at High Genetic Risk for Psychosis. **2023**, 2023, 1-10 ○
- 64 Psychometric and clinical evaluation of schizophrenia remission criteria in outpatients with psychotic disorders. **2023**, 23, ○

- 63 Fronto-striato-thalamic circuit connectivity and neuromelanin in schizophrenia: an fMRI and neuromelanin-MRI study. ○
- 62 Capgras Syndrome in a Child with Obsessive Compulsive Disorder: A Case Report. **2023**, 30, 89-92 ○
- 61 Deficits in odor discrimination versus odor identification in patients with schizophrenia and negative correlations with GABAergic and DNA methyltransferase mRNAs in lymphocytes. 14, ○
- 60 Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study. **2023**, 13, 577 ○
- 59 Intra and inter-individual variability in functional connectomes of patients with First Episode of Psychosis. **2023**, 38, 103391 ○
- 58 Culturally adapted family intervention for people with schizophrenia in Indonesia (FUSION): a development and feasibility study protocol. **2023**, 9, ○
- 57 Smoking and attention in schizophrenia spectrum disorders: What are we neglecting?. 14, ○
- 56 Association of the Level of Serum Prolactin with Polymorphic Variants of the GRIN2A, GPM3, and GPM7 Genes in Patients with Schizophrenia Taking Conventional and Atypical Antipsychotics. **2023**, 57, 39-46 ○
- 55 Basal glutamate in the hippocampus and the dorsolateral prefrontal cortex in schizophrenia: Relationships to cognitive proficiency investigated with structural equation modeling. 1-19 ○
- 54 Assessing the delivering of i MA gery-focused therapy for PS ychosis (i MAPS) via telehealth. ○
- 53 Brain texture as a marker of transdiagnostic clinical profiles in patients with recent-onset psychosis and depression. ○
- 52 Metabolic profile in first episode drug naïve patients with psychosis and its relation to cognitive functions and social cognition: a case control study. **2023**, 13, ○
- 51 Demoralization in Schizophrenia: A Pathway to Suicidal Ideation?. 1-15 ○
- 50 Fibre density and fibre-bundle cross-section of the corticospinal tract are distinctly linked to psychosis-specific symptoms in antipsychotic-naïve patients with first-episode schizophrenia. ○
- 49 Comparisons of 25 cerebrospinal fluid cytokines in a case-control study of 106 patients with recent-onset depression and 106 individually matched healthy subjects. **2023**, 20, ○
- 48 The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis. **2023**, 13, ○
- 47 Antiviral treatment in schizophrenia: a randomized pilot PET study on the effects of valaciclovir on neuroinflammation. 1-9 ○
- 46 Functional network interactions in patients with schizophrenia with persistent auditory verbal hallucinations: A multimodal MRI fusion approach using three-way pICA. **2023**, ○

- 45 Amygdala signal abnormality and cognitive impairment in drug-naïve schizophrenia. **2023**, 23, ○
- 44 Exploring the role of serum uric acid as a biomarker in patients with schizophrenia, bipolar affective disorder, and major depressive disorder. **2023**, 30, ○
- 43 Prodromal symptoms and the duration of untreated psychosis in first episode of psychosis patients: what differences are there between early vs. adult onset and between schizophrenia vs. bipolar disorder?. ○
- 42 The associations between cognitive functions and TSNAX genetic variations in patients with schizophrenia. **2023**, 225, 173554 ○
- 41 Cognitive Stress Regulation in Schizophrenia Patients and Healthy Individuals: Brain and Behavior. **2023**, 12, 2749 ○
- 40 Discrimination in clinical diagnosis between patients with schizophrenia and healthy controls using eye movement and cognitive functions. ○
- 39 Longitudinal evaluation on negative symptoms in young people at Ultra-High Risk (UHR) of psychosis: results from a 2-year follow-up study in a real-world care setting. ○
- 38 Associations of internalized stigma with psychosocial functioning and quality of life in people with schizophrenia. 002076402311640 ○
- 37 Non-linear variations in glutamate dynamics during a cognitive task engagement in schizophrenia. **2023**, 111640 ○
- 36 Executive functions in daily living skills: A study in adults with autism spectrum disorder. 14, ○
- 35 Inequality and barriers in psychosis prevention: A systematic review on clinical high-risk for psychosis studies from developing countries. 14, ○
- 34 Association of perceived social support with sociodemographic, clinical, and psychosocial variables in patients with first-episode psychosis. **2023**, 162, 30-36 ○
- 33 Case series: Cariprazine in early-onset schizophrenia. 14, ○
- 32 Offenders and non-offenders with schizophrenia spectrum disorders: Do they really differ in known risk factors for aggression?. 14, ○
- 31 VR-SOAP, a modular virtual reality treatment for improving social activities and participation of young people with psychosis: a study protocol for a single-blind multi-centre randomized controlled trial. **2023**, 24, ○
- 30 Impact of excessive abdominal obesity on brain microstructural abnormality in schizophrenia. ○
- 29 Optimal cutoff scores of the Chinese version of 15-item negative symptom assessment that indicate prominent negative symptoms of schizophrenia. 14, ○
- 28 Recognizing schizophrenia using facial expressions based on convolutional neural network. ○

- 27 Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial. Volume 19, 929-938 ○
- 26 The efficacy of homestyle rehabilitation on negative symptoms in chronic schizophrenia: A randomized controlled trial. 14, ○
- 25 Trajectories of Emotion Recognition Training in Virtual Reality and Predictors of Improvement for People with a Psychotic Disorder. **2023**, 26, 288-299 ○
- 24 Predictors of medication adherence in a large one-year prospective cohort of individuals with schizophrenia: Insights from the Multicentric FACE-SZ Dataset. ○
- 23 Prospective memory in early and established psychosis: An Indian perspective. ○
- 22 Recovery of auditory evoked response attentional gain modulation following the first psychotic episode indexes improvements in symptom severity. ○
- 21 Lower levels of cortical [3H]pirenzepine binding to postmortem tissue defines a sub-group of older people with schizophrenia with less severe cognitive deficits. **2023**, 255, 274-282 ○
- 20 Weight Changes Following Treatment with Aripiprazole, Risperidone and Olanzapine: A 12-Month Study of First-episode Schizophrenia Patients in China. **2023**, 103594 ○
- 19 Cannabis Use and Endocannabinoid Receptor Genes: A Pilot Study on Their Interaction on Brain Activity in First-Episode Psychosis. **2023**, 24, 7501 ○
- 18 Widespread alterations of diffusion tensor imaging metrics in patients with schizophrenia without current auditory hallucinations. ○
- 17 Effects of low-dose combined olanzapine and sertraline on negative and depressive symptoms in treatment-resistant outpatients with acute exacerbated schizophrenia. 14, ○
- 16 Exploring the influence of functional architecture on cortical thickness networks in early psychosis  longitudinal study. **2023**, 120127 ○
- 15 Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders. Publish Ahead of Print, ○
- 14 Increased Functional Connectivity Involving the Parahippocampal Gyrus in Patients with Schizophrenia during Theory of Mind Processing: A Psychophysiological Interaction Study. **2023**, 13, 692 ○
- 13 Association between subclinical hypothyroidism and psychotic features in Chinese young adults with first-episode and untreated major depressive disorder. **2023**, ○
- 12 Automatic evaluation-feedback system for automated social skills training. **2023**, 13, ○
- 11 Differential expression of diacylglycerol kinase β s involved in inferior parietal lobule-related dysfunction in schizophrenia with cognitive impairments. ○
- 10 Resting state hyperconnectivity of the default mode network in schizophrenia and clinical high-risk state for psychosis. ○

- 9 Iterated Rock-Scissors-Paper Game Play Predictive of Subscores of Self-Reported Measure of Autistic Personality Traits. ○
- 8 Feasibility of six-month outpatient cognitive remediation in schizophrenia: Experience from the randomized controlled integrated social cognition and social skills therapy study. **2023**, 33, 100285 ○
- 7 Application of Lipidomics in Psychiatry: Plasma-Based Potential Biomarkers in Schizophrenia and Bipolar Disorder. **2023**, 13, 600 ○
- 6 Investigation of momentary negative symptoms in patients with early psychosis in daily life: An experience sampling study. **2023**, 325, 115234 ○
- 5 A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder. **2023**, 73, 65-74 ○
- 4 Measures of Social and Occupational Function in Early Psychosis: A Systematic Review and Meta-analysis. ○
- 3 Altered MANF and RYR2 concentrations associated with hypolipidemia in the serum of patients with schizophrenia. **2023**, 163, 142-149 ○
- 2 Functional and Clinical Outcomes of Delusional Disorder and Schizophrenia Patients after First Episode Psychosis: a 4-year Follow-up Study. ○
- 1 Combining automatic speech recognition with semantic natural language processing in schizophrenia. **2023**, 115252 ○